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Oligodendrocytes in the central nervous system (CNS) are responsible for 
wrapping axons with myelin in order to insulate them and allow for a faster 
conduction of the nervous impulse. The axonal signals that determine whether an 
axon is myelinated, and what regulates the number of wraps is still not fully 
understood. The importance of signals that initiate myelination is significant 
because they may point to novel therapies for Multiple Sclerosis, where 
remyelination prevents the axon degeneration that is thought to underlie chronic 
disease. 
Neuregulin 1 (Nrg1) has been identified as a key axonal signaling molecule that 
regulates myelin thickness and glial fate in the peripheral nervous system (PNS). 
In the PNS, neuregulin I type III is a necessary and sufficient signal that regulates 
axoglial interaction. The role of neuregulin in the CNS remains unclear and 
controversial. 
Integrins, the major family of extracellular matrix (ECM) receptors are involved 
in the regulation of many fundamental cellular functions. Interaction with a wide 
range of receptors including growth factor receptors is well described. Our lab 
showed that α6β1 integrin regulates oligodendrocyte survival signaling by 
amplification of neuregulin activity. 
We have found that mice expressing a dominant-negative β1 integrin (that reduces 
β1 integrin signaling independently of ligand binding) in myelinating 
oligodendrocytes require a larger axon diameter to initiate myelination. These 
results suggest that there are other signals in the axon that also contribute to 
initiation of myelination. We therefore hypothesized that β1 integrin and 
neuregulin act in concert and play a role in axoglial interactions that sense the 
axon size and initiate myelination. By crossing the dominant negative β1 integrin 
mice with heterozygous mice for neuregulin 1 and analyzing myelination, we 
have found that neuregulin does not enhance the phenotype previously described. 




ErbB4 (the neuregulin receptors expressed on oligodendrocytes) have normal 
CNS myelin sheaths demonstrates that neuregulin 1 is not required for CNS 
myelination.  
Interestingly, neuregulin 1 has been associated as a susceptibility gene in 
schizophrenia, a disease independently associated with myelin abnormalities 
(Davis et al., 2003; Hakak et al., 2001). Post-mortem brains of schizophrenic 
patients showed an increased level of neuregulin 1 type IV. We have analysed 
mice overexpressing neuregulin 1 type IV (Nrg1 type IV) and show that increased 
levels of neuregulin 1 type IV does not alter the brain morphology or myelin 
pattern and integrity. A possible explanation is that since neuregulin 1 type IV is 
human specific, the mice lack species-specific receptors or other neuregulins have 
compensatory equilibrium mechanism that are not destabilized by overexpression 
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The overall aim of this PhD thesis is to understand the role of integrins and 
neuregulins in the process of myelination in the central nervous system (CNS).  
 
The signals that determine whether an axon is myelinated and that govern the 
number of wraps around the axon are poorly understood. All axons over a critical 
diameter become myelinated, with the threshold axon diameter for myelination being 
0.2 µ.oipm in CNS and 1 µm in the peripheral nervous system (PNS) (Waxman and 
Bennet, 1972; Voyvodic, 1989). The thickness of the sheath formed is linked to the 
axon diameter – the so called g-ratio (Friede, 1972). In the PNS, neuregulin 1 type III 
has been identified as a necessary and sufficient signal to regulate myelination 
(Taveggia et al., 2008). Such an analogue thus far has not been described for CNS. 
Integrins, a major family of extracellular matrix (ECM) receptors, are involved in the 
regulation of many cellular processes and previous work from our lab showed that 
α6β1 integrin regulates oligodendrocyte survival signalling through amplification of 
neuregulin activity (Colognato et al, 2002). Therefore we hypothesized that β1 
integrin and neuregulin 1 may have a cooperative role in CNS myelination. 
 
The introduction of this thesis will review the current knowledge related to myelin 
and the myelination process.  Subsequent chapters will discuss work carried out in 
relation to integrins, neuregulins and schizophrenia and relevant literature will be 
discussed in each chapter. 
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1.1 Organization of the nervous system 
 
During evolution, animals adapted in order to better cope with their environment. 
One of the most amazing evolutionary adaptations is related to the development of 
the nervous system.  The nervous system is responsible for gathering information 
from the environment, processing this information, and attributing a specific signal 
that will lead to an adequate response. In lower organisms, the nervous system is 
very simple, but becomes increasingly complex in higher organisms. 
 
One of the most important features of the nervous system is to conduct information 
in the form of a nervous impulse. This has to be both efficient and fast; therefore the 
nervous system could evolve in two distinct ways to achieve this, either by 
increasing the dimensions of the axon, or by insulating the axons with a lipidic 
membrane – myelin – to allow rapid conduction of the nervous impulse. Conduction 
velocity is directly proportional to the axon diameter in unmyelinated axons. By 
increasing the axon diameter the conduction is raised due to the lower resistance 
registered in the fibres. This type of evolutionary mechanism can be found in squid 
(with its famous giant axon), fruit flies and copepodes. One of the setbacks for this 
type of mechanism is the correlation between the size of the animal and the size of 
the axon. Bigger animals would need a substantial increase in their axon diameter in 
order to improve performance. The second strategy allows a faster propagation of the 
impulse by insulating the axon with myelin which increases the resistance and 
decreases the electrical capacitance due to its non-conducting properties (reviewed 
by Allen and Barres, 2009; Colman, 2007). This strategy allowed these organisms to 
increase their size, without the need to increase their cranium, enabling a fast reactive 
response, giving these organisms a complex but compact nervous system, a reduction 
of energy requirements (the squid giant axon requires 5000 times more energy than a 
12 µm myelinated axon of a frog) and correct propagation of the nervous impulse 
(Hartline, 2008; Pedraza et al., 2001; Quarles. 2006).  
 
Chapter 1 – Literature review 
4 
 
Vertebrates possess a highly demanding and intricate nervous system that comprises 
peripheral nervous system (PNS), which consists of the peripheral nerves and their 
ganglia, and central nervous system (CNS) comprising the brain and spinal cord 
(Stevens et al., 1997). Both systems share the same type of cells: neurons and glia. 
Neurons are responsible for gathering information from sensory receptors, 
processing that information and generating appropriate signals to effector cells by 
transmitting electrical signals in the form of action potentials (Stevens et al., 1997). 
Neurons have three distinct areas: the soma or cell body, axon and dendrites. Glial 
cells in the CNS were first described by Richard Virchow who named them 
“nervenkitt”, which means “nerve glue” and were once thought to be the brain’s 
connective tissue, helping with support functions (reviewed by Somjen, 1988).  
 
In more recent years glial cells have been more thoroughly described and it is now 
established that they have a more defined role as regulators of CNS development and 
function (reviewed by Allen and Barres, 2009). Glial cells outnumber neurons and 
are a large part of the nervous tissue and their proportion increases with the degree of 
evolution, from 25% in fruit flies to 90% in the human brain (reviewed by Pfrieger 
and Barres, 1995). The CNS comprises microglia and macroglia (oligodendrocytes 
and astrocytes), while in PNS there are Schwann cells, enteric glia and satellite cells 
(Jessen, 2004). 
 
The glial cells in the CNS are derived from neural precursor cells of the ventricular 
zone (Jessen, 2004). Microglia are the resident immune cells of the CNS, they survey 
the brain for damage and infection and act as immune regulators by secreting 
cytokines/growth factors and act as macrophages by engulfing dead cells and debris 
(Ruckh et at., 2012). Astrocytes outnumber oligodendrocytes, with a star like 
appearance and many processes radiating in all directions. These processes control 
axonal outgrowth and maintain blood-brain barrier (BBB) integrity which is crucial 
for CNS protection against foreign substances; they are also involved in 
embryogenesis, fluid transport, energy metabolism, neurotransmitter homeostasis 
and synaptogenesis (by removing excess neurotransmitter molecules from the 
extracellular space and helping the accurate encoding of synaptic signals and 
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neurotransmission) and structural support  (Allen and Barres, 2009; Jessen, 2004; 
Purves et al., 2001; Stevens et al., 1997). Oligodendrocytes were first characterized 
in the 1920s by Rio Hortega, using silver impregnation (Hortega, 1928). Work by 
Wilder Penfield confirmed the identity of oligodendrocytes, and further suggested 
that they were the myelin forming cells of the CNS (Penfield, 1924). 
Oligodendrocytes extend several processes that contact and form distinct myelin 
internodes, sometimes on different axons (a single oligodendrocyte can myelinate up 
to 30-40 axons) (Jessen, 2004). Myelination occurs discontinuously along the axon 
forming the internodes, leaving unmyelinated gaps, known as nodes of Ranvier. This 
allows for membrane depolarization to be located specifically in the nodes, termed 
saltatory conduction, by enabling current flow across the axolemma to the nodes of 
Ranvier which have a high concentration of voltage-dependent sodium channels 
(Sherman and Brophy, 2005).  
 
Glial cells in the PNS derive from the neural crest (Dulac et al., 1991). The enteric 
glia, found in the ganglia of the gut, are structurally and biochemically similar to 
astrocytes and are involved in the synaptic and muscular digestive processes 
(reviewed by Sofroniew and Vinters, 2010). Satellite glial cells are small support 
cells that surround neurons in ganglia to which they supply nutrients (Jessen, 2004; 
Stevens et al., 1997). Schwann cells can either be myelinating or non-myelinating. 
The non-myelinating Schwann cells play a role in metabolic and mechanical support, 
while the myelinating Schwann cells are analogous to oligodendrocytes, wrapping 
axons with myelin sheaths (Sherman and Brophy, 2005). 
 
 
1.2 Glial cells and myelination 
 
Oligodendrocytes form one of the most highly specialised cellular structures in the 
body, the myelin sheath. They ensheath axons with myelin, in order to form 
electrical insulation around nerve fibres, allowing axon potentials (the electrical 
impulses propagated along them), to be transmitted faster in a process known as 
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saltatory conduction. During saltatory conduction, axon potentials leap among 
specialised gaps in the myelin sheath, called nodes of Ranvier where sodium 
channels are clustered  (Baumann et al., 2001; Jessen, 2004) 
 
Myelination is a highly demanding process, with myelin being one of the most 
specialised cellular structures in the body. An oligodendrocyte in the rat brain, during 
the active process of myelination, has to produce approximately 5000 µm
2
 of myelin 
surface daily, and approximately 10
5
 myelin proteins per minute (Jessen, 2004; 
Pfeiffer et al., 1993).  
 
 
1.2.1  PNS vs CNS myelination 
 
In this next section the differences between PNS and CNS myelination will be 
reviewed. As mentioned previously Schwann cells are responsible for PNS 
myelination, whilst in the CNS this function is mediated by oligodendrocytes. 
Whereas a single oligodendrocyte in the CNS can myelinate multiple axons and 
extend up to 40 different processes, in the PNS, Schwann cells myelinate in a 1:1, 
Schwann cell:axon ratio (Fig. 1.1) (Sherman and Brophy, 2005).  
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Figure 1.1 – Myelination in the peripheral and central nervous system. Glial cells are 
responsible for wrapping myelin along the axon to provide insulation and increase the 
propagation of the nervous impulse. In the peripheral nervous system Schwann cells (A) 
myelinate in a 1:1, cell:axon ratio while in the central nervous system oligodendrocytes (B) 
are capable of extending multiple processes and interact with different axons. Reproduced 
with minor changes from Sherman and Brophy, 2005. 
  
In the PNS, Schwann cells arise from the neural crest and can be myelinating or non-
myelinating. This distinction is based on the calibre of the axon they initially 
associate with. If a Schwann cell establishes contact with a large diameter axon it 
will differentiate and become a myelinating cell, whilst those in contact with small 
diameter axons maintain their non-myelinating phenotype. These non-myelinating 
Schwann cells form the Remak bundle by surrounding multiple small diameter 
axons. The number of axons engulfed by non-myelinating Schwann cells varies 
depending on location, with large numbers of axons observed in these bundles in L5 
dorsal root ganglion (DRG) (in 50% of cases these bundles present more than 20 
axons), and small numbers in the distal nerve segments (with an average of 3 axons) 
(Murinson and  Griffin, 2004). Transgenic mice in which these bundles were 
perturbed showed progressive axonal degeneration and neuropathy (Chen et al., 
2003), revealing the role of non-myelinating Schwann cells in axonal integrity 
maintenance (Nave and Trapp, 2008).  Myelinating Schwann cells surround a group 
of nerves and in a process termed radial sorting, sort axons to the periphery of the 
bundle establishing contact and extending myelin over the internode (Sherman and 
Brophy, 2005).  
 
Myelination in the PNS and CNS is regulated by different signals, and although 
myelin shares its main components across both systems, there are differences in the 
proteins expressed by PNS and CNS. 
 
A comparison of myelin proteome from CNS and PNS showed a high percentage of 
proteins are shared between both systems (Monasterio-Schrader et al., 2012). Myelin 
basic protein (MBP) is one such protein that is highly abundant and involved in 
myelin compaction. However, there are myelin proteins expressed selectively in PNS 
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or CNS; PNS myelin has P0 (Ig-CAM myelin protein zero) as one of its main 
constituents, whilst in the CNS this protein is not present, being replaced by the 
tetraspan proteolipid protein (PLP) (Schliess and Stoffel, 1991).  There are other 
examples of exclusive proteins such as claudin 11 (Bronstein et al., 2000) in the CNS 
and periaxin (Prx) in the PNS (reviewed by Kursula, 2008). 
 
Whereas myelin proteins can differ in the PNS and CNS, there are signals that can 
modulate both systems, such as beta-site amyloid precursor protein-cleaving enzyme 
1 (Bace1). Bace1 is a protease responsible for cleaving the β-amyloid precursor 
protein (APP) into amyloid-β peptides (Aβ), which aggregate in brains of 
Alzheimer’s disease patients (Sisodia and George-Hylop, 2002). Bace1 is commonly 
expressed in neurons and modulates APP processing through Nogo (a component of 
myelin) (Woolf, 2003). Bace1 null-mice show hypomyelination from early stages of 
development and reduced myelin thickness, with a reduction of compact myelin 
protein levels (MBP and PLP), but no alteration of uncompacted myelin proteins 
(MAG and MOG) both in PNS and CNS, which leads to impaired neurological 
function such as reduced grip strength and a lower pain threshold . Axonal secreted 
neuregulin 1 is cleaved by Bace1, since higher levels of full-length neuregulin 1 type 
III, and not the cleaved and potentially active form, were found in these mutant mice. 
Neuregulin 1 activates the cell surface receptor ErbB which leads to activation of 
phosphatidylinositol-3-OH kinase (PI3K) and Akt. A possible mechanism that could 
explain these observations would be that neuregulin 1 cleavage by Bace1 is 
necessary for serine/thereonine kinase (Akt) phosphorylation (since Akt 
phosphorylated levels were also decreased in these mice) (Hu et al., 2006). 
Transgenic mice that overexpress a constitutively active Akt in oligodendrocytes 
have increased numbers of myelin sheaths wrapped around the axon (therefore 
enhancing myelination) but show no alteration in oligodendrocyte development (i.e., 
proliferation or survival). Together, these observations suggest that impairment in 
this signalling pathway leads to abnormal myelination both in CNS and PNS 
(Narayanan et al., 2009). 
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Signals that regulate axoglial interaction and myelination have long been 
investigated. In the PNS, neuregulin 1 type III has been identified as one of these 
regulators with the capacity of solely affecting myelination and myelin thickness. 
The levels of axonal neuregulin 1 type III in the PNS determines both the decision 
for Schwann cells to myelinate and the number of myelin wraps around the axon. 
Overexpression of neuregulin 1 type III in vitro promotes myelination of axons that 
would normally be unmyelinated; while transgenic mice with increased levels of 
neuregulin 1 type III in peripheral nerves generate thicker myelin sheaths (Michailov 
et al., 2004; Taveggia et al., 2005). Further studies were carried out in the CNS to 
investigate the role of neuregulin 1 type III. In vitro, the addition of exogenous 
neuregulin 1 to myelinating co-cultures of oligodendrocytes and dorsal root ganglion 
(DRG) neurons showed an increased in myelination (Wang et al., 2007), and 
myelination is significantly reduced in co-cultures of neuregulin 1 type III-deficient 
DRG neurons (Taveggia et al., 2008).  In vivo, transgenic mice expressing a 
dominant-negative ErbB receptor in oligodendrocytes and mice haplosuffficient for 
neuregulin 1 type III showed hypomyelination (Roy et al., 2007; Taveggia et al., 
2008).  
 
In the PNS, myelinating Schwann cells establish contact with a bundle of axons (a 
process termed radial sorting) and interdigitate processes to establish contact with 
unmyelinated axons in order to ensheathe an internode (Jessen and Mirsky, 2005). 
This process requires the intervention of β1 integrin and focal adhesion kinase (FAK, 
a downstream signalling molecule from the integrin pathway) (Grove et al., 2007; 
Nodari et al., 2007). In the CNS, myelination is delayed and oligodendrocytes 
acquire a higher threshold for myelination in dominant negative β1 integrin mice, 
suggesting that integrins are necessary for detection of the axonal signal that initiates 
myelination (Câmara et al., 2009). Integrins are a major family of extracellular 
matrix (ECM) receptors comprising two subunits (α and β) that heterodimerize in 24 
known combinations. Integrins bind ECM ligands and signal through the PI3K and 
MAPK pathways (Hynes, 2002) and interact with different receptors, including the 
ErbB receptor family that regulates neuregulin signalling, thereby amplifying 
neuregulin signalling.  




Although there are similarities between PNS and CNS myelination, previous 
research has demonstrated that these two systems diverge in terms of signalling 
pathways that regulate myelination. CNS seems to be a more complex system which, 
unlike the PNS, does not have an identified factor that has an exclusively instructive 
role, but rather is governed by sequential events dependent on temporal expression of 
positive and inhibitory factors (Fig. 1.2). 
 
Figure 1.2– Signalling pathways regulating myelination in peripheral and central 
nervous system. In the peripheral nervous system neuregulin 1 type III has been identified 
as a key regulator of myelination, capable of controlling myelin thickness and the Schwann 
cell decision to myelinate. In the central nervous system such key molecule has not been 
described yet.  
 




1.2.2 Composition of myelin 
 
Myelin is highly conserved in mammals (Kirschner et al., 1989; Waehneldt, 1990). 
Myelin is a low hydrated structure containing 40% water and its dry weight is 
characterized by a high proportion of lipids (70%) and a lower proportion of proteins 
(30%)  (Baumann et al., 2001; Siegel et al., 1999). It has a high lipidic content with 
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approximately 32% glycolipids (from which 20% are of galactocerebroside, GalC), 
26% cholesterol, and 42% phospholipids (Pfeiffer et al., 1993).  
 
GalC concentration in the brain is directly proportional to the amount of myelin 
(Siegel et al., 1999). UDT-galactose ceramide galactosyltransferase (CGT) is 
necessary for the activation of GalC and its derivative sulphatide. In CGT knockout 
mice myelin formation is apparently normal, apart from some minor differences in 
structure and changes in axon conduction velocity with mice showing tremors and 
mild ataxia and developing progressive hind limb paralysis with age (Coetzee et al., 
1996; Siegel et al., 1999). This suggests that the lack of GalC (which plays a role in 
the establishment of the axoglia contact) may be compensated by glucocerebroside 
(GlcC), explaining the absence of a severe phenotype, therefore we can conclude that 
it is not necessary for myelin formation but is crucial for insulating capacity and 
stability (Dupree et al., 1998; Siegel et al., 1999). 
 
Myelin membrane contains a high percentage of lipids from which cholesterol is a 
major component. Cholesterol concentration in the brain abruptly increases after 
birth in mice due to myelin production by oligodendrocytes, going from 3.5 mg/g in 
the newborn to 12 mg/g after only 3 weeks and reaching its peak (19mg/g) during 
adulthood (Dietschy and Turley, 2004). Transgenic mice lacking the ability to 
synthesise cholesterol in myelinating oligodendrocytes developed ataxia, tremor and 
had impaired control of hind limbs and several unmyelinated axons around P20. This 
phenotype is transient, with most axons being myelinated by P100, improving the 
trembling phenotype. This transient effect is thought to be due to oligodendrocytes 
taking up cholesterol from astrocytes, as a compensatory mechanism for the lack of 




Myelin proteins account for approximately 30% of its dry weight, making myelin a 
biological membrane with a simple protein composition since most biological 
membranes have higher levels of proteins than lipids (Quarles et al., 2006). 




Proteolipid protein (PLP) is also known as Folch-Lees protein (Lees et al., 1984). 
PLP is a tretaspan protein corresponding to 50% of CNS myelin proteins (Baumann 
et al., 2001), and has the physical property of solubility in organic solvents (Siegel et 
al., 1999). PLP is the common isoform, but the splicing of the 5’ part of exon 3 (from 
7 exons that constitute the PLP gene, located on the X chromosome both in mice and 
humans), leads to a 35 amino acid deletion that originates the DM-20 isoform 
(Baumann et al., 2001). A variety of naturally occurring mutations affecting both 
PLP and DM-20 has been described in rodents, among them are jimpy, jimpy 
msd 
and 
jimpy 4j (Baumann et al., 2001; Billings-Gagliardi et al., 1995; Siegel et al., 1999). 
Jimpy mice revealed a myelin deficiency with a reduced number and thickness of 
myelinated axons, with the few myelinated axons showing an abnormal compaction 
and no intraperiodic line (Duncan et al., 1989); jimpy mice die prematurely (Nave et 
al., 1986). Although one would expect PLP and DM-20 to be necessary for compact 
multilamellar myelin, it is now known that, although they serve important functions, 
they are not essential (Siegel et al., 1999). PLP/DM-20 knockout mice showed a 
relatively normal myelin formation (Klugmann et al., 1997). Oligodendrocytes were 
able to myelinate axons and compact myelin sheaths, despite a difference at the level 
of intraperiodic line, which was abnormally condensed (Baumann et al., 2001; Siegel 
et al., 1999). 
 
Myelin basic protein (MBP) is an essential protein for myelin formation. It is a 
cytoplasmic, extrinsic membrane protein that constitutes 30-40% of total myelin 
content in the CNS and 10-20% in the PNS (Jacobs, 2005; Pfeiffer et al., 1993). 
MBP has an important role in myelin compaction and mutations in the MBP gene 
cause severe dysmyelination (Pfeiffer et al., 1993). MBP is encoded by a gene 
containing 7 exons, located on chromosome 18 both in mouse and human, from 
which different protein isoforms are generated by alternative splicing of RNA (Ferra 
et al., 1985; Roach et al., 1985; Siegel et al., 1999). The mutant shiverer mouse 
results from one of the major deletions of the MBP gene, presenting a phenotype 
where hypomyelinated axons possess uncompacted myelin sheaths, with no major 
dense line (Siegel et al., 1999). Shiverer mice display tremors from P10 to P12, 
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followed by tonic seizures, dying 4 or 5 months after birth (Baumann et al., 2001; 
Privat et al., 1979; Rosenbluth, 1980). Although these mice lack MBP in both PNS 
and CNS, there is no phenotype in the PNS suggesting that other proteins, such as 
P0, can compensate for the loss of MBP (Baumann et al., 2001; Boggs, 2006). 
 
2′:3′-Cyclic nucleotide-3′-phosphodiesterase (CNP) exists in two isoforms (46 and 
50kDa), representing 4% of the total of CNS myelin proteins (Pfeiffer et al., 1993). 
CNP is highly expressed in the CNS myelin and oligodendrocytes but has a lower 
level of expression in Schwann cells at the initial stage of myelination. CNP is not a 
major component of compact myelin but is concentrated in the cytoplasm of 
uncompacted myelin, inner and outer tongue processes and lateral loops (Siegel et 
al., 1999; Trapp et al., 1988). Cnp1 (CNP gene that comprises 4 exons) knockouts 
display largely normal myelin; the mutation perturbs myelin formation and causes 
abnormal oligodendrocyte membrane expansion, with mice developing neurological 
symptoms like ataxia, hind limb weakness and hunched posture at 4 months, and 
dying prematurely (Baumann et al., 2001; Lappe-Siefke et al., 2003). 
Oligodendrocytes in mutant mice over-expressing human CNP extend an increased 
number of longer processes, although with low myelin compaction, redundant 
myelin and intra-myelin vacuoles (Gravel et al., 1996). It has been proposed that 
CNP is involved in the cytoskeletal network of myelin since it binds to F-actin and 
tubulin, and overexpression of CNP in non-neuronal cells stimulates process 
outgrowth (Quarles et al., 2006; Siegel et al., 1999).  
 
Myelin-associated glycoprotein (MAG) is a heavily glycosylated protein present in 
both PNS and CNS and is a minor constituent of myelin (approximately 1%). MAG 
comprises 2 isoforms generated by alternative splicing, S-MAG (with a short 
cytoplasmic domain) and L-MAG (with a long cytoplasmic domain) (Pfeiffer et al., 
1993; Siegel et al., 1999). MAG has a role in initial axon-myelin interactions, since it 
is not present in compact myelin but is located at the periaxonal membrane. This 
emphasizes the role of MAG as a recognition molecule, binding ligands and 
mediating axoglial interaction (Pfeiffer et al., 1993). MAG knockout mice display 
largely normal myelination, but exhibit subtle periaxonal structural abnormalities (Li 
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et al., 1994; Montag et al., 1994; Siegel et al., 1999). At 9 months, null mutants 
develop a dying-back oligodendropathy, a degeneration of the distal periaxonal 
oligodendrocyte processes, and a peripheral neuropathy affecting both myelin and 
axons (Lassmann et al., 1997; Siegel et al., 1999). A transgenic mouse, expressing a 
truncated form of the L-MAG, yet maintaining S-MAG expression, showed a similar 
CNS phenotype to the MAG KO mice, suggesting that L-MAG is essential for CNS 
myelination (Baumann et al., 2001; Miescher et al., 1997).  
 
Figure 1.3 - Schematic representation of myelin composition in the central nervous 
system and peripheral nervous system. The myelinating cells of the central 
(oligodendrocyte) and peripheral (Schwann cell) nervous system differ from one another, not 
only in the number of internodes each one can myelinate at a time, but also the proteins 
synthesized. Central myelin is mainly constituted by MBP, in contrast to peripheral myelin 
which has P0 as its main constituent. Whilst in the PLP is present in the CNS, this protein is 
substituted in the PNS by PMP-22. Reproduced from Saher et al., 2011 




As depicted in figure 1.3, peripheral and central myelin share most of their 
constituents, but in the PNS, PLP function is substituted by P0 and PMP-22. Myelin 
protein P0 is a major constituent of peripheral myelin (Saher et al., 2011). Disruption 
of the MPZ gene (that encodes both P0 and PMP-22) results in demyelination of 
peripheral nerves and will be described in the next section. 
 
1.2.3  Myelin disorders 
 
There are different pathologies that affect myelin which can be caused by genetic or 
toxicological factors, autoimmunity, viral infections or mechanical trauma. These 
can affect the myelin layer, the neurons or the myelinating cell itself (Quarles et al., 
2006). Myelin deficiencies can be divided into acquired and genetic disorders of 
myelin, and also into demyelinating and dysmyelinating diseases (Siegel et al., 
1999).  
 
Figure 1.4 - Schematic representation of the demyelinating process. Myelin wrapped 
around axons is degraded due to genetic, autoimmune or toxic factors leading to the 
exposure of axons that without the structural support of oligodendrocytes degenerate in a 
situation of no repair, or in the case where a regenerative process occurs can be 











A demyelinating disease is characterized by damage and loss of the myelin sheath 
leading to axon degeneration. Demyelination can be caused by genetic or 
inflammatory factors that lead to myelin degradation which impairs the conduction 
of the nervous impulse that can cause movement, cognitive, visual, or sensory 
damage. If there is no repair these will lead to axon degeneration, although in some 
situations regeneration takes place and these axons are remyelinated (Fig. 1.4). 
 
Multiple sclerosis (MS) and leukodystrophies are examples of demyelinating 
diseases of the CNS, while Charcot-Marie-Tooth disease and Guillain-Barré 
syndrome are characteristic of the PNS. 
 
Charcot-Marie-Tooth disease (CMT) is the most frequent human inherited 
neuropathy of the PNS (prevalence 1:2500) caused by abnormalities in the PMP-22 
gene (a glycoprotein that play a role in myelin structure and compaction). The 
phenotype of these mutations can lead to either increased or decreased expression of 
PMP-22 with similar symptoms showing the importance of tight regulation in myelin 
proteins (Rosso et al., 2012). CMT is characterized by demyelination that slows the 
conduction velocity, leading to weakness and numbness (Kedlaya, 2007; Siegel et 
al., 1999). The Trembler-J mouse has a mutation on the PMP-22 gene that confers a 
model for CMT due to an abnormal folding of the protein preventing normal 
myelination (Meekins et al., 2004). 
 
Guillain-Barré syndrome (GBS) is an acquired disorder of the PNS characterized by 
an acute inflammatory demyelinating polyneuropathy which appears one or two 
weeks after a bacterial or viral infection and it is initially characterized by leg 
weakness and can cause paralysis (Quarles et al., 2006; Siegel et al., 1999).  GBS is 
the most common cause of acute flaccid paralysis thought to be induced by 
autoimmunity (reviewed by Yuki and Hartung, 2012). One of the animal models 
used to help understand this syndrome is the experimental allergic neuritis (EAN), 
induced through immunization with PNS specific proteins (reviewed by Soliven, 
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2012). This mouse model showed that the P2 myelin protein plays an important role 
in the demyelinating process, although this protein has not been consistently shown 
to have a role in GBS (Spies et al., 1995). A new line of research has been following 
a different route by using animal models immunized against gangliosides, which 
have been documented to be associated with the human GBS by reacting with a 
carbohydrate epitope of MAG, P0 and PMP-22 (Zhu et al., 1994). Further 
investigation into antibodies and pathological causes linked to this disease are 
required for the development of better models (Quarles et al., 2006). 
 
Leukodystrophies are genetic diseases of the CNS caused by multiple genetic defects 
affecting specific myelin proteins and are characterized by a progressive 
degeneration of the white matter (Siegel et al., 1999). Typically leukodystrophies 
have an early onset and new lines of treatment that include cell transplantation have 
been used, but have not been proven to promote myelination regeneration (Orchard 
and Tolar, 2010). Krabbe disease is a demyelinating disorder caused by a mutation of 
the galactocerebrosidase (GalC) gene, which prevents its degradation by 
oligodendrocytes and Schwann cells leading to progressive demyelination in the 
CNS and PNS. The animal model used in this specific type of leukodystrophy is the 
twitcher mouse that has a mutation in the GalC gene leading to a lack of GalC 
enzyme. This model is used to test different therapies such as oligodendrocyte 
precursor cells and bone marrow transplantation (reviewed by Duncan et al., 2011). 
 
Multiple Sclerosis (MS) is one of the most common inflammatory diseases of the 
CNS affecting 2.5 million people worldwide (Compston et al., 2002). MS is 
characterized by inflammation, demyelination, degeneration of oligodendrocytes 
(that then fail to remyelinate in chronic phases of disease), resulting in progressive 
loss of vision and paralysis (Baumann, 2001; Siegel et al., 1999). MS can be 
subdivided into 4 types.  Relapsing-remitting MS, the most common subtype, is 
characterized by acute attacks (relapses) followed by a recovery process (remission). 
This subtype can then evolve to secondary progressive MS, which is progressive due 
to the absence of recovery periods. Primary progressive MS is less common but 
clinically more aggressive and defined by a steady increase of disability with no 
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recovery periods. The rare progressive-relapsing MS starts as progressive and gets 
worse due to super-imposed attacks (reviewed by Goldenberg, 2012). Animals 
immunized against myelin encephalitogenic proteins develop an acute or chronic 
demyelinating disease of the CNS termed experimental allergic encephalomyelitis 
(EAE) and are currently used as a model for MS. The different types of antigen used 
to immunize these animals lead to distinct models that mimic different pathological 
aspects or a specific subtype of MS (reviewed by Constantinescu et al., 2011). 
 
Chang and co-workers reported that human MS lesions contain oligodendrocytes that 
extend multiple processes that associate with demyelinated axons but fail to 
myelinate them (Fig. 1.5). Identification of the signals regulating the initiation of 
myelination may lead to the development of strategies to promote effective 
remyelination by oligodendrocytes within MS lesions that are arrested at the 
premyelinating stages and therefore unable to contribute to repair, and prevent the 










Figure 1.5 – Schematic representation of multiple sclerosis (MS) lesion. In normal 
circumstances the oligodendrocyte extends a process that contacts the axon and myelinates 
the internode. In MS lesions oligodendrocytes migrate into the lesion and establish an initial 




Dysmyelination is associated with defective myelin structure and function, which is 
abnormal and can lead to axonal degeneration (Quarles et al., 2006). Unlike 
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demyelinating diseases that can have different triggers, dysmyelinating disorders 
have a genetic background that prevents the formation of normal myelin usually due 
to biochemical abnormalities.  
 
Pelizaeus-Merzbacher disease (PMD) is a rare disorder of the CNS caused by 
mutations in the PLP gene that encodes two proteins in the oligodendrocyte: PLP and 
DM20 (smaller isoform of the PLP protein). The severity of the symptoms varies 
depending on the mutation, with mutations that only affect PLP being less severe 
(Pearlman and Mar, 2012). The main symptoms of PMD are delays in coordination, 
motor abilities and intellectual function, although motor skills are more affected then 
intellectual skills, such as memory and language. Since PMD can be caused by 
multiple types of mutations, there are also different animal models described in the 
literature that attempt to mimic this pathology (Gruenenfelder et al., 2011). The 
myelin deficient (md) rat overexpresses PLP and simulates the more severe case of 
PMD with demyelination and early death (Cziza and Lahunta, 1979; Jackson and 
Duncan, 1988). A mouse model termed jimpy also mimics PMD by decreased 
expression of PLP, with these mice showing hypomyelination and early 
oligodendrocyte death (Wight et al., 2007). The fact that over- and under-expression 
of the PLP gene results in the same hypomyelinating phenotype indicates that the 
PLP gene is dosage sensitive (Griffiths et al., 1995). 
 
 
1.3 Anatomy of myelination 
 
Many models of actual myelin wrapping and formation have been described over the 
years with the help of electron microscopic (EM) data. One of these models, “carpet 
crawler” (Sobottka et al., 2011), describes the myelination process as an analogy to 
rolling up a carpet, where the glial cell establishes contact with the axon, defines the 
size of the internode, extends a process along the axon with the specific width 
required and rolls several layers of myelin conferring a smooth aspect to myelin 
(Bunge et al., 1989). This model has shortcomings since other EM studies have 
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reported that the myelin surface is not smooth or concentrical (Knobler et al., 1976). 
A different model that tried to reconcile these differences, termed the “serpent” 
model (Sobottka et al., 2011), describes that myelination is made in a spiral fashion 
(since myelin proteins have been observed forming a helical pattern along the 
internode) (Brockschnieder et al., 2006), wrapping myelin in a unidirectional way 
along the axon (Pedraza et al., 2009). The divergences in both these models have 
recently been addressed by two different groups that suggest complementary 
myelination models. The fact that there are different observations is an indicator that 
all of these models may all be part of the myelination process.   
 
Sobottka and co-workers published their findings describing a new myelination 
model termed the “liquid croissant” model based on data from high-resolution 
confocal time lapse imaging of organotypic cerebellar slice cultures. Myelination is 
described as being driven bidirectionally in a coiled manner, with the non-smooth 
myelin surface wrapped around the axon in a triangular shape (Sobottka et al., 2011). 
Interestingly, another model has been described recently based on time lapse analysis 
of in vitro (myelinating cultures of mouse spinal cord) and ex vivo (spinal cord 
explants of shiverer mice) data. In this model myelination is defined by wrapping in 
a corkscrew fashion followed by a longitudinal extension of the membrane to form 
the concentrical structure observed by EM (Ioannidou et al., 2012). 
 
The fact that all of these models depict a different way of wrapping and extending 
processes suggests that the entire process of myelin formation is a very complex one 
that might encapsulate either different forms of myelination in different areas of the 
brain, or that all of these models are complementary and represent different stages of 
the myelination process. 
 
Oligodendrocytes and Schwann cells have the ability to myelinate different sizes of 
axons. While the Schwann cell myelinates only one internode it is known that these 
can have different lengths; the same applies to oligodendrocytes that extend and 
contact multiple axons and myelinate different internodes at one time. The 
complexity of this problem has been a long-lasting debate, trying to understand if 
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this is an intrinsic ability of the glial cells, if it is controlled by the axon, or if this 
process is influenced mutually by glial cells and neurons. 
 
Friede showed that there is a tight relation between the diameter of the axon and the 
thickness of the myelin sheath, termed the g-ratio, characterized by the ratio between 
the inner and outer circumferences of the myelin sheath (Fig. 1.6) (Friede, 1972). 
The g-ratio is an indicator of optimal axonal myelination with its value representing 
the optimal myelin thickness required to achieve maximum efficiency of conduction. 
The optimal g-ratio value can be theoretically calculated by taking into account 
axonal volume. In 2009, it was reported that the optimal g-ratio value for CNS is 
approximately 0.77, whilst in the PNS is approximately 0.6 (Chomiak and Hu, 2009).  
 
Figure 1.6 – G-ratio as an indicator of optimal axonal myelination. The ratio between the 
axon diameter and the axon diameter with the myelin layer (g-ratio) is used to analyse 
myelin morphology and thickness. 
    
With a different range of axon diameters (although the diameter is maintained along 
the length of the axon (Friede and Martinez, 1970)), the question remains: how does 
a glial cell determine which axon to myelinate and how many wraps to make? 
 
One of the approaches taken by Elder and co-workers was to generate mutant mice 
lacking either midsize or heavy neurofilament subunits, or both, leading in all three 
cases to a decrease in axon diameter of myelinating axons. This work showed that 
the intrinsic process of establishing myelin sheath thickness differs from 
oligodendrocyte to Schwann cells. In these mice, the PNS fibres were 
hypermyelinated: the amount of myelin wrapped around the axons corresponded to 
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the thickness observed in normal caliber axons. These shows that Schwann cell-
mediated myelination is not dependent on axon size. As for the CNS, 
oligodendrocytes are more complex due to their ability to establish multiple 
internodes on different axons that might have different diameters, thus demanding a 
more complex mechanism where each process has to contact an axon and decide the 
correct amount of myelin to generate. Interestingly, these mice do not show major 
myelinating defects in the CNS, with oligodendrocytes myelinating each axon with 
the correct number of sheaths expected for its diameter, which demonstrates the 
oligodendrocytes’ ability to adjust its myelin production to axonal size (Elder et al., 
2001). 
 
Recent research has proposed a mechanism by which oligodendrocytes regulate 
myelin sheath thickness. Furusho and co-workers analyzed two lines of mice that 
lacked the fibroblast growth factor (FGF) receptor 1 and receptor 2 in 
oligodendrocytes. FGF has previously been shown to have a role in oligodendrocyte 
precursor cell proliferation and differentiation (reviewed by Webster, 1997). These 
mice show no defect in terms of proliferation or differentiation, with the main 
phenotype being hypomyelination and decreased expression of major myelin genes, 
such as MBP and PLP. Due to the fact that no changes where seen in the earlier 
stages of myelination,  this work suggests that FGF receptors are important 
regulators of late stages of myelination by regulating the amount of sheaths wrapped 
around axons in accordance to diameter (Furusho et al., 2012). 
 
Oligodendrocytes arise from distinct regions of the subventricular zone and have 
different migratory pathways, with some oligodendrocytes making their way to the 
optic nerve (area characterized by small diameter axons) or spinal cord (area that 
comprises a mixture of small and large axons) for example. It was thought that 
oligodendrocytes had an intrinsic commitment to myelinate the type of axon caliber 
related to the region from which they originated. In 1998, Fanarraga and co-workers 
reported that oligodendrocytes are not committed to myelinate specific sizes of 
axons, using transplantation of oligodendrocytes from the optic nerve into 
demyelinating regions of the spinal cord. If these oligodendrocytes had the innate 
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ability to only myelinate a specific size of axon and wrap a specific number of 
sheaths, they would retain this property and only myelinate the smaller axons in the 
region, or only produce a set amount of myelin sheaths around any given axon. This 
experiment showed that oligodendrocytes are actually able to adapt and judge the 
axonal dimensions of the neurons they contact, since the oligodendrocytes from the 
optic nerve could correctly identify the size of the axon and myelinate accordingly 
(Fanarraga et al., 1998).  
 
Other animal models of myelination can also prove very useful in answering this 
question. Zebrafish has been established as one of these models and recent work 
where mutated fish acquire several extra Mauthner axons (zebrafish possess two of 
this large caliber axons, one for each half of the body) showed that oligodendrocyte 
myelination can be regulated by an increased number of axons. Oligodendrocytes 
that normally would only myelinate one of these axons were able to myelinate 
several of this very large caliber axons. Additionally, oligodendrocytes that would 
commonly myelinate only small diameter axons could also myelinate large caliber 
ones. This represents a new perspective on the idea that oligodendrocytes could only 
myelinate either several small caliber axons, or few large diameter axons, since this 
work shows that oligodendrocytes have the ability to myelinate different sizes of 
axons simultaneously (Almeida et al., 2011). 
 
 
1.4 Molecular regulation of myelination 
 
Myelination is characterized by the extension of processes, selection of the axons to 
myelinate, initiation of axoglial contact, followed by the initial wrapping, regulation 
of myelin thickness and assembly of the nodes of Ranvier, and finally the 
compaction of myelin (Fig. 1.7). 




Figure 1.7 – Different stages of oligodendrocyte development. Oligodendrocytes extend 
several processes and contact axons in order to initiate myelination. Oligodendrocytes are 
able to sense the axon diameter and ensheath the correct number of wraps and form the 
compact myelin sheath.   
Reproduced from http://www.crm.ed.ac.uk/research/group/myelination-and-repair-cns 
 
 
1.4.1  Initiation – axoglial contact and extension 
 
One of the most crucial events in myelination is axoglial contact. Oligodendrocyte 
development comprises a series of overlapping stages during which the cells migrate 
and proliferate. Oligodendrocytes able to establish axonal contact will differentiate 
and become myelinating cells, while those who fail undergo apoptosis (Barres et al., 
1992, Trapp et al., 1997). Cells which eventually become myelinating cells associate 
with an axon, establish axoglial contact, define the appropriate myelin thickness, and 
extend membranes in order to wrap the myelin sheath. 
 
Throughout the nervous system it is possible to encounter myelinated and 
unmyelinated axons. The reason why some axons are kept unmyelinated is not fully 
understood, although it is known that there is a diameter threshold for axons to be 
myelinated (1 µm in the PNS and 0.1 µm in the CNS) (Waxman and Bennett, 1972; 
Voyvodic, 1989). This suggests that the axon controls the signal read by the glial cell 
which needs to assess whether or not that axon is meant to be myelinated. It has been 
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proposed that these small caliber axons are not myelinated in accordance to 
physiological properties, since being ensheathed by a myelin layer probably would 
not enhance the rates of nerve impulse conduction (reviewed by Sherman and 
Brophy, 2005). These unmyelinated fibres express L1 and neural cell adhesion 
molecule (NCAM) which are downregulated in myelinated axons, which would be 
an indicator that these adhesion molecules negatively regulate myelination (Charles 
et al., 2002; Haney et al., 1999). It is known that L1 can regulate axonal outgrowth 
and maintenance of axoglial interactions in both PNS and CNS (Nave and Trapp, 
2008; Coman et al., 2005) but since the L1 knockout mouse shows no defects in 
myelination (Cohen et al., 1998), it is currently not possible to conclude whether L1 
is responsible for determining whether an axon will be myelinated. 
 
Unlike the PNS, where growth factor neuregulin 1 type III has been identified as a 
pivotal signaling molecule that regulates myelination (Michailov et al., 2004; 
Taveggia at al., 2005), in the CNS such a signal remains to be identified. 
Neuregulins and their ErbB receptor family are key regulators of Schwann cell 
development and myelination (reviewed by Birchmeier and Nave, 2008; Birchmeier, 
2009). Neuregulin 1 type III is expressed on the axonal surface and in the PNS can 
regulate whether an axon is myelinated and the myelin thickness (Michailov et al., 
2004; Taveggia at al., 2005). Studies in the CNS on neuregulin 1 type III are 
controversial and do not seem to support this same role as in the PNS. A full 
description of neuregulin regulation and the PNS/CNS paradigm will be further 
discussed in Chapter 4. 
 
Integrins (and their ligand: laminins) are also candidates to play a role in the 
initiation of myelination. Laminin-2 can enhance myelination in oligodendrocytes in 
culture (Buttery and ffrench-Constant, 1999) and the lack of lamininα2 in mice and 
humans leads to a dysmyelinating phenotype (Jones et al., 2001; Chun et al., 2003). 
It has been established that α6β1 integrin, a receptor for laminin expressed by 
oligodendrocytes at the time of myelination, regulates oligodendrocyte survival 
signaling by amplification of neuregulin activity (Colognato et al., 2002). 
Furthermore, integrin β1 can delay initiation of myelination on small caliber axons. 
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Using a dominant negative β1 integrin under control of the MBP promoter 
(expressed only in oligodendrocytes), it was observed a reduction in the number of 
internodes produced by each oligodendrocyte suggesting that these oligodendrocytes 
produce less myelin, and a higher axonal diameter threshold is required for 
myelination (Câmara et al., 2009). An overview of the role of integrins and 
associated signaling pathways will be presented in Chapter 3. 
 
The activity of GTPases such as Cdc42, Rac1 and RhoA (expressed by 
oligodendrocytes (Esrchbamer et al., 2005)) can be modulated by integrins which 
influence oligodendrocyte development. Liang and co-workers (2004) showed that 
Cdc42 and Rac1 can promote process extension and branching, on the other hand 
RhoA seems to have the opposite effect and act as an inhibitor (Liang et al., 2004). 
Two years later it was described that Cdc42 and Rac1 have a stage-specific and 
crucial role in myelination. When Cdc42, Rac1, or both, where inactivated in CNP-
expressing oligodendrocytes, myelination was abnormal, presenting outfoldings due 
to a defect in compaction with accumulation of cytoplasm that progressively 
worsened with age (Thurnherr et al,. 2006). Since both these GTPases are known 
cytoskeletal regulators, their ablation during myelination and the consequent 
phenotype shows that cytoskeletal organization is necessary for cytoplasm exclusion 
and myelin compaction. 
 
Neurotrophins, a family of target-derived growth factors, also play a role in the 
initial stage of myelination. The brain-derived neurotrophin factor (BDNF) promotes 
myelination by binding to glial p75 receptor (Chan et al., 2006). In the PNS, BDNF 
binds to the truncated tropomyosin receptor kinase (Trk) B to limit myelination 
whilst in the CNS, BDNF binds to the full-length Trk molecules and promotes 
differentiation (Xiao et al., 2009). Nerve growth factor (NGF), a prototypical 
neurotrophin has contrasting effects in Schwann cells and oligodendrocytes. NGF 
promotes myelination in the PNS and inhibits it in the CNS, which indicates that 
these cells respond differently to the same axonal signals (Chan et al., 2004). 
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Netrins are a family of secreted molecules. Netrin1 is widely expressed by neurons 
and oligodendrocytes in the CNS of adult mammals (Ellezam et al., 2001; Manitt et 
al., 2001). Netrin1 and its receptor deleted in colorectal cancer (DCC) have been 
described as important factors for axonal path finding, acting either as attracting cues 
(Kennedy et al., 1994; Metin et al., 1997) or as repellents (Colamarino and Tessier-
Lavigne, 1995; Guthrie and Pini, 1995). Other than affecting glial recruitment, 
netrins have also been shown to a have a role in CNS myelination by promoting 
oligodendrocyte branching and membrane extension via Fyn and RhoA 
(Rajasekharan et al., 2009).   
 
There is a current debate as to whether electrical activity of axons is required to 
initiate myelination. Axonal electrical activity has been shown to modulate 
oligodendrocyte proliferation and myelination. Adding tetrodotoxin (TTX), which 
blocks sodium-dependent action potentials, decreases OPC numbers by 80% (Barres 
and Raff, 1993) and blocks myelination in vivo and in vitro (Demerens et al., 1996; 
Stevens et al., 2002). A recent study where DRG neurons were treated with 
botulinum toxin A (BnTX) showed activity-dependent regulation of MBP synthesis 
which regulates initiation of myelin formation by oligodendrocytes on electrically 
active axons (Wake et al., 2011). However, oligodendrocytes are able to myelinate 
fixed neurons which lack axonal activity (Rosenberg et al., 2008), suggesting that 
other axonal factors may encourage myelination. In the PNS, release of adenoside 
triphosphate (ATP) dependent on axonal activity acts on purinergic receptors and 
inhibits myelination (Stevens and Fields, 2000).  
 
Myelination requires a fine balance between positive and inhibitory signals to 
successfully control the timing of myelination. One of these inhibitory factors is 
Notch, a cell surface protein family that comprises four members. Its signalling 
pathway is crucial for glial cell development and myelination in the nervous system. 
The type of ligand defines whether the signalling pathway will follow the canonical 
or non-canonical route, with Jagged1 being responsible for the canonical and Deltex 
for the non-canonical signalling pathway. Oligodendrocytes only express Notch1, 
known to inhibit both oligodendrocyte maturation and myelination (reviewed by 
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Jurynczyk and Selmaj, 2010). When OPCs were cultured with Jagged1 expressing 
cells or a soluble form of Jagged1, they fail to extend processes and differentiate 
(Wang et al., 2008; John et al., 2002). In mice with deficient expression of Notch1 
signalling, myelination is increased (Givogry et al., 2002), whilst blocking Notch1 in 
OPCs leads to promotion of differentiation (Zhang et al., 2009). Notch influences 
oligodendrocyte differentiation and myelination in a time-dependent manner, since 
there is a decline of Jagged1 expression during development in the rat optic nerve 
(Wang et al., 1998). In the PNS, Schwann cells express Notch1, whilst Jagged1 is 
expressed by Schwann cells and neurons. Notch 1 promotes Schwann cell maturation 





In order to successfully myelinate an axon, glial cells have to synthesize large 
amounts of myelin proteins and lipids, trigger the polarisation of plasma membrane 
in order to form myelin, and contact an axon to myelinate. After the axoglial contact 
has been established, the glial cell has to wrap the axon with the correct amount of 
layers to properly insulate the neuron. Zebrafish studies showed that process 
extension is a dynamic process with oligodendrocytes establishing axoglial contact 
but also retracting some of its processes before fully committing to myelination, 
which can be explained by the need to regulate a constant spacing of 
oligodendrocytes and uniform nodes (Kirby et al., 2006).  
 
During myelination glial cells undergo a dramatic change of shape mediated by the 
reorganization of the actin cytoskeleton (Novak et al., 2011). The oligodendrocyte 
cytoskeleton comprises microtubules and microfilaments, but unlike Schwann cells, 
do not have intermediate filaments. In the CNS, microtubules accumulate in the cell 
body and myelin processes and are involved in primary process outgrowth and basic 
process stability, whilst microfilaments extend continuously from the cell body to the 
cells’ periphery and are responsible for their long term stability (reviewed by Bauer 
et al., 2009). 




Despite the fact that it is relatively easy to observe initial stages of myelination, the 
late process of wrapping is difficult to examine. Much research has been carried out 
regarding oligodendrocyte development, but not much is known about the wrapping 
and compaction processes. Brockschnieder and colleagues used microarray 
expression profiling of oligodendrocyte-ablated mutant mice (where 
oligodendrocytes express a diphetheria toxin receptor and mice were treated with the 
toxin) to delve into the mechanisms of wrapping and compaction. A cytoskeletal 
protein expressed exclusively in oligodendrocytes was identified, Ermin. This protein 
is mainly expressed during late stages of myelination (expressed exclusively in MBP 
expressing oligodendrocytes) suggesting a role in the cytoskeleton rearrangement 
necessary for myelin wrapping and/or compaction. Ermin binds to F-actin and 
reorganizes it, showing the ability to modify cell shape and induce process extension 
(Brockschnieder et al., 2006). 
 
Contrary to the CNS, in the PNS different signals have been shown to have a role in 
process extension and wrapping. When Schwann cells’ cytoskeleton is disturbed via 
actin polymerization inhibitor cytochalasin D or by blocking myosin II, myelin 
wrapping decreases (Fernandez-Valle et al., 1997; Wang et al., 2008). Different 
members of the Rho-GTPase family have been implicated in the process of 
wrapping. Process branching and intermodal length are regulated by Rho signalling 
(Pereira et al., 2009; Melendez-Vasquez et al., 2004), while Rac1 in conjunction 
with β1 integrin regulate process extension (Benninger et al., 2007) and Cdc42 is 
involved in axon ensheathment and promotes Schwann cell decision to become a 
myelinating cell (Benninger et al., 2007; Krause et al., 2008). Recent data has 
identified the Neural Wiskott–Aldrich syndrome protein (N-WASP) as a regulator of 










The process of myelin compaction that occurs after wrapping is characterized by the 
extrusion of cytoplasm towards the edges of each myelinated internode and the 
formation of the node of Ranvier. The compaction of the several membrane wraps is 
formed by the apposition of external surfaces (named intraperiod lines) and internal 
surfaces (termed major dense lines) of the glial cell. This periodic ultrastructure can 
be observed by electron microscopy, where it is possible to identify the periaxonal 
space (extracellular gap between the first layer of myelin and the axon) and an area 
of uncompacted myelin which contains cytoplasmic matrix, enriched with specific 
proteins and forming the paranodal loops. Glial cells wrap myelin in the internode 
leaving unmyelinated gaps where Na
+
 channels cluster, the node of Ranvier, where 
action potentials are generated (Pfeiffer et al, 1993) (Fig. 1.8). 
 
 
Figure 1.8 – Structural composition of compact myelin and its proteins. Compact 
myelin is formed by the fusion of the intermodal glial membranes, comprising the  
intraperiod lines (IPL – represented as a double structure) and the major dense lines (MDL).   
Adapted from Jahn et al., 2009 
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2’,3’-cyclic nucleotide 3’-phosphodiesterase (CNP) is one of the markers used for 
myelinating oligodendrocytes. CNP is present in the cytoplasm of the myelin 
membrane of oligodendrocytes but it is absent in compacted myelin. It has been 
previously described to impact oligodendrocyte migration, membrane expansion 
during myelination and also to inhibit MBP accumulation and myelin compaction 
(reviewed by Fulton and Campagnoni, 2010). Trapp and co-workers described the 
localization of CNP in high concentration in the developing oligodendrocyte ahead 
of myelin compaction (Trapp et al., 1988) and transfection of CNP into non-
myelinating cells promotes the production of filopodia and process extension (De 
Angelis and Braun, 1994). Transgenic mice overexpressing CNP produce an 
abnormal myelin membrane, and compact myelin has a decrease in major dense lines 
(MDL) which have reduced expression of MBP and increased levels of CNP (Yin et 
al., 1997). The observation that CNP affects myelin compaction is also consistent 
with the phenotype observed in shiverer mice that lack MBP, which have a complete 
absence of MDL (Roach et al., 1983).  
 
CNP expression can also be modulated by thyroid hormone (TH), since 
oligodendrocytes express active receptors for TH (Fierro-Renoy et al., 1995), which 
regulates the synthesis of enzymes crucial for expression of myelin proteins and 
lipids (Rodriguez-Peña et al., 1993). Neonatal hypothyroidism presents itself with 
delayed myelinogenesis, diminishing number of myelinated axons, and decreased 
myelin gene expression (Guadaño Ferraz et al., 1994; Muñoz et al., 1991).  The 
myelin markers appear in a timely sequential manner, with CNP expression 
occurring prior to the expression of MBP, PLP (Lemke, 1993) and MOG (Pfeiffer et 
al., 1993) in oligodendrocyte development. In the hypothyroid rodent model CNP 
expression is transiently impaired (Kanfer et al., 1989). Myelinogenesis is dependent 
of TH and PDGF. In the presence of PDGF but absence of TH, OPC proliferation 
and differentiation are blocked. The rescue experiment where TH is added only 
promotes differentiation (Barres et al., 1994). Further studies in hypothyroid rodent 
models showed a delayed expression of CNP, an abnormal distribution of CNP that 
resulted in less myelin compaction, and an ablation of the number of CNP expressing 
axons (Barradas et al., 2000).   
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The glycoprotein P0 is the most abundant protein in PNS myelin and plays a crucial 
role in myelin compaction and stability. Rodent models with mutations in the MPZ 
gene, that encodes P0, lead to myelin disruption (Uyemura et al., 1994; Warner et 
al., 1996).  Studies using an in vitro membrane-mimetic system showed that P0 
needs to undergo a specific conformational change in order for myelin compaction to 
be successful and promote myelin stability. This conformational change of the P0 
protein occurs faster when in the presence of cholesterol, which is abundant in the 
myelin layer, suggesting an interaction between proteins and lipids from the myelin 
membrane to achieve compaction (Luo et al., 2007). Similarly to the CNP mutant 
mice, Martini and co-workers have described that double mutations on the P0 and 
MBP protein lead to absence of MDL in the PNS. However, when mice are deficient 
only in P0, they can partially compact myelin. MBP deficiency shows the presence 
of MDL in compacted myelin, suggesting that both proteins engage in the process of 
MDL generation (Martini et al., 1995).   
 
Evolution of myelination enabled a faster propagation of the nervous impulse with a 
decreased energy requirement, when compared to unmyelinated fibres. The rapid 
conduction allowed by myelination was crucial for the development of a complex, 
yet compact, nervous system but myelination and glial cells conferred other 
advantages such as maintenance of neuronal integrity and survival. This property is 
independent of myelination and is due to the lifelong interaction between the glial 
cell and corresponding axon. Mice with mutations in the PMP22 (trembler mice) and 
MBP (shiverer mice) proteins present a dysmyelinating phenotype that translates into 
a reduction of axonal calibre (Brady et al., 1999; de Waegh et al, 1992), suggesting 
an additional role for myelination other than enabling fast conduction. Trembler mice 
show demyelination in large calibre axons that undergo repeated myelination and 
demyelination, resulting in little or no compact myelin explained by changes in the 
cytoskeleton (Low, 1976a,b). Further studies in other models of PNS 
hypomyelination corroborate the view that myelination regulates cytoskeleton 
assembly (Cole et al., 1994; Hsieh et al., 1994; Mata et al., 1992).  In the CNS, 
similar studies were carried out by analysing the shiverer mouse (which owes its 
name due to their “shivering” phenotype). These mice lack compact myelin in the 
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CNS due to the absence of MBP and show no significant alterations in the PNS apart 
from a mild hypomyelination (Gould et at., 1995), this might be explained by 
compensation of loss of MBP by P0  (Rosenbluth, 1980). These mice present a 
decreased rate of axonal transport, altered cytoskeletal structure, decreased axon 
diameter and neuronal gene expression, arguing that assembly of compact myelin is 
necessary for maturation of neuronal cytoskeleton in large diameter axons of the 
CNS (Brady et al., 1999). MBP homozygotic mice express approximately ¼ of 
normal MBP levels and have a higher g-ratio (ie, thinner myelin sheaths) but these 
seems to be enough to alleviate the “shivering” phenotype and increase life span 
(Readhead et al., 1987). 
 
Myelination comprises an initial stage of axonal recognition, where the glial cell 
establishes contact with the axon to myelinate. Intrinsic and extrinsic cues allow the 
glial cell to sense the axon calibre, extend processes and start the ensheathment of the 
internode, leaving unmyelinated gaps (node of Ranvier), assembling the paranodal 
loop and compacting myelin by extrusion of cytosol followed by the elongation of 
the myelin unit (Fig 1.9). Myelin not only enhances nerve conduction but also 
provides neuronal support. Neuronal loss is often a result of long term demyelination 
although observations of demyelinating models has demonstrated that demyelination 
is not equivalent to axonal loss. Since we cannot establish an interdependent 
mechanism between the degree of demyelination and axon loss, it is evident that 
other mechanisms other than myelin loss are involved in axon degeneration 
(reviewed by Nave and Trapp, 2008). Lappe-Siefke and colleagues examined 
transgenic mice with inactivated CNP protein and showed that this protein is 
essential for axonal survival. These mice demonstrated axonal swelling and 
neurodegeneration, but the structure of the myelin was not compromised, showing 
evidence that myelination per se is not sufficient to promote axonal survival, it is 
also necessary for glial support (Lappe-Siefke et al., 2003). 




Figure 1.9 – Overview of the myelination process. Oligodendrocytes differentiate into 
myelinating glia and upon axonal contact extend a lipidic membrane, myelin, that provides 
insulation and a faster propagation of the nervous impulse between the nodes of Ranvier. 
Myelination is a tightly regulated process with oligodendrocytes wrapping only the necessary 
number of myelin sheath necessary to enable rapid impulse conduction. Image kindly 
provided by Dr. Nina Bauer. 
 
 
1.5 Project overview 
 
The nervous system and myelination have been thoroughly investigated over the 
years. It is clear that although involving different glial cells, PNS and CNS 
myelination have diverged from the same process and share the same function: 
enhancing impulse propagation. PNS has been the most described and researchers 
continusouly attempt to apply these observations to central myelination, but it is clear 
that a far more complex process occurs in oligodendrocytes, either as a preventative 
mechanism to avoid major impairments or due to the natural evolution of these cells. 
Myelin membrane is one of the most studied membranes due to the fact that it is easy 
to isolate and purify, which has enabled us to understand its composition, but far 
more remains unknown. So far, the scientific community is still trying to find an 
adequate model for myelination and understand how the deposition of myelin occurs.  
 
One of the key features of myelination is the axoglial contact. Glial cells need to 
establish contact with an axon and wrap a precise number of myelin sheaths to 
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ensure an appropriate insulation of the axon. The work described in this thesis 
attempts to clarify some of the mechanisms involved in the axoglial contact by 
showing that β1 integrin regulates the initial axoglial contact and provides a 
threshold for myelination. In the PNS, such molecules that regulate the myelination 
process have been previously described. Neuregulin 1 type III can regulate the 
myelin thickness and the overexpression of neuregulin 1 type III in the PNS leads to 
myelination of axons that are normally unmyelinated (Taveggia et al., 2005). In the 
CNS, it is thought that a complex of molecules and parallel pathways regulate the 
initiation of myelination. Our hypothesis is that β1 integrin would act in concert with 
neuregulin 1 type III, but no effect was shown, leading to the conclusion that there 
are compensatory mechanisms to the disruption of signalling of both molecules. 
 
Interestingly, although neuregulin 1 does not regulate myelination in the CNS, it has 
been linked as a genetic susceptibility factor for schizophrenia. Analysis of post-
mortem brains of schizophrenic patients shows an increased expression of neuregulin 
1 type IV. Patients often show decreased white matter volume that is thought to 
direct a loss of cognitive skills. Here we show that overexpression of neuregulin 1 




The central hypothesis of this PhD project is that integrins and neuregulins regulate 
the axoglial signals that control myelination in the central nervous system. 
 
Statement of aims 
1. To characterize myelination in the dominant negative β1 integrin mice by 
electron microscopy 
2. To characterize myelination in transgenic mice used as control for dominant 
negative β1 integrin mice (ie, dominant negative β3 integrin mice, β1 integrin 
knockout mice, focal adhesion kinase knockout mice) by electron microscopy 
3. To characterize myelination in mice crossed between dominant negative β1 
integrin and neuregulin 1 type III heterozygous mice by electron microscopy 
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4. To characterize myelination in mice overexpressing neuregulin 1 type IV by 
















Materials and Methods 
 




Material and Methods 
 
This chapter describes general materials and methods used for the work this PhD 
thesis concerns.  
 
 
2.1. Transgenic mice (dominant negative 1, 
dominant-negative 3, 1 integrin knockout, FAK 
knockout, dominant negative 1 integrin// 
neuregulin 1 type III
+/-
, neuregulin 1 type IV 
overexpressing mice) 
 
Dominant negative β1 (dnβ1) and β3 (dnβ3) mice were produced by Dr. Joana 
Câmara under the MBP promoter and are described elsewhere (Câmara et al., 2009). 
Focal adhesion kinase (FAK) knockout mice were provided by Professor Peter 
Brophy’s group, in Edinburgh, under the CNP promoter and are described by Grove 
and co-workers (Grove et al., 2007). Promoters drive specific expression in pre-
myelinating oligodendrocytes.  1 integrin knockout mice were provided by Dr. João 
Relvas’s group, in Zurich, using the CNP promoter and have been previously 
described by Benninger and co-workers (Benninger et al., 2006). Neuregulin 1 type 
III
+/-
 mice were provided by Dr. Carla Taveggia in Milan, and have been described in 
Wolpowitz et al., 2000. Neuregulin 1 type IV overexpressing mice were provided by 
Dr. Amanda Law (Maryland, USA) and have been described elsewhere (Deakin et 
al., 2009). With exception for dnβ1, dnβ3 and dnβ1//neuregulin 1 type III
+/- 
mice all 
other mice were bred, genotyped and perfused in the respective labs that provided 
them and tissue was shipped to our lab for dissection and processing for electron 
microscopy. 




All animal work was done in accordance with the UK Animals (Scientific 
Procedures) Act, 1986 and had local ethical approval. Animals were kept in 
contained cages with ad libitum water and food supplies, and a 12h light/dark cycle.  
 
Animals were not randomized due to the genetic nature of the experiments, since 
most of the mutations are either chromosome linked or have a 50% inheritance. 
Littermates were used as transgenic and control, since the transgenic approach was 
not dominant. Unless otherwise stated, all animals used in the work described in this 
thesis were males. All experiments were done blind, all male offspring was 





2.2.1 Dominant negative β1 and β3 integrin mice 
 
Ear notch biopsies were collected from animals and incubated in 1 mg/ml of 
proteinase K (Sigma) containing lysis buffer (100 mM Tris-HCl, pH 8.5, 5 mM 
EDTA, pH 8.0, 0.2% SDS, 200mM NaCl) overnight at 55ºC to digest the tissue and 
destroy proteins. The following morning, samples were vortexed vigorously and 
boiled at 95ºC for 10 minutes to inactivate Proteinase K. A 1 in 20 dilution of the 
previously described sample was prepared to be use in the PCR reaction. For each 
sample two different reactions were prepared, one to identify the wildtype allele 
(Primers: Pf - HPRT mus (5’ - gagggagaaaaatgcggagtg - 3’) and Pr - HPRT mus (5’- 
ctccggaaagcagtgaggtaag - 3’)) and the other for the transgenic allele (IL2R/MBP 
Primers: Pf - ESIL2RB1II (5’-cagagcttgtgcattgacattg-3’) and Pr: pE9.5 (5’- 
ggctgcaggaattcgatatca - 3’)), both producing a 300 bp band.  
 
PCR reactions were prepared to a final volume of 25 l, according to the following 
ratios: 13.65 l of PCR water, 2.5 l of Buffer Taq, 1 l dNTPs (stock at 10 mM), 1 
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l Pf, 1 l Pr, 1.6 l DMSO, 4 l DNA and 0.25 l of Taq polymerase. A negative 
control reaction was prepared in parallel with the volume of DNA substituted by 
distilled water. 
 
The PCR reactions were submitted to a PCR thermocycle of: 
-94 C     3 minute 
-94 C     1 minute  
-58 C     1 minute  
-62 C     1 minute  
-72 C     1 minute  
     * repeated the last 4 steps 29 times 
-72 C      10 minutes 
 
The products of the PCR reaction were run in a 1.5% - agarose/TBE gel together 
with a 100bp DNA ladder.  
 
2.2.2 Dominant negative 1 integrin//neuregulin 1 type III+/- 
mice 
 
These mice had to be genotyped for both transgenes: dominant negative β1 integrin 
(explained above) and for the neuregulin 1 type III mutation (detailed below). 
 
Tail pieces were collected from mice (0.6 - 0.8 cm) and digested overnight at 55°C in 
lysis buffer (100 mM Tris-HCl, pH 8.5, 5 mM EDTA, pH 8.0, 0.2% SDS, 200mM 
NaCl) with 5 ml of 10mg/ml Proteinase K. The following morning the DNA was 
extracted with 500 µl of phenol/chlorophorm/isoamyl alchol 25:24:1. The DNA was 
precipitated with ice cold 100% EtOH followed by one wash in cold 80% EtOH and 
finally re-suspended in 200 µl TE. 
 
A PCR reaction was performed using the GO Tak kit (Promega) according to 
manufacturer instruction. Succinctly: a PCR reaction of a final volume of 25 µl was 
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prepared with 5 µl GoTaq Flexi Buffer 5X (Promega), 2.5 µl MgCl2 (25mM), 1 µl 
dNTP mix (10mM), 1 µl 1960GUP (5’- actttcttcttcccattctgt -3’), 1 µl 3622GWT (5’- 
tttactcttcctttacggtcta -3’), 1 µl 2462GMUT (5’- tttctcttgattcccactttg -3’), 1 µl DNA 
solution, 12.25 µl of H2O for PCR and 0.25 µl GoTaq Polymerase (Promega). 
 
The PCR sample submitted to a PCR thermo cycle: 
- 94ºC     4 minutes 
-94ºC     30 seconds 
-72ºC     1 minute 
-72ºC     1 minute 
  * The last 3 steps repeated 35 times 
-72ºC    7 minutes 
 
The PCR product was run on a 2% agarose – TBE gel for 1 hour at 100V, with a 
100bp DNA ladder. 
The wildtype allele was identified by a 700 bp and heterozygous with double bands 
with 700bp and 734bp.  
 
Genotyping of all other transgenic animals used in this thesis was performed by the 
laboratories providing the samples and encoded to ensure a blind analysis in order to 




Animals were anesthetized by injecting 25 l euthatal (90mg/kg). Following a 
negative response to a reaction test the animal was placed in the operating table, in 
the spine position, and fixed with needles to a cork board. Ear or tail biopsies were 
collected for genotyping. Access to the heart was achieved by cutting through the rib 
cage from the diaphragm. Intracardial perfusion was achieved by insertion of a 
butterfly needle into the left ventricle, and pumped with 0.1M phosphate buffer in 
order to remove all blood from the body. With the aid of forceps the right atrium was 
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nicked to allow ensanguination, followed by perfusion of 50ml per animal of fixative 
solution (4% paraformaldehyde and 3% glutaraldehyde in 0.1M phosphate). The 
tissue of interest was excised following perfusion and emerged in the same fixative 
solution overnight at 4ºC. The following morning the tissue was rinsed twice in 0.1M 
PB and kept immerged in phosphate buffer at 4ºC until processing for electron 
microscopy. 
 
All perfusions of dominant negative β1 integrin, dominant negative β3 integrin and 
dominant negative β1 integrin // neuregulin 1 type III 
+/- 
mice was performed by the 
author of this thesis. All other transgenic animals used were perfused by the 
laboratories of the collaborators where these mice were housed. In the cases where 
the author did not perform the perfusions, the head of the animals was sent to the 
author for dissection and subsequent tissue processing and analysis. 
 
 
2.4 Embedding of samples 
 
Following fixation, tissue was incubated in 1% osmium tetroxide overnight at 4ºC in 
a dark plastic container. 
Tissues were dehydrated in a succession of 15 second baths of crescent 
concentrations of ethanol (70%, 90%, 3 times 100%). Following dehydration, the 
samples were immerged twice in propylene oxide for 15 seconds, followed by an 
overnight incubation in 50/50 propylene oxide/resine TAAB. Embed in new TAAB 
resine mix the following day. Samples dry at 60ºC overnight.  
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2.5 Electron microscopy 
 
The embedded samples were cut by the author of this thesis in the Department of 
Anatomy, University of Cambridge, and prepared using a Leica ultra-cut UCT 
microtome. Semi-thin sections were stained with methylene blue. Ultra-thin sections 
were cut and stained with saturated uranyl acetate in 50% ethanol and lead citrate, 
and ready to the electron microscope. The ultra-thin sections were examined in a 
Philips CM100 transmission electron microscope.  
 
The sections results were captured with a 3.90k magnification, and 10 to 12 different 
non-overlapping regions were chosen to take photos.   
 
 
2.6 Computational analyses 
 
G-ratio and percentage of myelinated axons measurements involve drawing the axon 
outline, and the axon outline with myelin. These were performed with Openlab 
image analysis software (Improvision). Excel (Microsoft) was used to calculate the 
axon, and axon with myelin, radius or diameter. 
 
The g-ratio measurements are the ratio between the axon radius and the axon radius 
with the myelin. The number of axons drawn was at least 100, from 5 or more non-
overlapping images for each sample.  
 
The percentage of myelinated axons was obtained by drawing the outline of all 
myelinated and unmyelinated axons. The number of axons drawn was at least 300, 
from 3 or more non-overlapping images for each sample.   
 
All computational analyses was performed by the author of this thesis. 
 
 





For imaging purposes full brains were perfused in 0.4% paraformaldehyde in 0.1M 
phosphate buffer, post-fixed over night and snap-freezed the following day. Sections 
were obtained using a cryostat and tissue morphology was assessed by H&E 
(performed at the QMRI automated service – Shandon Varistain Gemini ES) and 
luxol fast blue. 
 
 
2.7.1 Snap Freezing Brains 
 
Following perfusion and dissection of the brain, brain was post fixed (4% PFA) 
overnight at 4ªC. The next day brains were placed in 30% sucrose solution (the brain 
should float) at 4ºC. Once brain had sank (usually within 24h), brains were placed 
over a paper towel to blot the excess sucrose solution. 
 
Brains were placed in a small Petri dish and covered with OCT embedding matrix. A 
clean cut was performed to divide the brain using a razor blade. Brains were snap 
frozen in ice cold acetone, previously placed in dry ice, and left for 20 seconds. 
Frozen brains were stored at -20ºC for 24h followed by storage at -80ºC. 
 




10 m sections were cut from the frozen blocks and mounted onto Superfrost plus 
slides, previously keep at room temperature. 
 
All cryostat sectioning was carried through by the author of this thesis. 
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2.7.3 Haemotoxylin and Eosin 
 
Haemotoxylin and eosin (H&E) was performed in the Shandon Varistain Gemini 
ES, from Thermo Fisher according to manufactures instructions. Briefly, a pre-
stain step of a 3 cycles of xylene (2 minutes, 1 minute, 1 minute) was followed by 
3 cycles of alcohol (1 minute each) and rinsed with water (1 minute). 
Heamotoxilyn was added (4 minutes), rinsed with water (1 minute), followed by 
acid alcohol (15 seconds), rinsed with water (1 minute), blueing agent (1 minute), 
rinsed with water (1 minute), aqueous eosin (1 minute), rinsed with water (1 
minute). A post-stain step followed with 3 cycles of alcohol (1 minute each) and 3 
cycles of xylene (1 minute each).  
 
H&E staining was performed by the Histology Department, QMRI, Edinburgh, 
UK. 
 
2.7.4 Luxol Fast Blue 
 
Sections were stain in Luxol fast blue overnight and washed in water in the following 
morning. Sections were incubated in a 0.1% lithium carbonate bath for 5 for seconds, 
followed by 70% alcohol for 20-30 seconds. Rinsed with water for 20 seconds and 
counterstained in 0.1% cresyl violet for 10 minutes in 1% acetic acid. Sections were 
dehydrated in a crescent concentration of ethanol baths followed by clearing and 
mounting. 
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2.8 Myelinating co-cultures 
 
Dorsal Root Ganglia (DRGs) were dissected from E14 – E16 rats and digested for 50 
minutes at 37ºC with 1.2 U/ml Papain (Worthington), 0.24 mg/ml L-cystein (Sigma-
Aldrich), and 40 g/ml Dnase (Sigma-Aldrich). Papain solution was previously 
incubated for 10 minutes at 37ºC to ensure papain full activation.  DRGs were plated 
onto 22 mm coverslips pre-coated with poly-D-lysine (10 g/ml, Sigma) and growth 
factor reduced matrigel (1:40 dilution, BD Biosciences) at a density of 15 x 10
4
 
cells/ml.   
 
Neurons were grown for 17 days in dulbecco’s modified eagle’s medium (DMEM, 
Gibco) supplemented with 10%  fetal bovine serum (FCS, Gibco) and nerve growth 
gactor (NGF, 100 ng/ml, AbD Sevote). Cultures were pulsed with intercalated 
growth (NGF) and anti-mitotic (fluorodeoxyuridine – Fdu, 10 M, Sigma) factors.  
 
Oligodendrocyte precursor cells (OPCs) were obtained from forebrains of P0 to P2 
rats. Cerebral cortices were dissected and meninges removed, transferred to a small 
vial with 1ml of minimum essential medium (MEM, Gibco), triturated and 
dissociated with 1.2 U/ml Papain (Worthington), 0.24 mg/ml L-cystein (Sigma-
Aldrich), and 40 g/ml Dnase (Sigma-Aldrich). Papain solution was previously 
incubated for 10 minutes at 37ºC to ensure papain full activation.  Dissociated cells 
were plated on poly-D-Lysine (10 g/ml, Sigma) coated T75 tissue culture flasks and 
grown at 37ºC in DMEM (Gibco) supplemented with FCS (Gibco). 
 
After 10 days the OPC cultures were shaken at 250 rpm for 1 hour at 37ºC to remove 
loosely adherent microglia and debris. Medium was change, and cultures were then 
shaken again overnight (250 rpm, 37ºC) to detach the top layer of OPCs and 
remaining glia. Incubating cells in bacteriological plastic dishes (Sterilin) for 20 – 25 
minutes at 37ºC removes microglia. 
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OPCs were added to each coverslip with purified neurons at a density of 15 x 10
4
 
cells/ml in myelination medium: 250ml Neurobasal medium, 250ml of DMEM (high 
glucose), add 5ml Glutamine, 5ml Pen/Strep, 5ml insulin and transferase supplement, 
5ml of 10x Sato, 10ml B27, 500 μl NAC and 500 μl D-biotin 1000x. Made up in 
filter unit. 
 
Co-cultures were maintained for 14 days, with fresh medium added every 2 days. 
Co-cultures were treated with CD29 antibody (1 integrin blocking antibody, BD 
Pharmigen) and an IgM control antibody (1 Monoclonal Immunoglobulin Isotype 
Standard, BD Pharmigen). Different coverslips received antibody at different time 
points. These antibodies were added either at same time as OPCs (T=0), one (T=1) or 
three (T=3) days after adding OPCs. 
 




Cultures were fixed with 4% paraformaldehyde (PFA) for 10 – 15 minutes at RT, 
blocked for 20 – 30 minutes with blocking solution (PBS containing 40% Goat 
Serum (Sigma) and 0.4% Triton at RT. Rinsed with PBS, followed by incubation of 
1.30 – 2 hours with primary antibodies: rat anti-MBP (1:100), rabbit anti-NG2 ( 
1:200) and chicken anti-neurofilament (1:5000). After rinsing with PBS cells were 
incubated for 1.30 – 2 hours with secondary antibodies: MBP (Alexa 488 anti-rat 
antibody; 1:500), NG2 (Alexa 555 anti-rabbit antibody; 1:500) and neurofilament 
(Amca anti-chicken; 1:100). After secondary antibodies, coverslips were rinsed again 
with PBS and carefully placed in the middle of Superfrost Plus glass slides, with a 
drop of Flourmount-G. 
 
All immunocytochemistry was executed by the author of this thesis. 
 
 




2.8.2 Confocal microscopy and quantification 
 
10 to 12 pictures with a 20x objective for MBP, NG2 and neurofilament staining 
were taken in the Leica Confocal Microscope. For each coverslip, myelination was 
quantified by counting the number of myelinating MBP positive oligodendrocytes as 
a percentage of the total number of MBP positive oligodendrocytes. 
 
All confocal imaging was performed by the author of this thesis.  
 
2.9  Statistical Analysis  
 
Statistical analysis was performed using the GraphPad Prism software (GraphPad 
Software Inc.). Data shows mean ± SEM. G-ratio analysis using Student’s t test; 
percentage of myelination per axon diameter analysis using two-way ANOVA; 
average axon diameter and percentage of unmyelinated axons analysis using 
Student’s t test; percentage of dysmyelination analysis using Wilcoxon signed-rank 












Role of β1 integrin in central 
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Chapter 3  
 






Oligodendrocytes in the central nervous system (CNS) and Schwann cells in the 
peripheral nervous system (PNS) go through a cytoskeleton morphological change 
to produce myelin, a lipidic membrane with insulating properties that facilitates 
efficient saltatory conduction and therefore a faster propagation of the nervous 
impulse. The signals that mediate this process have long been researched and one 
of the potential regulators of myelination is a major family of extracellular matrix 




The central hypothesis is that integrins contribute to the axoglial signals regulating 
the initiation of myelination, Since most of the available data in the literature was 
performed in vitro (β1 integrin knockout mice are embryonically lethal) a new 
transgenic approach of a dominant negative β1 integrin could shed light into the role 
of integrins in myelination. 
 
Statement of aims 
1. To characterize myelination of dominant negative β1 integrin mice by 
analysing the g-ratio, percentage of myelination and percentage of 
unmyelinated axons by electron microscopy at different time points and 
different brain structures. 
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2. To quantify the percentage of oligodendrocytes in co-cultures in the presence 
of β1 integrin blocking antibody. 
3. To characterize myelination of dominant negative β3 integrin mice, used as a 
control for the transgenic approach for the generation of dominant negative 
β1 integrin mice, by analysing the percentage of myelination and percentage 
of unmyelinated axons by electron microscopy at different time points. 
4. To characterize myelination of the β1 integrin knockout mice, used as a 
control for the different expression of β1 integrin, by analysing the 
percentage of myelination and percentage of unmyelinated axons by electron 
microscopy. 
5. To characterize myelination of the focal adhesion kinase knockout mice. 
Focal adhesion kinase is a downstream signalling molecule from β1 integrin 
that should replicate the same phenotype as the dominant negative β1 integrin 
mice, by analysing the g-ratio, percentage of myelination and percentage of 
unmyelinated axons by electron microscopy at different time points. 




3.1.1 Integrins  
 
Integrins are the most abundantly expressed family of ECM-binding receptors and 
are involved in the regulation of many fundamental cellular functions such as 
proliferation, migration and survival (reviewed by ffrench-Constant, 2004).  
The term integrin was originally coined in 1987 to describe an emerging family of 
integral membrane proteins linking ECM to the cytoskeleton (Hynes, 1987). The 
term “integrin” is representative of their integrating function since they can bind 
cytoplasmic proteins, ECM ligands and soluble ligands (reviewed by Takada et al., 
2007) initiating and regulating several intracellular signalling pathways (Giancotti et 
al., 1999; Hynes, 2004; Schwartz, 2011).  
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Integrins are only present in metazoans and are conserved throughout different 
species such as mammals, chicken, zebrafish, Drosophila melanogaster and C. 
elegans, which has proven to be very important in understanding the function of 
many integrins (reviewed by Takada et al., 2007). 
 
3.1.2 Integrin structure and activation 
 
Integrins form a highly conserved family of heterodimeric transmembrane receptors 
present in all metazoans (Arnaout et al., 2005), comprising two non-covalently 
associated subunits: α and β, each encoded by separate genes. In mammals there are 
18 α subunits and 8 β subunits which can heterodimerize into 24 different integrin 
receptors, which vary in their ligand binding, cellular functions and expression 
patterns (Fig. 3.1B) (Hynes et al., 2000; Hynes, 2002).  
 
The α and β subunits that form the integrin receptor are type 1 glycoproteins 
characterized by a large cellular domain, a single transmembrane domain and a short 
cytoplasmic domain. The large transmembrane domain is responsible for ligand 
binding and comprises up to 1104 residues for the α subunits, whilst the β subunit 
has up to 778 residues. The single-spanning α-helical transmembrane domain is 
formed from 25 to 29 amino acids, and the short cytoplasmic domain which spans 
from 20-40 amino acids, to 45-60 amino acids for the α and β subunits, respectively 
(Hynes, 2002). β4 integrin is an exception as it binds to intermediate filaments 
instead of the actin filaments and therefore its cytoplasmic domain is composed of 
1018 residues (de Pereda et al., 1999). Half of the α subunits have a von Willebrand 
Factor type A domain (I/A), an additional extracellular domain of 190 amino acids 
that is the major site of ligand binding (Arnaout et al., 2005). 
 





Figure 3.1 – Integrin activation and their ligands. Integrins comprise an α and β subunit 
that can heterodimerize and are activated by ligand binding to extracellular matrix molecules. 
(A) Schematic representation of the three conformational states of integrins (inactive, primed 
and active) which exist in a dynamic equilibrium (Adapted from Luo et al., 2007). (B) The 
combination of the 18α and 8β subunits generates 24 known mammalian integrins, with 
differing ligand specificity (Adapted from Hynes, 2002). 
 
 
Xiong and co-workers published the crystal structure of the extracellular domain of 
the αvβ3 integrin (an I/A-lacking domain integrin) in its unligated form (Xiong et al., 
Chapter 3 – Integrins and myelination 
54 
 
2001) and ligated form with a RGD peptide (Xiong et al., 2002) showing that the α 
(β propeller) and the β (βI domain) subunits establish contact to form the ligand 
binding “head” region. This forms a bent conformation resulting in a low affinity 
state. The “head” region comprises two legs each with four domains. The α subunit 
leg comprises a thigh, genu/knee, calf1 and calf2 domains while the β subunit leg 
includes an immunoglobulin-like hybrid domain, a N-terminal plexin-semaphorin-
integrin (PSI) domain, four epidermal growth-factor (EGF)-like repeats and a β tail 
domain (βTD) (Fig. 3.1A). This allows integrins to adopt different conformational 
states of activation with different affinity levels; these are thought to be modulated 
either by their ligands or intracellular signals (Lou, 2006).  
 
Integrins can have three different conformational states: inactive, primed and active 
(Fig. 3.1A). The inactive state is characterised by its bent conformation and closed 
head piece and it is considered a low affinity state (Shimaoka et al., 2000). Although 
it is termed inactive, it is known to bind ligands such as fibronectin fragments (Adair 
et al., 2005). By adding Mn
2+
 or RGD peptide (ligand mimetic peptides), the integrin 
structure is extended and forms the two other known conformational states. The 
primed state (also termed intermediate stage) has a closed head piece and extended 
conformation and corresponds to an activated state with intermediate affinity. Finally 
the active state consists of an extended conformation with the head piece open and 
the presence of a ligand and corresponds to the highest affinity state (reviewed by 
Takagi and Springer, 2002).  
 
These conformational states exist in equilibrium and one of the models proposed to 
explain the conformational and activation changes is the hybrid-domain swing-out 
model. This model was based on observations made through electron microscopy by 
comparing the structure of the inactive αvβ3 and the active αIIbβ3 integrins. In these 
structures the β subunit hybrid domain undergoes a 60º shift, generating the 
separation of the α and β subunit knees (genus). It is considered that the β1 domain 
α7 helix undergoes a downward displacement due to this swing, which in turn is 
responsible for allowing accessibility to the β1 domain metal-ion-dependent adhesion 
site (MIDAS), which increases ligand affinity. Ligand binding stabilizes the 
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structural extension, but extension per se is not enough to increase affinity, a higher 
ligand-binding affinity results from conformational changes in the head piece (Xiao 
et al., 2004). The two transmembrane domains separate upon ligand binding (Luo et 
al., 2004). This activation model is specific for extended conformations, but an 
alternative deadbolt model has been suggested, since there is evidence that integrins 
are still able to bind ligands when in a bent structure (Adair et al., 2005; Arnaout et 
al., 2007; Xiong et al., 2003; Xiong et al., 2002).  
 
Integrin activation and function also depends on the short cytoplasmic domain which 
has conserved amino acid sequences both in the α and β subunit. These conserved 
amino acids are the NPxY motif in the β subunit and membrane proximal GFFKR 
(in the α subunit) and LLV-IHDR (in the β subunit) (Fig. 3.2). Integrins can be 
activated by mutations on the membrane proximal highly conserved regions, 
achieved by mutation on the arginine 935 (R in the GFFKR sequence) of the αIIb 
subunit or mutation of the aspartate 723 (D in the IHDR sequence) of the β3 subunit 
(Hughes et al., 1996; O’Toole et al., 1994). Interestingly, mutations converting 
arginine 935 into aspartate, and the aspartate 732 into arginine do not affect integrin 
activation suggesting the presence of a salt bridge between the α and β subunits that 
preserves the integrin inactive state (Hughes et al., 1996). Vinogradova and co-
workers (2002) showed by nuclear magnetic resonance imaging an interaction 
between the membrane proximal regions of the α and β subunit during their study of 
the structural mechanisms of αIIbβ3 integrin activation. In this study it is described 
how αIIbβ3 integrin can be activated by disrupting this short bridge through point 
mutations or interactions with the cytoplasmic protein talin (Vinogradova et al., 
2002). Takagi and co-workers showed that in the α5β1 integrin, the separation of the 
cytoplasmic domains can be achieved by the unclasping of the membrane proximal 
regions suggesting that separation of the cytoplasmic domains might be a mechanism 
for either initiation of inside-out signalling or a late stage of outside-in signalling 
(Takagi et al., 2001).  




Figure 3.2 – Schematic representation of the conserved domains and respective 
amino acid sequences of the α and β subunit cytoplasmic tails. Bold letters represent 
near-invariant residues, italic letters represent residues conserved in at least 3 integrin 
subunits and dashes represent non-conserved residues. The dotted line represents the salt 
bridge between R995 and D723. NPxY motifs are in blue. Adapted from Hynes, 2002 and 
Liu et al., 2000.  
 
3.1.3 Integrin bidirectional signalling  
 
The role of integrins in adhesion is characterized by the unusual feature of 
bidirectional signalling across the plasma membrane. This bidirectional signalling 
links the ECM outside the cell and the cytoskeleton inside the cell (Hynes, 2002; 
Legate et al., 2009). Inside-out signalling (also referred to as upstream signalling or 
integrin activation) is characterized by the regulation of extracellular binding affinity 
by intracellular signals. Outside-in signalling (or downstream signalling) is 
associated with ECM binding to integrin that modulates their intracellular signalling 




Inside-out activation of integrins relies on the separation of the cytoplasmic and 
transmembrane regions of the α and β subunits (Kim et al., 2003; Luo et al., 2004; 
Vinogradova et al., 2002). This separation leads to a conformational change of the 
integrins’ structure which goes from a bent to an extended conformation increasing 
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their ligand-binding affinity (Luo and Springer, 2006; Takagi and Springer, 2002). 
Work done by O’Toole and co-workers where either the full or part of the 
cytoplasmic domain was deleted, resulted in a constitutively active integrin (O’Toole 
et al., 1994; O’Toole et al., 1991).  
 
Integrins can be activated by different cytoplasmic proteins that bind to the α and β 
subunits such as calcium integrin binding protein (CIB), cytohesin-1, β3-endonexin, 
talin and kindlin-2 (Bledzka et al., 2012; Calderwood, 2004; Hughes and Pfaff, 
1998). 
 
The current model of integrin activation is based on talin. Talin is a cytoskeletal 
protein that comprises a C-terminal rod domain (responsible for dimer formation and 
encloses binding sites for vinculin and actin) and an N-terminal FERM (F for 4.1 
protein, E for ezrin, R for radixin and M for moesin) domain (also termed the head 
region) comprising the main binding sites for focal adhesion kinase (FAK) and 
phosphatidyl inositol biphosphate (PIP2) (Nayal et al., 2004; Wegener et al., 2007). 
The FERM domain comprises three subdomains: F1, F2 and F3. The F3 domain 
itself is sufficient to activate integrin, since it is a phosphotyrosine binding (PTB)-
like domain with high affinity binding properties to the β subunit (Wegener et al., 
2007). Binding of the PIP2 to talin results in the exposure of the PTB domain in the 
head region of talin, which binds the membrane proximal NPxY motif of the β 
integrin cytoplasmic domain (Garcia-Alvarez et al., 2003). This talin head interaction 
with the integrin β-tail disrupts the salt bridge between the α and β subunits, known 
to stabilise the bent conformation (Fig. 3.3) (Hughes et al., 1996; Kim et al., 2003; 
Wegener et al., 2007). The binding of talin to the β subunit is a common final step of 
integrin activation (Tadokoro et al., 2003; Tanentzapf and Brown, 2006). Recently, 
kindlin-2 was described to function in a similar way to talin to activate integrins. 
Like talin, kindling-2 also has a FERM domain and interacts with the β1 and β3 
cytoplasmic tails (whilst talin interacts with β1, β2 and β3 subunits). Bledzka and co-
workers showed that although talin and kindling-2 do not interact, they can act 
simultaneously at the β3 tail suggesting a cooperating mechanism for integrin 
activation (Bledzka et al., 2012).  
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Inside-out signalling in integrins has been associated with three major signalling 
pathways: PKC, PI3K and Ras superfamily of small GTPases pathways. 
 
 
Figure 3.3 - Integrin inside-out signalling. Upstream signalling of integrins is dependent of 
a ligand, this will lead to a disruption of the non-covalent clasp between both subunits and a 
subsequent binding of talin (hexagonal shape) which lead to a conformational change from a 
bent state to a constitutive activation of the integrin receptor. α subunit is in brown, β subunit 




Integrin inside-out activation increases the affinity binding of specific integrins to 
ECM ligands, but the avidity of this interaction needs to be increased to allow 
stronger cellular adhesion; this is accomplished by integrin clustering. The clustering 
of integrins allows a high number of weak interactions (in the order of hundreds or 
thousands) to increment the signalling and form a tight and strong adhesion unit. 
This increased avidity is a result of collaborative effects to resist bond deterioration 
(Yu et al., 2010). Initially integrins cluster into nascent adhesions (Choi et al., 2008), 
a portion of these nascent adhesions follow on maturation and became focal 
adhesions, and lastly fibrillar adhesions and podosomes (Geiger et al., 2001; Lock et 
al., 2008).These complexes are responsible for integrin outside-in signalling (Legate 
et al., 2009).  
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Integrins modulate different cellular functions such as: cell shape, migration, 
differentiation, growth and survival (Grashoff et al., 2004; Legate et al., 2009; 
Ridley et al., 2003; Shattil and Newman, 2004). Activation of integrins depends of 
extracellular ligands, although interaction with transmembrane and cytoskeletal 
proteins can also have the same function. Binding of such proteins to these adhesion 
complexes modulates different pathways such as the extracellular signal regulated 
kinase/mitogen-activated protein kinase (ERK/MAPK), phosphatidylinositol 3-kiase 
(PI3K), Akt/protein kinase B (PTB), Jun-amino terminal kinase/JUN (JNK/JUN), 
and nucleofactor kB (NF-kB).  
 
The short integrin cytoplasmic tails lack enzymatic activity, so integrins depend on 
the recruitment of adaptor molecules and signalling proteins (such as talin and 
vinculin) which are responsible for the interactions between integrins and 
cytoplasmic proteins like FAK, Src, ILK and paxilin, in order to reorganize the 
cytoskeleton and provide catalytic activity to the focal adhesion (Wiesner et al., 
2005). The interaction of integrins with the actin cytoskeleton occurs via adaptor 
proteins. Talin binding to the β subunit and the actin cytoskeleton is essential for the 
initial integrin-cytoskeleton association (Priddle et al., 1998; Zaidel-Bar et al., 2003; 
Zhang et al., 2008). Talin binding is followed by a conformational change that 
exposes the vinculin binding and dimerisation sites. Binding of vinculin to the 
nascent adhesion stabilises the talin-actin bond (Gallant et al., 2005; Humphries et 
al., 2007). Other proteins are known to also be recruited for the stability of this 
interaction such as α-actinin, a binding partner of talin and vinculin; integrin-linked 
kinase (ILK) that binds to actin via parvin; focal adhesion kinase (FAK); kindlins, 
which act in concert with talin; paxillin, with an early recruitment to the cell-matrix 
adhesion, tensin and zyxin both being involved in late stages (Legate et al., 2009). α-
actinin also regulates maturation and growth of adhesion sites in response to 
mechanical tension (Fig. 3.4) (Askari et al., 2009). 




Figure 3.4 – Integrin outside-in signalling. Upon interaction with the ECM and ligand 
binding (the final step of upstream signalling) there is a recruitment of signalling proteins 
(such as talin) triggering focal contact formation, this will lead to tension in the integrin 
receptor, allowing for a further outward movement of the hybrid domain, leading to the 
activation of the downstream signalling pathways. α subunit is in brown, β subunit is in green 
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Integrin downstream signalling pathways 
 
Figure 3.5 – Integrin downstream signalling. Different pathways and respective cellular 
functions controlled by integrin downstream signalling. Downstream signalling of integrins, 
through FAK/Src controls different pathways involved in several cellular processes such as 
survival, proliferation, differentiation, migration, adhesion and polarity,  (Adapted from Legate 
et al. 2009) 
 
As previously mentioned, integrins can modulate different cell functions through 
several signalling pathways (Fig 3.5). Focal adhesion kinase (FAK) is a tyrosine 
kinase localized at sites of adhesion that can mediate adhesion and signalling through 
different pathways. FAK is recruited to the nascent focal adhesion through direct 
interaction with the cytoplasmic tail of the β subunit, or through interaction with 
cytoskeletal proteins such as talin and paxilin (Giancotti and Ruoslahti, 1999).  FAK 
is a 125 kDa protein that comprises a FERM domain and a focal adhesion targeting 
(FAT) domain which are responsible for the multiple FAK binding partners that act 
as effectors of many downstream functions (Mitra el al., 2005). Although FAK is a 
tyrosine kinase, it acts more like a non-kinase since it lacks the ability to 
phosphorylate other molecules, with its main role being to recruit other proteins. 
Instead, FAK can phosphorylate itself or can be phosphorylated by the Src family 
protein tyrosine kinase (SFKs), which comprise nine members, such as Src, Fyn and 
Yes (Legato et al., 2009). 
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Src is a non-receptor tyrosine kinase that constitutively associates with the integrin β 
subunit (Arias-Salgado et al., 2005; de Virgilio et al., 2004) and forms the Src-FAK 
complex which is a central point for integrin activation (Martin et al., 2002). 
Activation of the Src-FAK complex follows integrin ligation and clustering as a 
result of (1) the dissociation of Csk (an Src inhibitor) from the integrin; (2)  
transphosphorylation of Src; and/or (3) recruitment of tyrosine phosphatases (such as 
RPTPα or PTP1B) (Arias-Salgado et al., 2005; den Hertog et al., 1993; Liang et al., 
2005; Obergfell et al., 2002; von Wichert et al., 2003). In response to integrin 
ligation,  FAK is activated by autophosphorylation at tyrosine residue 397 (Y397) 
which is followed by the recruitment of the Src-homology domain (SH) 2 that 
stabilises the active conformation of Src, which leads to maximal FAK activity by 
phosphorylation of FAK at Y576, Y577, Y861 and Y925. This results in full 
activation of both kinases (Schlaepfer et al., 1994; Calalb et al., 1996; Thomas et al., 
1998). Phosphorylation at Y416 activates Src, whilst phosphorylation at Y527 has 
the opposite effect and inhibits Src (Mitra et al., 2006; Schlaepfer and Hunter, 1997). 
The Src-FAK complex is responsible for recruitment and phosphorylation of 
different adaptor proteins, such as p130
CAS
 and paxilin that results in the activation of 
the ERK/MAPK, JNK/Jun and/or NF-kB signalling pathways. Activation of 
ERK/MAPK pathways by FAK is also achieved by recruiting the growth-factor-
receptor-bound-2 (Grb2) and son-of-sevenless (SOS) complex. FAK can also 
directly activate the Akt/PKB pathway via PI3K and PIP3 (Legate et al., 2009). 
 





Figure 3.6 - FAK domain structure, phosphorylation sites and protein binding sites. 
The three domains of FAK: FERM, kinase and FAT. P – represents phosphorylation; arrows 
- protein binding sites. Adapted from Schwartz, 2001, Mitra et al., 2006, Mitra, et al., 2005, 
by Dr Colin Chan.  
 
The mitogen activated protein kinase (MAPK) pathway is the major signalling 
pathway downstream of the Src-FAK complex (Wu et al., 2008), which activates the 
ERK pathways through integrated signals from Shc, Grb2; SOS and Ras (Danen and 
Yamada, 2001; Giancotti and Ruoslahti, 1999; Roovers and Assoian, 2000). There 
are different mechanisms for regulation of the ERK pathway by integrins since ERK 
is a promiscuous kinase that can phosphorylate more than 100 substrates (Ramos, 
2008). One of these mechanisms is through FAK phosphorylation at Y925 via Src, 
leading to activation of Ras and the downstream ERK pathway (Juliano, 2002). 
Another mechanism is through activation of caveolin (but does not involve FAK). 
Grb2 and SOS are recruited by the adaptor protein Shc after its phosphorylation. Shc 
is phosphorylated after Fyn activation by integrin ligation (Giancotti and Ruoslahti, 
1999). Another mechanism is via Shc, which is phosphorylated by Src and FAK. 
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This leads to ERK translocation to the nucleus followed by gene transcription by 
phosphorylation of transcription factors (Aplin and Juliano, 2001). The existence of 
several different mechanisms able to activate downstream pathways shows the 
complexity of integrin signalling.  
 
FAK activation can also recruit PI3K to adhesion complexes, leading to activation of 
Akt which regulates cell survival (Chen and Guan, 1994). Akt can be activated by 
rapamycin (mTOR) or integrin-linked kinase (ILK), depending on the cellular 
context. ILK lacks kinase activity and binds directly to β1 and β3 integrin and also 
functions as an adaptor protein which can link integrins to its binding partners 
(Fukuda et al., 2009). ILK interacts indirectly with actin through parvin, its main 
binding partner. Cytoskeleton interaction with ILK can also occur via paxilin, which 
binds parvin and vinculin (Legate et al., 2006). Studies in C. elegans, Drosophila, 
mice and zebrafish show that ILK is essential for stabilising integrin-actin interaction 
(Zervas et al., 2001; Mackinnon et al., 2002; Postel et al., 2008, Wang et al., 2008). 
Under physiological conditions, mTOR is the main kinase and localizes 
predominately in the endoplasmic reticulum and the Golgi, and since Akt 
phosphorylation takes place in the plasma membrane; it is proposed that integrins 
can switch this pathway on and off since Akt activation through mTOR occurs 
indirectly via protein phosphatase 2A (PP2A). β1 integrin interacts and activates 
PP2A, which can dephosphorylate and inactivate Akt. PP2A is also inactivated by 
mTOR (Peterson et al.,1999; Ivaska et al., 2002). It has also been proposed that since 
ILK binds rictor (an important component of mTOR complex 2), ILK acts as a 
platform to localize mTOR activity to cell-matrix adhesions (McDonald et al., 2008). 
Lastly, it is also possible that mTOR and ILK act upstream of Akt via an unknown 
kinase that would control Akt phosphorylation (Legate et al., 2009). 
 
Another family of enzymes that is linked to outside-in integrin signalling are the 
GTPases, responsible for a variety of cellular functions such as cytoskeleton 
organization, transcription factor activity, cell cycle progression, membrane transport 
pathways, migration and cell adhesion (Schwartz and Shattil, 2000). GTPases have a 
highly conserved G domain that is hydrolysed through intrinsic GTPase-activity, 
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modulating GTPase cycling from the active (GTP-bound) to an inactive (GDP-
bound) state. The GTPases, cycling from active to inactive state are regulated by 
guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and 
guanine nucleotide dissociation inhibitors (GDI) (Legate et al., 2009). The GTPase 
family comprises 5 categories: Ras, Rho, Rab, Arf and Ran (Etienne-Manneville and 
Hall, 2002).  
 
The initial integrin ligation triggers the activation of Cdc42 and Rac which are 
involved in cell spreading through formation of actin structures. Cdc42 is known to 
regulate extension of fillopodia, while Rac is associated with lamellipodia (Burridge 
and Chrzanowska-Wodnicka, 1996). Cell spreading promotes the upregulation of 
Rho that induces the formation of actin stress fibres and the maturation of focal 
adhesions which is followed by an increased FAK activity and paxilin 
phosphorylation (Ren et al., 1999). Cdc42 is also involved in activation of PI3K, Akt 
and MAPK pathways (Clark et al., 1998; Yan et al., 1999). Rac has been associated 
with activation of MAP and JNK (Dolfi et al., 1998). Rho has been involved in 
activation of MAPK and FAK (Renchaw et al., 1996; Barry et al., 1997). 
 
3.1.4 Integrins and oligodendrocytes 
 
Myelination occurs caudo-rostrally in the brain, and rostro-caudally in the spinal 
cord. Mouse myelination starts in the spinal cord at birth, with the brain being 
completely myelinated at P45-60, whereas in humans it starts during the fourteenth 
week of fetal development, achieving its peak during the first year after birth 
(Baumann et al., 2001). 
 
Oligodendrocytes are the myelinating cells of the central nervous system (CNS) and 
express a limited set of integrin heterodimers during development. Oligodendrocyte 
development comprises a series of overlapping stages, during which the cells 
induced from the neuroephithelium migrate through the CNS while proliferating, and 
eventually differentiate, become myelinating cells and either contact an axon and 
initiate myelination or undergo programmed cell death (Trapp et al., 1997). Raff and 
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co-workers showed that oligodendrocyte development in vitro resembles (in terms of 
time scale) that observed in vivo. This allows for a thorough description of the events 
involved in oligodendrocyte proliferation, migration and differentiation and for 
analysing the respective integrin expression pattern during these events through 
immunoprecipitation methods (Raff et al., 1985; Milner and ffrench-Constant, 1994). 
From the 24 integrin heterodimers that have been characterized, only 5 of them are 
expressed in oligodendrocytes: αvβ1, αvβ3, αvβ5, αvβ8 and α6β1.  The class of αv 
integrin receptors are expressed in a sequential manner suggesting a specific role for 
each of these integrins at the specific time of their expression, with αvβ1 being 
associated with migration, αvβ3 with proliferation and αvβ5 with differentiation. The 
two other remaining integrins (αvβ8 and α6β1) are expressed throughout 
oligodendrocyte development and differentiation (Fig. 3.7) (Milner and ffrench-
Constant, 1994; Milner et al., 1997). With an unknown function, the β8 subunit 
differs from other β-subunits since its cytoplasmic domain is distinct and does not 
contain any of the known conserved sequences involved in cytoskeletal interaction, 
such as the NPxY motif (Moyle et al., 1991). 
 
Figure 3.7 – Pattern of integrin expression during oligodendrocyte development. 
Adapted from http://www.brc.cam.ac.uk/pages/ffrench.html by Dr. Joana Câmara. 
 
Despite the extensive in vitro research to identify specific integrins in the different 
stages of oligodendrocyte development, some issues have arisen. Integrin studies 
Chapter 3 – Integrins and myelination 
67 
 
were performed via immunoprecipitation of biotinylated lysates from non-ionic 
detergent extraction at 4ºC (Milner and ffrench-Constant, 1994). Microdomains 
insoluble at 4ºC (termed lipid rafts) have been shown to associate with integrins and 
growth factors and regulate oligodendrocyte signalling, so it is possible that other 
integrin heterodimers have been discarded in the insoluble pellet during these 
experiments, and therefore might be other integrins that have not yet been identified 
(Baron et al., 2003; Decker et al., 2004; Decker and ffrench-Constant, 2004). 
Furthermore, most of these in vitro findings have not been reproduced in vivo. Some 
integrin knockout transgenic animals with ablation of integrins in the whole 
organism cause early lethality, i.e. the β1, β8 and αv integrin knockouts (Bader et al., 
1998; Fässler and Meyer, 1995; Zhu et al., 2002). Knockout mice for either β3 or β5, 
or both, survive until adulthood but show no CNS phenotype (Hodilava-Dilke et al., 
1999; Reynolds et al., 2002). To gain more insight into the function of integrins in 
oligodendrocyte development, different approaches, such as conditional mutants, 
should be examined. Conditional mutants using recombination under the nestin 
promoter (CNS specific) for β1, β8 and αv integrins have already been reported. In 
these studies, β1 and β8 conditional knockout did not disturb oligodendrocyte 
development, but αv conditional knockout showed cerebral haemorrhage and 
demyelination of the spinal cord and cerebellum (Graus-Porta et al., 2001; McCarty 
et al., 2005; Proctor et al., 2005). When performing histology in these mice, αvβ8 
was only detected in cerebellar and spinal cord axons, and not in oligodendrocytes, 
suggesting that the phenotype described was due to a loss of αvβ8 integrin that would 
perturb the axoglial contact (McCarty et al., 2005). 
 
Several in vitro and in vivo studies have been performed and help to understand the 
role of integrins during oligodendrocyte development and myelination. A brief 
overview of these studies will be discussed next. 
 
Integrins in oligodendrocyte development 
 
Oligodendrocytes arise from the neuroepithelium and actively migrate through the 
CNS to reach the area which they will eventually myelinate. In vitro, an agarose 
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migration assay showed that OPC migration is inhibited by blocking antibodies 
against β1 integrin and RGD peptides (which block αv but not α6 integrins), when in 
the presence of both PDGF and aphidicholin (a mitotic inhibitor) (Milner et al., 
1996; Tiwari-Woodruff et al., 2001). Migration is promoted by fibronectin and 
laminin and is inhibited by tenascin-C and the integrin ligand collagen. These results 
show an integrin-dependent mechanism for oligodendrocyte migration (Frost et al., 
1996; Milner et al., 1996). 
 
Integrins can regulate growth factor signalling, with PDGF stimulating OPC 
proliferation through αvβ3 integrin activation (Garcion et al., 2001). Over-expression 
of αvβ3 integrin in the CG-4 oligodendrocyte cell line promotes proliferation, while 
both anti-β3 integrin blocking antibodies and β3 integrin dominant negative 
expression inhibit proliferation in vitro  (Baron et al., 2002; Blaschuk et al., 2000). 
 
During differentiation oligodendrocyte precursor cells differentiating into 
myelinating oligodendrocytes show an up regulation of αvβ5 integrin levels (Milner 
et al., 1994).  Furthermore, in vitro, CG4 cells supplemented with αvβ5 integrin 
blocking antibody show a reduction of MBP positive oligodendrocytes. Removal of 
the antibody leads to a recovering ability of oligodendrocytes to differentiate 
(Blaschuk et al., 2000). Laminin-α2 and α6β1 integrin stimulate immature 
oligodendrocyte maturation and the formation of myelin membrane sheets 
(Colognato et al., 2002).  
 
Oligodendrocytes that fail to establish axonal contact undergo apoptosis (Trapp et 
al., 1997). Oligodendrocyte survival depends on the presence of axons and is 
restricted by the availability of axonal-derived survival factors, one such trophic 
factor is laminin-2 that interacts with integrin receptors expressed on 
oligodendrocytes (Barres et al., 1992; 1999). In vitro, α6β1 integrin contacts axonal 
laminin and stimulates an increase in oligodendrocyte survival (Barres et al., 1993). 
Work from our lab showed that oligodendroglial integrins amplify growth factor 
signalling (specifically, the Scr family kinases) promoting either differentiation and 
survival, or proliferation (Colognato et al., 2004). Fyn interacts with α6β1 integrin 
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and is required for amplifying PDGF-mediated survival signalling and promotes 
myelin sheath formation. Therefore, Fyn regulates both differentiation and survival; 
Lyn, another member of the Src family kinases is involved in proliferation 
(Colognato et al., 2004). Another study using oligodendrocytes from transgenic mice 
lacking the α6 integrin (a laminin receptor), showed a switch in the survival 




Myelination in the CNS is a very intricate process and the major players that regulate 
this process have yet to be identified. Central myelination is performed by 
oligodendrocytes which after development acquire the capacity to myelinate multiple 
axons. Different approaches to study oligodendrocyte development and key players 
involved in myelination have been made throughout the years. In 1980, McCarthy 
and Vellis described the first protocol for isolation of relatively pure 
oligodendrocytes (McCarthy and Vellis, 1980). This was a major step towards 
understanding the myelination process since it was now possible to study 
oligodendrocyte development in vitro. New advances were made with the co-culture 
of oligodendrocytes with dorsal root ganglion neurons that has been established as an 
in vitro model to study myelination. In these cultures, it is possible to culture axons 
and glial cells, and track the developmental process of axon ensheathment (Lubetzki 
et al., 1993). Although these models allowed major breakthroughs in the field, new 
and more complex systems are needed to fully understand myelination in all its 
complexion, taking into account not only axoglial interaction but also the full 
environment that can influence myelination. Ex-vivo models have also been 
described, where slices of tissue are maintained in culture permitting a better 
overview of myelination, since this culture maintains cell-cell and cell-ECM 
interactions observed in vivo. All of these techniques are crucial for myelination 
research, but an in vivo approach is necessary to fully understand the complexity 
surrounding myelination, using transgenic animals. Mutant models give us insightful 
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tips of the molecules regulating different aspects of myelination and associated 
diseases. 
 
Statistical analysis was performed in all data sets with at least three animals, while 
for data sets comprising less than three animals only the average g-ratio or 
percentage of myelination was calculated, since with a low n number of samples no 
nonparametric test is going to show significance. Average g-ratios and percentage of 
myelination were given as an indication of trend showing that no abnormalities were 
observed. The focus of this chapter is the phenotype seen in the optic nerve, an area 
comprised of small diameter axons, where the effect of the dominant negative β1 
integrin was clear in increasing the axon diameter threshold necessary for 
myelination. Corpus callosum, an area that encompasses both small and large axons 
was used as a control to confirm the phenotype was specific for small diameter 
axons. All other structures (ie, cerebellum and spinal cord, characterized by large 
diameter axons) were included only as exploratory research to confirm these areas do 
not follow the same trend. Subsequently, this is not critical data for the conclusion of 
this chapter and does not lessen the conclusions. 
This chapter describes the results obtained using different in vivo models to 
understand the process of regulation of myelination. 
 
3.2.1 Analysis of the dominant negative β1 integrin mice 
 
Dominant negative β1 integrin mice were engineered by Dr. Joana Câmara, as 
previously described (Câmara et al., 2009). In brief, these animals were generated by 
replacing the β1 integrin extracellular and transmembrane domains with the non-
signalling α subunit of the human interleukin-2 receptor (IL2Rα), under the MBP 
promoter, making it specific to myelinating oligodendrocytes. Due to this change, the 
integrin intracellular domain is unable to dimerise with an α subunit, bind ligands or 
cluster with other integrins.  
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As mentioned in Chapter 1, Friede showed that the ratio between the axon radius and 
the axon radius plus myelin – termed g-ratio – is suitable to assess normal 
myelination (Friede, 1972). These mice were characterized throughout development 
to understand the effect of β1 integrin during myelination. In order to examine 
myelination, we performed an ultrastructural electron microscopy analysis of 
different structures of the nervous system. To preserve the integrity of the tissue, 
mice were intracardially perfused with a solution of glutaraldehyde and 
paraformaldehyde fixative. Tissue was dissected and processed (by overnight 
postfixation followed by dehydration and embedding in resin). Ultrathin sections for 
electron microscopy (prepared in the Department of Anatomy, University of 
Cambridge, UK) were examined and photographs of non-overlapping regions were 
taken. For quantification of myelination, these pictures were analysed by drawing the 
outline of the inner and outer circumferences of the axon (for g-ratio) with a 
minimum of 100 axons per animal, or the inner circumferences of myelinated and 
unmyelinated axons with a minimum of 300 axons per animal in at least 3 non-
overlapping pictures. This data was generated using Openlab image analysis software 
(Improvision) and all analyses was done blind, with codes given to each sample only 
revealed after complete analysis. As exclusion criteria, if the images showed myelin 
disruption due to inadequate perfusion, that sample would be excluded and not 
quantified. This allowed for reduction of treatment bias. 
 
In mice, myelination starts around P9, reaches its peak at P17, is complete around 
P22/23, and by P60 reaches a stable turnover (Wei et al., 2005). In this project we 
have covered these key time points of myelination. 
 
We have analysed optic nerve and spinal cord of P9-P10 mice. Optic nerve is 
characterized by small diameter axons and these mice showed no difference between 
wildtype (g-ratio average = 0.83) and dnβ1 (g-ratio average = 0.80) (Fig. 3.8). Spinal 
cord is an area with typically larger calibre axons, and consistent with the optic nerve 
observations, we saw no significant difference between wildtype and dnβ1, with 
average g-ratios of 0.84 and 0.85, respectively (Fig. 3.9). Only one animal per 
genotype was analysed in both optic nerve at postnatal day 9 (Fig. 3.8), and spinal 
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cord at postnatal day P10 (Fig. 3.9) since these were previous samples from Dr. 
Joana Câmara that were later analysed to verify if these mice showed a transient 
trend of myelin deficits. No statistical analysis was performed, and comparison was 
done based on the average g-ratios. 
 
 
Figure 3.8 – Analysis of optic nerve of dominant negative β1 integrin mice at postnatal 
day 9. Upper panel: representative electron micrographs of optic nerve of wildtype and 
dominant negative β1 integrin mice at postnatal day 9. Magnification: 3.90K. Scale bar: 2 
μm.  Bottom panel: scatter plot displays g-ratios of individual myelinated axons as a function 
of their respective axon sizes, with the linear regression of the measurements for each 
animal (1 animal analysed per genotype). Blue circles represent wildtype (n = 55 axons; 
average g-ratio = 0.83) and red circles represent dominant negative β1 integrin mice (n = 55 
axons; average g-ratio = 0.80). 
 





Figure 3.9 – Analysis of spinal cord of dominant negative β1 integrin mice at postnatal 
day 10. Upper panel: representative electron micrographs of spinal cord of wildtype and 
dominant negative β1 integrin mice at postnatal day 10. Magnification: 3.90K. Scale bar: 2 
μm.  Bottom panel: scatter plot displays g-ratios of individual myelinated axons as a function 
of their respective axon sizes, with the linear regression of the measurements for each 
animal (1 animal analysed per genotype). Blue circles represent wildtype (n = 100 axons; 
average g-ratio = 0.84) and red circles represent dominant negative β1 integrin mice (n = 
100 axons; average g-ratio = 0.85).  
 
This initial evaluation of CNS myelination in dnβ1 mice showed that early in the 
process of myelination there is no obvious abnormality in the mutant when compared 
to the wildtype. Since P9-P10 corresponds to an initial stage of myelination, we 
analysed these mice at P17, when myelination is not completed but is well underway. 
We started by comparing the percentage of unmyelinated axons to understand if the 
mutant mice had any abnormality associated with the decreased β1 integrin 
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signalling. To quantify the percentage of unmyelinated axons, at least 4 non-
overlapping electron microscopic images were analysed, by counting every single 
axon present and cataloguing it as myelinated or unmyelinated. Analysis of the optic 
nerve demonstrated no difference (P=0.67) between wildtype (average of percentage 
of unmyelinated axons = 55.94% ± 6.4, from 3 animals) and dnβ1 (average of 
percentage of unmyelinated axons = 61.97% ± 11.65, from 3 animals). Both spinal 
cord and cerebellum showed no difference, with cerebellum wildtype averages of 
48.77% and dnβ1 50.0%, from one animal; spinal cord averages of 51.21% and 
48.53% for wildtype and dnβ1, respectively, from two animals. After quantifying the 
optic nerve, cerebellum and spinal cord, there was no discrepancy between these 
structures when comparing mutant and wildtype animals (Fig. 3.10).  
 
 
Figure 3.10 – Unaltered percentage of unmyelinated axons of different structures of 
dominant negative β1 integrin mice at postnatal day 17. The bars represent the average 
of the percentage of unmyelinated axons. Blue bars represent wildtype animals. Red bars 
represent dnβ1 animals. In the optic nerve 3 animals were analysed for each genotype with 
an average of percentage of unmyelinated axons of 55.94% ± 6.4 and for dnβ1 of 61.97% ± 
11.65 (P=0.67). In the spinal cord, wildype showed an average of unmyelinated axons of 
51.21%, whilst the dnβ1 average was 48.53% (n = 2 animals per genotype). In the 
cerebellum only 1 animal per genotype was analysed with wild type average of 48.77% and 
50.0% for the dnβ1. A Student’s t test was used for statistical analysis.  
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Following the same strategy used with the P9-P10 tissue, g-ratio was performed in 
different areas of the CNS (i.e., spinal cord, cerebellum and optic nerve). The 
morphology of myelin was unaltered in these regions with average g-ratios for 
control and mutants being 0.79 and 0.78 in spinal cord, 0.77 and 0.78 in cerebellum, 
and 0.79 ± 0.01 and 0.81 ± 0.02 in optic nerve, respectively (Fig. 3.11 – 3.13) . This 
demonstrated that there were no differences in terms of myelin thickness and 
compaction of myelin in these structures between mutant and wildtype animals. 
Originally, the project was focused only on areas of small diameter axons (i.e., optic 
nerve) and samples of the spinal cord and cerebellum were only collected from one 
pair of animals to check the quality of perfusion. These were later analysed, but only 
one sample per genotype was available. Therefore, no statistical test was used with 
these samples, and a simple average g-ratio comparison was used. 
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Figure 3.11 – Analysis of spinal cord of dominant negative β1 integrin mice at 
postnatal day 17. Upper panel: representative electron micrographs of spinal cord of 
wildtype and dominant negative β1 integrin mice at postnatal day 17. Magnification: 3.90K. 
Scale bar: 2 μm.  Bottom panel: scatter plot displays g-ratios of individual myelinated axons 
as a function of their respective axon sizes (1 animal analysed per genotype). Blue circles 
represent wildtype (n = 153 axons; average g-ratio = 0.79) and red circles represent 
dominant negative β1 integrin mice (n = 112 axons; average g-ratio = 0.78).  
 
 
Figure 3.12 – Analysis of cerebellum of dominant negative β1 integrin mice at 
postnatal day 17. Upper panel: representative electron micrographs of cerebellum of 
wildtype and dominant negative β1 integrin mice at postnatal day 17. Magnification: 3.90K. 
Scale bar: 2 μm.  Bottom panel: scatter plot displays g-ratios of individual myelinated axons 
as a function of their respective axon sizes (1 animal analysed per genotype). Blue circles 
represent wildtype (n = 107 axons; average g-ratio = 0.77) and red circles represent 
dominant negative β1 integrin mice (n = 83 axons; average g-ratio = 0.78).  






Figure 3.13 – Analysis of optic nerve of dominant negative β1 integrin mice at 
postnatal day 17. Upper panel: representative electron micrographs of spinal cord of 
wildtype and dominant negative β1 integrin mice at postnatal day 17. Magnification: 3.90K. 
Scale bar: 2 μm.  Bottom panel: scatter plot displays g-ratios of individual myelinated axons 
as a function of their respective axon sizes, with the linear regression of the measurements 
for each animal (4 animals analysed per genotype). Blue circles represent wildtype (n = 401 
axons; average g-ratio = 0.79 ± 0.01) and red circles represent dominant negative β1 
integrin mice (n = 400 axons; average g-ratio = 0.81 ± 0.02). P = 0.65. Statistical analysis 
done by performing a Student’s t test. 




Figure 3.14 – Wildtype mice have a small population of myelinated small calibre axons 
which are absent from dominant negative β1 mice. This were the premilinary results 
where the dominant negative β1 integrin phenotype was first observed and based on this 
observation, a new method of myelin quantification (Percentage of myelination) was 
developed to further explore this phenotype. Scatter plot displays g-ratios of individual 
myelinated axons as a function of their respective axon sizes (1 animal analysed by 
genotype). Blue circles represent wildtype (n = 101 axons; average g-ratio = 0.78) and red 
circles represent dominant negative β1 integrin mice (n = 100 axons; average g-ratio = 0.81).  
 
Interestingly, while analysing this data we noticed that there was a small population 
of myelinated axons of small calibre axons present in the wildtype, which was absent 
in the mutant mice (Fig. 3.14), suggesting that wildtype oligodendrocytes would be 
able to recognize smaller axons and initiate myelination while dnβ1 oligodendrocytes 
could not. Our hypothesis was that mutant oligodendrocytes required a higher 
threshold in terms of axon size to initiate myelination. In order to test our hypothesis 
we performed an analysis of the percentage of myelinated axons, where we 
compared the relationship between axon size and the percentage of myelination.  The 
quantification of the percentage of myelination was done by measuring the axon 
diameter of at least 400 axons, and scoring them as myelinated or unmyelinated. The 
percentage of myelinated axons was plotted against 0.1μm intervals of the axon 
diameter. Spinal cord, cerebella and optic nerve were analysed, with spinal cord and 
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cerebella not showing a difference with an average percentage of myelination for 
spinal cord being 64.77 and  66.40 for wildtype and mutant mice, respectively; and in 
cerebella,  64.85 and 65.62 for wildtype and mutant mice, respectively (Fig. 3.15 and 
3.16). According to the initial study plan, the focus of this project was on the optic 
nerve, therefore there were limited samples from both spinal cord and cerebellum, 
since these were only collected as a control on the quality of the perfusion. 
Therefore, when only one or two samples per genotype was available, it was not 
possible to statistically analyse the data, and an average comparison was performed. 
 
Figure 3.15 – Spinal cord of dominant negative β1 integrin shows no alteration of 
myelination at postnatal day 17 (P17). Graph representing 2 animals for each genotype of 
the percentage of myelinated axons with a polynomial trend line curve adjusted to the data 
shows no difference between the wildtype (average = 64.77, n=1021 axons) and dnβ1 
(average = 66.40, n=735 axons). No statistical analysis was performed due to low number of 
samples, this graph shows the trend of the percentage of myelination in the spinal cord of 
dominant negative β1 mice. 





Figure 3.16 – Analysis of the cerebellum of dominant negative β1 integrin mice at 
postnatal day 17 (P17) shows no alteration of myelination. Graph representing 1 animal 
for each genotype of the percentage of myelinated axons with a polynomial trend line curve 
adjusted to the data shows no difference between the wildtype (average = 64.85, n = 61 
axons) and dnβ1 (average = 65.62, n = 416 axons). 
 
In the optic nerve, the percentage of myelination corroborated the observations seen 
with the g-ratios and confirmed that disruption of β1 integin signalling affects 
myelination with dnβ1 mice having a lower percentage of myelination in small 
diameter axons (Fig. 3.17).  




Figure 3.17 – The axon diameter required to initiate myelination is increased in the 
dominant negative β1 integrin mice. Representative graph from one litter showing the 
percentage of myelinated axons plotted against 0.1µm intervals of axon diameter depicts a 
reduced percentage of myelination in the dominant negative β1 integrin mice when 
compared to the wildtype (*, P < 0.05), with a more striking discrepancy in axons with 
diameter below 0.6 µm (**, P< 0.01). Wild type mice showed an average of percentage of 
myelination of 66.30 ± 10.09% (n = 2506 from 3 animals), contrasting to the  dnβ1 average 
of 62.08 ± 10.55%( n = 2494 from 3 animals), with a (P = 0.023). When plotting the data to 
consider only small diameter axons (< 0.6 µm) the differences are more prominent (P = 
0.0085). A two-way ANOVA was performed to statistically analyse the data. 
 
The percentage of myelination showed that mutant mice need a higher axon diameter 
to initiate myelination (P = 0.023), with percentage of myelination being 66.30 ± 
10.09%, for wildtype (n = 2506 from 3 animals) and 62.08 ± 10.55% for dnβ1 (n = 
2494 from 3 animals). This difference is accentuated in small axons with a diameter 
of less than 0.6 µm (P = 0.0085) and it is more striking in the 0.3-0.4 µm interval (P 
= 0.0023). 
 
To further assess the process of myelination in the dnβ1 mice, we carried out the 
same type of investigation at P28, an age where myelination is complete. Since this 
phenotype was restricted to the optic nerve we repeated the same ultrastructural 
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analysis in this area. The g-ratio of optic nerve showed that myelin integrity is 
preserved (P=0.57) in these mice with average g-ratios of 0.79 ± 0.013 (3 animals, 





Figure 3.18 – Analysis of optic nerve of dominant negative β1 integrin mice at 
postnatal day 28. Upper panel: representative electron micrographs of optic nerve of 
wildtype and dominant negative β1 integrin mice at postnatal day 28. Magnification: 3.90K. 
Scale bar: 2 μm.  Bottom panel: scatter plot displays g-ratios of individual myelinated axons 
as a function of their respective axon sizes, with the linear regression of the measurements 
for each animal (3 animals analysed per genotype). Blue circles represent wildtype (n = 300 
axons; average g-ratio = 0.79 ± 0.013) and red circles represent dominant negative β1 
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integrin mice (n = 300 axons; average g-ratio = 0.77 ± 0.02). P = 0.57. Statistical analysis 
performed by a Student’s t test. 
 
We further investigated if at this later stage of myelination the percentage of 
myelination would still be affected at P28. We observed no differences (P=0.97) 
between the wildtype littermates (73.46 ± 10.40, n=2421 axons from 3 animals) and 
their mutant counterparts (75.31 ± 10.28, n=2750 axons from 3 animals), showing 
that our phenotype of delayed myelination is transient and β1 integrin signalling is 
only necessary for the initiation of myelination, and is not a long-lasting effect 
throughout the entire process of myelination (Fig. 3.19). To further assess any 
possible alteration in terms of myelination and axon calibre, we have plotted the 
percentage of myelinated axons according to small (≤ 0.6 μm) and large (> 0.6 μm) 
diameter (Fig. 3.19). This demonstrated that at P28, both wildtype and dnβ1 mice 
have the same percentage of myelinated axons, showing that mutant 
oligodendrocytes are able to restore their ability of myelinating small diameter axons 
with time. When comparing the percentage of myelinated axons in P17 and P28 in 
different axon diameter intervals we observed that for axon diameters of 0.2-0.3 μm, 
the percentage of myelination is 1.2% at P17 and 6.1% at P28; for axon diameters of 
0.3 – 0.4 μm, percentages of myelination are 12.7% and 51.4% at P17 and P28, 
respectively; for axon diameters of 0.4 – 0.5 μm, the percentage of myelination is 
37.2% at P17 versus 83.6% at P28. The increase observed from P17 to P28 shows 
that mutant oligodendrocytes restore their ability to myelinate small calibre axons 
over time. 





Figure 3.19– The threshold diameter needed for initiation of myelination in the 
dominant negative β1 mice is restricted to postnatal day 28 (P28). Upper panel: 
Percentage of myelinated axons in dominant negative β1 mice at postnatal day 28 (P28) 
 (average of 75.31 ± 10.28, n = 2750 axons from 3 animals)  shows no difference when 
compared to wildtype mice (average of 73.46 ± 10.40, n = 2421 axons from 3 animals)   (P = 
0.97), showing that disruption of β1 integrin signaling affects predominantly the initial stages 
of myelination. Bottom panel: The percentage of myelination in the mutant does not 
significantly differ from wild-type in small, large or total axons (same n numbers as upper 
panel). A Student’s t test was used to statistically analyse the data. 




To further access the role of β1 integrin in myelination, β1 integrin blocking 
antibody was added to myelinating cocultures of dorsal root ganglia (DRGs) where 
oligodendrocyte precursor cell (OPCs) were added. Cocultures were supplemented 
with blocking antibody at different time points: 0, blocking antibody was added at 
the same time as OPCs were seeded onto DRGs; 1, one day after adding OPCs; and 
3, three days after OPCs were added to DRGs. These results support the idea that β1 
regulates oligodendrocyte myelination since it was observed a decreased in the 
percentage of myelinating oligodendrocytes (calculated by dividing the number of 
oligodendrocytes with established internodes for the number of MBP positive 
oligodendrocytes) in all time points when compared with controls (no antibody and 
1 Monoclonal Immunoglobulin Isotype Standard antibody).   
 
 
Figure 3.20 – β1 integrin reduces myelination in vitro. β1 integrin blocking antibody was 
added to myelinating cocultures and reduced myelination in different time point. This graph 
comprises data from one set of experiments. Each bar represents 3 cover slips. Twelve rat 
embryos were dissected to extract dorsal root ganglia (DRGs for neuronal culture) and a 
further 16 rat pups were used to extract oligodendrocytes. Since it is only one set of 
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3.2.2 Analysis of the dominant negative β3 integrin mice 
 
Dominant negative β3 integrin (dnβ3) mice were also engineered by Dr. Joana 
Câmara following the same strategy described in the previous section (Câmara et al., 
2009). These mice were used as a control since β3 integrin is not expressed in 
myelinating oligodendrocytes and therefore any phenotype observed in the dnβ1 
would be specific to β1 integrin and not an artefact of the construct/transgenic-
approach. As previously observed in the dnβ1 mutant, dnβ3 mice show that the trend 
in terms of the percentage of unmyelinated axons is not different, with averages of 
43.66 % (n = 1486 axons from three animals) and 37.91 (n = 1140 axons from 2 
animals) for wildtype and mutant, respectively (Fig. 3.21). 
 
 
Figure 3.21 – Normal myelination of optic nerve of dominant negative β3 integrin mice 
(P18). Upper panel: representative electron micrographs of wildtype and dnβ3 mice optic 
nerve at postnatal day 18. Magnification: 3.90K. Scale bar: 2 μm.  Bottom panel: The bars 
represent the mean of the percentage of unmyelinated axons. Blue bars represent wildtype 
animals (average of 43.66, from 3 animals, n = 1486 axons). Red bars represent dnβ3 
animals. (average of 37.91, 2 animals, n = 1140 axons).  
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The dnβ3 line was a helpful control for the dnβ1 line since it shares the same 
construct which includes the cytoplasmic β integrin subunit. The percentage of 
myelination of these mice allowed us to exclude that a phenotypic change in 
myelination resulted from the transgenic approach, with no significant difference 
when compared to wildtype animals (P = 0.24) when looking at average percentage 
of myelination (wildtype: 54.07 ± 10.41 (n = 1397 axons from 3 animals, dnβ3: 
58.73 ± 10.54 (n = 1416 from 3 animals)) (Fig. 3.22). This proves that the delay in 
myelination observed in the dnβ1 is due to β1 integrin signalling rather than from a 
nonspecific effect of transgenic expression. 
 
 
Figure 3.22 – Dominant negative β3 mice show no delay of myelination.  
Representative graph of one litter of percentage of myelinated axons plotted against 0.1 μm 
intervals, showing no difference (P = 0.24) in terms of the threshold necessary for 
myelination between wildtype (average of 54.07 ± 10.41, n = 1397 axons from 3 animals) 
and dnβ3 mice (average of 58.73 ± 10.54, n =1 416 from 3 animals). Statistical analysis 
performed by two-way ANOVA. 
 
As predicted, the delay in myelination was specific to β1 integrin signalling and not 
due to the transgenic approach taken. To further prove this point we have repeated 
the percentage of myelination in the optic nerve of dnβ3 mice at P28 and no 
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difference was detected with average percentage of myelination being 69.75 (n = 502 
axons from 1 animal) for the wildtype and 72.31 (n = 364 axons from 1 animal) in 
the dnβ3 mice (Fig. 3.23). 
 
 
Figure 3.23 – Dominant negative β3 integrin mice show no abnormalities in 
myelination. Upper panel: representative electron micrographs of wildtype and dnβ3 mice 
optic nerve at postnatal day 28. Magnification: 3.90K. Scale bar: 2 μm. Bottom panel: 
representative graph of one litter of percentage of myelinated axons plotted against 0.1 μm 
intervals, showing a similar myelination between the dnβ3 (average of 72.31, n = 364 axons 
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3.2.3 Analysis of the β1 integrin knockout mice 
 
The β1 integrin knockout (β1KO) mice were kindly supplied by Dr. João Relvas and 
an extensive protocol for the transgenic approach has been previously described 
(Benninger et al., 2006). Benninger and co-workers concluded that by conditional 
inactivation of the β1 integrin gene in CNP-expressing oligodendrocytes, β1 integrin 
was not required for CNS axon ensheathment, myelination and remyelination 
(Benninger et al., 2006). It was proposed that due to the early expression of CNP, 
these oligodendrocytes would be deprived of β1 integrin expression from an early 
age (premyelinating stage) and that compensatory mechanisms (perhaps from 
another integrin) would take place and therefore inhibit a phenotype in these mice. 
We received 3 samples from a wildtype genotype and 3 from the β1 integrin 
knockout (these were littermates) and proceeded with the same type of analysis 
applied to the previous transgenic animals. These animals showed no difference in 
terms of percentage of unmyelinated axons with an average of 66.72 ± 8.98 (n = 
2292 axons) for wildtype, and 62.96 ± 6.28 (n = 2231 axons) for β1 KO (Fig. 3.24). 
 
Chapter 3 – Integrins and myelination 
90 
 
Figure 3.24 – Percentage of unmyelinated axons of optic nerve of β1 integrin knockout 
mice (P17). Upper panel: representative electron micrographs of optic nerve of wildtype and 
β1 integrin knockout mice at postnatal day 17. Magnification: 3.90K. Scale bar: 2 μm.  
Bottom panel: Percentage of unmyelinated axons of the optic nerve of wildtype and β1 
integrin knockout mice at postnatal day 17.The bars represent the average of the percentage 
of unmyelinated axons. Blue bars represent wildtype animals. Red bars represent β1 KO 
animals. Optic nerve bars represent 3 animals, wildtype average = 66.72 ± 8.98 (n = 2292 
axons) and β1 KO average = 62.96 ± 6.28 (n = 2231 axons), P=0.75. A Student’s t test was 
executed for statistical analysis. 
 
Performing the same analysis of the percentage of myelination in these mice showed 
no phenotype (Fig. 3.25), consistent with previous findings. Compensation by other 
integrins has been previously reported in Drosophila embryogenesis. In Drosophila 
PS integrins are necessary for the correct migration pattern during embryogenesis. 
Absence of this integrin results in disorganization of the visceral mesoderm and a 
migration delay. In contrast, ablation of either PS1 or PS3 (integrins from the PS 
integrins family) causes a modest delay in migration, or no effect, respectively 
(Martin-Bermudo et al., 1999).  
 
Figure 3.25 – Percentage of myelination of optic nerve of β1 integrin knockout mice at 
postnatal day 17. As expected from previous studies in these mice, no alterations in 
myelination were observed, giving rise to speculation that a knockout of β1 integrin at an 
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early stage will lead to compensatory mechanisms that ensure a correct and appropriate 
myelination. The bars represent the mean of the percentage of myelinated axons 
categorized by axon diameter. Blue bars represent wildtype animals. Red bars represent β1 
KO animals. Average percentage of myelination for wildtype mice = 56.41 ± 9.79 (n = 2292 
axons, 3 animals), and for β1 KO mice = 57.30 ± 9.45 (n = 2231 axons, 3 animals). P = 0.67. 
A two-way ANOVA was performed for statistical analysis. 
 
 
3.2.4 Analysis of the focal adhesion kinase knockout mice 
 
Focal adhesion kinase (FAK) is a downstream protein of β1 integrin and an integral 
part of integrin signalling. FAK is activated after binding to the integrin cytoplasmic 
domain with subsequent phosphorylation. It has been previously reported that loss of 
FAK results in hypomyelination of the optic nerve in vivo (Forrest et al., 2009).  We 
reasoned that if the phenotype seen in the dnβ1 mice was due to disturbances of the 
β1 integrin signalling then transgenic mice for downstream molecules of the same 
pathway would show the same delay in myelination. To test our hypothesis, we 
analysed focal adhesion kinase knockout mice (FAK KO), provided by Professor 
Peter Brophy and described previously (Grove et al., 2007). Briefly, these mice have 
ablated FAK expression achieved by crossing mice homozygous for a floxed FAK 
allele with a Cnp-Cre line (Grove et al., 2007). Initially, we investigated the integrity 
of myelin in these mice by analysing the g-ratio in P16 mice. As previously carried 
out, we initiated the analysis of the FAK KO mice by quantifying the percentage of 
unmyelinated axons, which in the wildtype was 66.46% (n = 1888, from two 
animals) and in the mutant was 76.65% (n = 1542 axon, from two animals), showing 
that the trend of unlyelinated axons does not differ from both genotypes (Fig. 3.26, 
middle panel).  The myelin integrity of these mice is normal, with 3 wildtype animals 
and an average g-ratio of 0.78 (n = 300 axons) and the 2 mutant animals with and 











Figure 3.26 – Normal myelination and myelin thickness in the focal adhesion kinase 
knockout mice in the optic nerve at postnatal day 16 (P16). Upper panel: representative 
electron micrographs of optic nerve of wildtype and FAK knockout mice at postnatal day 16. 
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Magnification: 3.90K. Scale bar: 2 μm.  Middle panel: Percentage of unmyelinated axons of 
the optic nerve of wildtype and FAK knockout mice at postnatal day 16.The bars represent 
the average of the percentage of unmyelinated axons. Blue bars represent wildtype animals. 
Red bars represent FAK KO animals. Optic nerve bars represent 2 animals, wildtype 
average = 66.46 (n = 1888 axons) and FAK KO average = 76.65 (n = 1542),. Bottom panel: 
scatter plot displays g-ratios of individual myelinated axons as a function of their respective 
axon sizes, with the linear regression of the measurements for each animal. Blue circles 
represent wildtype (n = 300 axons, from 3 animals; average g-ratio = 0.78) and red circles 
represent FAK KO mice (n = 200 axons, from 2 animals; average g-ratio = 0.80). . 
 
These initial results corroborate the findings in the dnβ1 animals, where these mice 
show no defect in the thickness of myelin or oligodendrocyte ability to compact 
myelin. To test our hypothesis that FAK KO mice share the same delay in 
myelination seen in the dnβ1, we analysed the percentage of myelination and saw a 
significant reduction in myelination (P = 0.087) with averages of 64.93 ± 10.70% (n 
= 2560 axons, from 4 animals) for wildtype and 57.37 ± 10.38% for mutants (n = 
2186 axons, from 4 animals) (Fig. 3.27). 
 
Figure 3.27 – Increased threshold for myelination in the focal adhesion kinase 
knockout mice. Graph shows the percentage of myelinated axons in the optic nerve of focal 
adhesion kinase knockout (FAK KO) mice and their wildtype counterparts with respect to the 
axon diameter. A polynomial trend line was adjusted to the data. FAK KO (average of 57.37 
± 10.38%, n = 2186 axons, from 4 animals) show a shift of the dose-response curve to the 
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right that is significant from the wildtype  (average of 64.93 ± 10.70%, n = 2560 axons, from 
4 animals) (**, P<0.001). A two-way ANOVA was performed for statistical analysis. 
 
While analysing these mice, it was clear, especially from one particular litter that 
these animals presented several myelin aberrations (such as “loops” of uncompacted 
myelin (Fig. 3.28 A, B) and “double wraps” where more than one axon is wrapped in 
the same myelin sheath (Fig 3.28 C, D). A significant difference (P = 0.0069) was 
observed in the P16 litter with average percentage of myelin aberrations of 1.62 ± 
0.28% and 5.19 ± 0.11% for wildtype and mutant, respectively. At P21, data trend 
seemed to be the same with percentage of myelin aberrations with wildtype 
presenting an average of 0.98 and FAK knockouts having an average of 0.96 (Fig. 
3.28). This might evidence the transient aspect of the phenotype described, with 
oligodendrocytes eventually recovering their ability to myelinate smaller axons and 
correctly compact myelin. 
 
 
Figure 3.28 –Percentage of myelin aberrations in the conditional focal adhesion 
kinase knock out mice at postnatal day 16 and 21 (P16 and P21). The P16 litter, 
comprised of 4 wildtype samples and 4 knockouts, and the P21 litter was composed of 6 
wildtype samples and 2 knockouts. The graph represents the average of the percentage of 
myelin aberrations of each sample, in the wildtype the P16 litter had 1,60% myelination, 
while in the P21 litter wildtype had 0,98% myelination. In the knockouts, at P16 there was 
5,19% myelination in contrast to 0,96% myelination in the P21 litter.  Myelin aberrations: (A) 
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and (B), Loops of myelin, (C) and (D) “double wraps”. (**, P < 0.001). This analysis was 
performed by two-way ANOVA. 
 
After showing that the FAK KO mice share the same phenotypic features as the dnβ1 
mice, we analyzed adult mice to assess if the delay in myelination was also transient. 
We performed g-ratio analysis and calculated the percentage of myelination in P60 
mice. G-ratios showed that at this age, the thickness of the myelin sheath is normal 
(P = 0.67) in the optic nerve with average g-ratios for wildtype of 0.83 ± 0.02 and 
0.82 ± 0.02 for FAK KO mice (Fig. 3.29).  
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Figure 3.29– Normal myelination in the focal adhesion kinase knockout mice at 
postnatal day 60 (P60). Upper panel: Upper panel: representative electron micrographs of 
optic nerve of wildtype and FAK knockout mice at postnatal day 60. Magnification: 3.90K. 
Scale bar: 1 μm. Bottom panel: No significant differences (P = 0.67) in myelin thickness were 
detected in the optic nerve in the absence of FAK at P60 in the three animals analyzed for 
each genotype, with average g-ratios for wildtype and FAK KO mice of 0.83 ± 0.02 (n = 300 
axons, from 3 animals) and 0.82 ±  0.02 (n = 300 axons, from 3 animals), respectively. A 
Student’s t test was used for statistical analysis. 
 
Similarly to what was observed in the dnβ1 mice, FAK KO mice also showed a 
transient effect, with P60 mice not showing a delay in myelination specific to small 
diameter axons. There is no difference (P = 0.78) between the percentage of 
myelinated axons in the wildtype 77.52 ± 10.09 (n = 1288, from 3 animals) when 
compared to mutant mice 74.40 ± 10.35 (n = 1268, from 3 animals) (Fig. 3.30). 
When we plotted the percentage of myelinated axons by small (≤ 0.6 μm) and large 
(> 0.6 μm) diameters, these values are comparable between genotypes (Fig. 3.30). 
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Figure 3.30 - Transient effect in myelination is observed in focal adhesion kinase 
knockout mice. Upper panel: Graph plotting the percentage of myelinated axons against 
the axon diameter at 0.1 µm intervals for P60 wild-type and FAK KO mice. A polynomial 
trend line was adjusted to the data. At P60, the percentage of myelinated for the FAK KO 
optic nerves (74.40 ± 10.35, n = 1268, from 3 animals) was not significantly different 
(P=0.78) from wild-type littermates (77.52 ± 10.09, n = 1288 from 3 animals). Bottom panel: 
Percentage of myelinated axons in the FAK KO mice (P60). As seen in the dnβ1 mice, the 
percentage of myelination in the mutant does not significantly differ from wild-type in small, 




β1 integrin has been implicated in central nervous system (CNS) myelination in 
vitro, but these findings have been difficult to translate into in vivo systems as many 
integrin knockouts are embryonic or prenatally lethal. In order to address β1 integrin 
myelination in vivo, our lab adopted a new transgenic approach by developing mice 
with dominant negative β1 integrin (dnβ1) expressed under the myelin basic protein 
(MBP) promoter that drives specific expression on myelinating oligodendrocytes. 
The dominant negative strategy used allowed us to analyse the effects of β1 integrin 
specifically in oligodendrocytes. The dnβ1 integrin transgenic mice bear a construct 
that comprises the cytoplasmic domain of the β1 integrin coupled to the extracellular 
and transmembrane domains of a small non-signalling α subunit of the human 
interleukin-2 receptor, which reduces signalling independently of ligand binding. 
After full characterization of β1 integrin expression of these mice, a structural 
analysis of the myelin was performed at different time points: postnatal day 9 (P9), 
when myelination is initiating; P17, when myelination is well underway but is not 
yet complete; and P28, when myelination is complete.  
 
The number of myelin wraps, and consequently after compaction, the myelin 
thickness, has long been known to be proportional to the axon diameter, allowing for 
calculation of the g-ratio (Friede, 1972). Structural analysis of myelination by 
electron microscopy (EM) enabled us to quantify the g-ratio in dnβ1 mice. At P9, 
dnβ1 mice showed no impairment in myelination. Interestingly, in the optic nerve, a 
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small population of myelinated axons of small calibre which were present in 
wildtype mice were absent in the dnβ1 mice. In order to confirm these results, we 
generated a new method of analysing myelination by quantifying the percentage of 
myelinated axons binned by axon diameter, allowing for the comparison of major 
differences between genotypes in different categories of axons. Oligodendrocytes of 
dnβ1 mice myelinated small-diameter axons less efficiently than wildtype and 
control (dominant negative β3 integrin mice) in the optic nerve, demonstrated by a 
shift to the right of the dose-response curve created based on the percentage of 
myelinated axons. This delay in myelination was observed at P17, when myelination 
is not completed. Analysis of spinal cord and cerebellum showed that this phenotype 
was specific to the optic nerve, an area characterized by small diameter axons. 
Analysis of older mice showed that this is a transient effect and that oligodendrocytes 
eventually catch up and are able to myelinate the smaller axons. 
 
As a control for the transgenic approach we also characterized dominant negative β3 
integrin (dnβ3) mice. These mice were generated using the same transgenic method 
having their extracellular and transmembrane domains replaced by a small non-
signalling α subunit of the human interleukin-2 receptor. β3 integrin is not normally 
expressed in myelinating oligodendrocytes,  proving that the phenotype observed in 
the dnβ1 mice is specific to the β1 integrin and not a construct artefact. These mice 
showed no structural or myelinating abnormalities, nor the delay in myelination 
observed in the dnβ1 animals.  
 
Further to the dnβ3 control, another two lines of mice were analysed, the focal 
adhesion kinase knockout (FAK KO) and the β1 integrin knockout (β1 KO). FAK is 
a downstream signalling molecule of the β1 integrin, and the FAK KO showed a 
similar effect than the one observed in the dnβ1 mice. The β1 KO showed no effect, 
consistent with the current literature, and may be explained by β1 integrin being 
deleted in oligodendrocytes at premyelinating stages, thereby likely allowing 
compensation by other integrins. 
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Together, these results showed no abnormalities in terms of myelin thickness, which 
suggests that dnβ1 oligodendrocytes, once they establish contact and myelinate an 
axon, do so according to its diameter. In vitro studies performed by Dr. Zhen Wang 
give more emphasis to the results described since internodal length of myelinated 
axons in co-culture with dominant-negative oligodendrocytes is normal (Câmara et 
al., 2009). Since the delay in myelination in the dnβ1 is a transient effect, we suggest 
that these dnβ1 oligodendrocytes require a higher axon size threshold to start 
myelinating. To further support this view, this observation was specific to the optic 
nerve, a region where the population of fibres is homogenously small, and no 
differences were detected in spinal cord or cerebellum, areas characterized by large 
calibre axons. Together these results suggest that β1 integrin is required to detect a 
signal on the axon important to switch on the myelination program. 
 
Oligodendrocytes with reduced β1 integrin signalling myelinate fewer small-
diameter axons, leading to a delay in initiation of myelination without affecting the 
signalling pathways that control the formation of the myelin sheaths. Therefore, 
integrins contribute to the axoglial interactions that initiate myelination, but do not 
affect myelin thickness once axoglial interactions have been established.  
 
Two different studies of the function of β1 integrin in central myelination appear 
contradictory (Benninger et al., 2006; Lee et al., 2006). Our project reconciles these 
studies. Benninger and co-workers reported the absence of a myelination phenotype 
in the CNS in a CNP-Cre β1 KO (the same mice analysed in this study, β1 KO) 
which corroborates our results that β1 integrin is necessary for initial axoglial contact 
but has no effect on myelin wrapping. Lee and co-workers generated dominant 
negative β1 integrin mice using a different strategy, where mice lack the C-terminal 
cytoplasmic tail (β1∆C) in oligodendrocytes. These mice showed a hypomyelination 
of the CNS that might be explained by the transgenic approach. β1∆C comprises the 
extracellular and transmembrane domains of the β1∆C and lacks its intracellular 
domain, which is the reverse strategy taken with our dnβ1. As opposed to our mice 
where signalling is reduced independent of ligand binding (dnβ1 is unable to bind α 
subunits and thus to bind laminin), the β1∆C mice are able to bind to β1 integrin 
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ligands, such as laminin, and heterodimerise with the α subunit, although due to the 
lack of the β tail, the signal is unable to be transmitted into the cell.  If we consider 
β1 integrin as the main laminin receptor involved in CNS myelination, these two 
transgenic approaches should inhibit β1 integrin signalling and disrupt myelination. 
The different outcomes from these three transgenic approaches can be explained by 
the existence of other laminin receptors essential for CNS myelination, which could 
reconcile the absence of a CNS phenotype in the β1 KO and also the different results 
shown in the dnβ1 and β1∆C. One of the candidates for a laminin receptor would be 
dystroglycan, since several studies have suggested a role for dystroglycan in PNS 
myelination (Occhi et al., 2005; Saito et al., 2003). Dystroglycan has been reported 
to be expressed by oligodendrocytes and in vitro myelin formation is inhibited by 
dystroglycan siRNA (Colognato et al., 2007; Wang et al., 2007). Given this 
evidence, we propose that the discrepancy between the phenotypes of our dnβ1 and 
the β1∆C is due to a requirement for dystroglycan in the latter in the later stages of 
myelin formation, with our dnβ1 showing a role for integrin during initiation of 
myelination.  
 
The results reported in this chapter show that β1 integrin regulates the initial axoglial 
contact in myelination, with a delay in myelination of small diameter axons in dnβ1 
mice. We also conclude that β1 integrin is not involved in myelin sheath formation or 
wrapping, since the internodal length and myelin thickness are normal in dnβ1 mice. 
Our findings thus suggest that β1 integrin is required to detect an axonal signal that 
induces myelination. The mechanism underlying this process could be explained by 
failure of oligodendrocyte differentiation, or a disturbance of the axoglial signalling 
that regulates initiation of myelination (Fig. 3.30). 
 




Figure 3.31 – Proposed mechanisms for delayed myelination of small-diameter axons 
in the dominant negative β1 integrin mice. Reproduced from Câmara et al., 2009. 
 
The first model assumes that reduction in β1 integrin signalling would preferentially 
affect small diameter axons, compared to large diameter axons, due to a failure of the 
oligodendrocyte to branch several processes for myelination. In agreement with this 
model, it has been shown that toad oligodendrocyte cell bodies associate closer to 
large fibres and have fewer processes than those related to small fibres (Hildebrand 
et al., 1993; Stensaas and Stensaas, 1968). Further evidence is provided by Matthews 
and Duncan’s observations that oligodendrocytes in rat white matter areas with both 
large and small diameter axons have fewer branches than areas composed of small 
axons only (Matthews and Duncan, 1971). It has also been suggested in the literature 
that ECM binding through β1 integrins and cytoskeletal reorganization are required 
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for the establishment of oligodendrocyte processes and myelin sheaths 
(Schoenwaelder and Burridge, 1999). To further support this view, a study of 
WAVE1 knockout mice showed that in the optic nerve and corpus callosum, these 
mice had a reduced number of myelinated axons, and the oligodendrocytes in vitro 
extended fewer processes than the wildtype (Kim et al., 2006). Given the 
comparatively high number of processes required to reach small axons, a reduction in 
β1 integrin signalling would be expected to be particularly harmful to small axons. 
This evidence would suggest that disruption of β1 integrin signalling in our dnβ1 
mice would lead to a decrease in the length of the internodes and a higher g-ratio 
(characteristic of hypomyelination). Our data goes against this hypothesis since in 
vitro the dnβ1 oligodendrocytes are able to myelinate normal internodal lengths, and 
the g-ratio at P17 is normal (Câmara et al., 2009).  
 
The second model proposed is that reduction of β1 integrin perturbs the signalling 
pathway that controls axoglial contact and initiation of myelination. When the 
oligodendrocyte contacts the axon it needs to detect a certain threshold level of β1 
integrin expression, controlled by the axon diameter, in order to decide to myelinate 
it. If there is a reduction in the detector molecule (β1 integrin), the prediction would 
be that the small axons will be below the required level and a reduced percentage of 
myelinated axons will be observed. By contrast, the large axons are already above 
the required level and will not be affected. This hypothesis is consistent with what 
has been observed in the PNS, where neuregulins have been shown to play a crucial 
role in both decision of whether an axon gets myelinated and in the regulation of 
myelin thickness (Michailov et al., 2004; Taveggia et al., 2005). The neuregulin 
effect in CNS myelination is controversial, and seems rather more complicated. The 
addition of exogenous neuregulin to myelinating co-cultures of oligodendrocytes and 
dorsal root ganglion (DRG) neurons increases myelination (Wang et al., 2007), 
whilst it is reduced when oligodendrocytes are cultured with neuregulin-deficient 
DRG neurons (Taveggia et al., 2008). In vivo studies of neuregulins in the CNS are 
inconclusive, since mice haploinsufficient for neuregulin 1 type III show a 
hypomyelination phenotype (Roy et al, 2007; Taveggia et al., 2008), but ablation of 
neuregulin 1, ErbB3 and ErbB4 (part of the ErbB receptor family that regulates 
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neuregulins) show no impairment in myelination (Brinkmann et al., 2008). Together 
these results show that neuregulins may play a role in the CNS, but unlike in the PNS 
where neuregulins are individually responsible for myelination, in the CNS other 
molecules may be required. 
 
Our lab has shown that integrins amplify neuregulin signalling. Integrin α6β1 is a 
laminin receptor that regulates oligodendrocyte survival signalling by amplification 
of neuregulin activity (Colognato et al., 2002). We hypothesised that integrins and 
neuregulins act in concert and form a multi-component signalling complex 
responsible for initiation and regulation of myelination in the CNS. This complex 
could explain the results described in this chapter, where oligodendrocytes with 
reduced β1 integrin signalling would receive other cues in order to myelinate, and 
explain this transient phenotype. 
 
The determination of the signals regulating the initiation of myelination is of the 
highest priority to promote the reset of the oligodendrocytes arrested at the 
premyelinating stage in the demyelinating disorder Multiple Sclerosis (Chang et al., 
2002; Kuhlmann et al., 2008). In addition, the understanding of the mechanisms 
regulating myelination of small and large axons is crucial to determine why in 
Krabbe’s disease, late myelinated tracts are preferentially affected in contrast to early 
myelinated tracts. The biological reason for this could lie in the differential 







Role of β1 integrin and neuregulin 












Myelination is a tightly controlled process where a glial cell wraps several layers of 
myelin around an axon in order to insulate it, improve conduction performance, and 
provide long term axonal integrity (Griffiths et al., 1998; Huxley and Stampfli, 
1949). Central nervous system (CNS) and peripheral nervous system (PNS) 
myelination differ in terms of the cells responsible for myelination (oligodendrocytes 
and Schwann cells, respectively) and some of the core proteins that constitute the 
myelin layer (PLP in the CNS vs P0 in the PNS). Oligodendrocytes can extend 
several processes and myelinate different axons, while Schwann cells can only 
myelinate one internode. For myelination to occur, a glial cell needs to establish 
contact with an axon and identify the number of wraps that will provide complete 
insulation of the axon. The thickness of the myelin sheath is regulated by the axon 
diameter (Friede, 1972) with an axonal threshold of 0.2 µm in the CNS and 1 µm in 
the PNS (Waxman and Bennet, 1972; Voyvodic, 1989) necessary for myelination to 
occur. The existence of a threshold for myelination together with the observation that 
in vitro oligodendrocytes are able to extend processes in the absence of neurons, but 
can only form compact myelin layers in the presence of axons, shows that axonal 
signalling and/or secreted molecules are necessary for initiation of myelination 
(Lubetski et al., 1993). Furthermore, transplantation of oligodendrocytes from the 
optic nerve (an area characterized by small calibre axons) into the spinal cord (with 
typically large diameter axons) leads to the correct amount of myelin sheaths being 
formed, showing that myelin thickness is not an intrinsic property of the 
oligodendrocyte, but regulated by the axon (Fanarraga et al., 1998). 
 
In the PNS, the levels of neuregulin 1 type III on the surface of the axon have been 
identified as a necessary and sufficient regulator for myelination. In the CNS, such a 
signal has yet to be identified. Work described in chapter 3 identified β1 integrin as a 
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regulator for axoglial contact, and we hypothesized that β1 integrin acts in concert 
with other signalling molecules, such as neuregulin 1 type III, to control myelin 




The central hypothesis of this project is that neuregulins act in concert with β1 
integrin to regulate the axoglial signalling necessary for the initiation of myelination 
 
Statement of aims 
1. Generate transgenic mice by crossing male dominant negative β1 integrin 
mice with neuregulin 1 type III heterozygous females 
2. To characterize myelination in the dominant negative β1 integrin // 
neuregulin 1 type III 
+/- 
mice by analysing g-ratio and percentage of 
myelination by electron microscopy.at different time points.and different 
structures of the brain. 
 
4.1.2 Neuregulins: structure and function 
 
The neuregulins are a family of growth and differentiation factors that mediate cell-
cell interactions in the nervous system, heart and breast (Falls, 2003). Investigations 
by two different groups identified neuregulin as a ligand for the ErbB2 receptor 
(Holmes et al., 1992; Peles et al., 1992; Wen et al., 1992); at the same time, a glial 
growth factor (GGF) that stimulates Schwann cell proliferation was also identified 
(Goodearl et al., 1993; Marchionni et al., 1993), as was a growth factor (ARIA) that 
stimulates acetylcholine receptor synthesis (Falls et al., 1993). It was later found that 
all of these proteins are encoded by the NRG1 gene (Falls, 2003). The neuregulin 
family comprises 4 distinct genes that encode neuregulin 1 (Nrg1), neuregulin 2 
(Nrg2) (Busfield et al., 1997; Carraway et al., 1997; Chang et al., 1997; 
Higashiyama et al., 1997), neuregulin 3 (Nrg3) (Zhang et al., 1997) and neuregulin 4 
(Nrg4) (Harari et al., 1999). They share an EGF-like domain essential for receptor 
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binding and activation. The biological functions of Nrg2, Nrg3 and Nrg4 have not 
been fully identified, and for the purposes of this thesis the focus will be on Nrg1. 
 
Nrg1 is encoded by a single gene comprising approximately 1.4 megabases. Through 
alternative splicing and multiple promoters, this gene encodes more than 30 different 
isoforms in humans. These were then subdivided into type I-VI, according to their 
membrane topologies (Mei and Xiong, 2008). All isoforms contain an epidermal 
growth factor (EGF)-like domain located in the extracellular region that is necessary 
and sufficient for activation of their receptors. As mentioned previously, throughout 
the years several proteins were identified such as neu differentiation factor (NDF), 
heregulin and acetylcholine receptor inducing activity (ARIA), that are now known 
to be part of the Nrg1 family and belong to type I Nrg1. The type I comprises an 
immunoglobulin (Ig)-like domain and a glycosylated domain. Their EGF-like 
domain can either be an α- or β-variant, which vary in their affinity to the receptor. 
Nrg1 type II, also termed glial growth factor (GGF), presents an Ig-like domain and a 
β-variant EGF-like domain. Its N-terminal comprises a classic signal peptide and a 
kringle-like domain. The kringle domain is responsible for mediation of protein-
protein interactions in other proteins, but thus far there are no known partners for 
Nrg1 type II. Nrg1 type III is the most abundant Nrg1 in the nervous system and its 
expression is mostly restricted to neurons. It is also called sensory and motor neuron 
derived factor (SMDF) and it has a cystein-rich domain (CRD) with a hydrophobic 
domain on the NH2-terminus and its EGF-like domain is β-variant. Both N- and C- 
terminals are located inside the cell since this isoform has a hydrophobic anchor 
sequence, giving this isoform a hairpin-shape membrane conformation (Fig. 4.1). 
 
Ngr1 isoforms I-III have different expression patterns, with Nrg1 type I being 
preferentially expressed during early embryogenesis, whilst Nrg1 type II is expressed 
during nervous system late development and after birth, and Nrg1 type III is 
predominantly expressed by sensory and motor neurons (Meyer and Birchmeier, 
1994; Meyer et al., 1997).  
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In recent years Nrg1 types IV-VI have been described. These isoforms all share the 
EGF-like and Ig-like domain, with type VI having its N-terminal specific region 
directly associated with the EGF-like domain. Not much is known about the 
processing of these proteins but it is thought that this process is similar to the 
processing of types I and II. 
 
Nrg 1 type I-III are considered the “classic” neuregulins (present in all vertebrates) 
while type IV-IV are considered “new” (restricted to primates) (Talmage, 2009). Not 
much is known about the function of these “new” neuregulins, so the main focus of 
this chapter will be on the “classic” neuregulins, more specifically on Nrg1 type III. 
Nrg 1 type IV has recently been implicated in schizophrenia and its role in mental 
disorders will be further discussed in Chapter 5. 
 
 
Figure 4.1 – Neuregulin 1 and respective isoforms. The different isoforms of neuregulin 1 
(Type I-IV) all share an EGF-like domain in the extracellular region and are classified 
according to their type specific sequences. Neuregulin 1 isoforms are synthesised as 
transmembrane proteins, and after proteolitic cleavage are shed and released as soluble 
factors (type I-II and IV-VI) except in the case of type III which has both the N- and C-
terminal inside the cell.  Stars: glycosalytion. Lightning: proteolitic cleavage. 
 
Chapter 4 – Integrins, neuregulins and myelination 
109 
 
Neuregulins are responsible for multiple functions and have a role in different organs 
of the organism. Different in vivo and in vitro approaches have suggested a critical 
role for neuregulins in cardiac development, neural development, mammary gland 
development and muscle metabolism. Neuregulin 1 has been associated with 
survival, proliferation, differentiation and myelination in Schwann cells. In 
oligodendrocytes, neuregulin 1 affects proliferation, survival, differentiation and 
myelination. The initial formation of the nerve muscle interaction in the 
neuromuscular synapse is also controlled by Nrg1, as is the muscle spindle 
development, and also regulates neuronal neurotransmitter receptors, amongst other 
functions (reviewed by Falls, 2003). 
 
4.1.3 Neuregulin 1 signalling and the nervous system 
 
ErbB receptor family 
 
The ErbB receptor tyrosine kinase is composed of four structurally related tyrosine 
kinases: ErbB1 (or HER1, or EGFR), ErbB2 (or neu in rodents, HER2 in humans), 
ErbB3 (or HER3) and ErbB4 (or HER4). All four tyrosine kinases share an 
extracellular ligand-binding region (or ectodomain with approximately 620 amino 
acids), a single transmembrane-spanning region and a cytoplasmic protein tyrosine 
kinase-containing domain (Holbro and Hynes, 2004). The ErbB family is expressed 
in several tissues through development and is involved in many cellular processes 
such as cell growth, division, migration, adhesion and apoptosis (Gerbin, 2010).  
ErbB receptor activation is spatially and temporally regulated by its ligands. ErbB 
ligands (EGF-related peptide growth factors) are synthesised as transmembrane 
precursors, their ectodomains are shed by proteolysis, responsible for soluble factor 
formation (Massagué and Pandiella, 1993). In mammals, ligand binding specificity is 
achieved by an EGF-like domain present in the ligands. There are 3 groups of ErbB 
ligands: 1) EGF, transforming growth factor-α (TGFα) and amphiregulin bind to 
ErbB1; 2) betacellulin, heparin-binding EGF (HB-EGF) and epiregulin which bind 
both ErbB1 and ErbB4; and 3) neuregulins, with two subgroups depending of their 
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ability to bind ErbB3 and ErbB4 (Nrg1 and Nrg2) or ErbB4 only (Nrg3 and Nrg4). 
So far no ligand for ErbB2 has been identified (Fig. 4.2) (Holbro and Hynes, 2004).  
 
Ligand binding to ErbB receptors induces homo- or heterodimerization and 
subsequent activation of the intrinsic kinase domains leading to specific tyrosine 
residues to be phosphorylated (which act as docking sites for ligands) in the 
cytoplasmic domain, which in turn activates the intracellular signalling pathways.  
 
Figure 4.2 – ErbB receptors and its ligands. Structure of the four tyrosine kinases (ErbB1, 
ErbB2, ErbB3 and ErbB4) and their respective ligands. ErbB receptors share an extracellular 
ligand-binding region (or ectodomain with approximately 620 amino acids), a single 
transmembrane-spanning region and a cytoplasmic protein tyrosine kinase-containing 
domain. Note that ErbB3 lacks tyrosine kinase and needs to heterodimerize with other ErbBs 
in order to be activated. 
 
The extracellular region of the ErbB receptor is composed of four domains (I-IV). 
ErbB1 inactive structure presents an intramolecular interaction between domains II 
and IV which mediates receptor-receptor interaction. Since the domain II and IV are 
located in the same dimerization arm, this confers the ErbB1 a closed conformation. 
In order to achieve an open conformation the ErbB1 domain needs to undergo 
rearrangement (Fergurson et al., 2003; Cho and Leahy, 2002). Interestingly, ErbB2 is 
always in a conformation that resembles the ligand-activated ErbB1, with no 
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interaction between the II-IV domains and an exposed dimerization loop. This may 
explain why ErbB2 is an orphan receptor, since the proximity of the domains I and 
III prevents EGF-related peptides ligation. ErbB3 lacks tyrosine kinase activity and 
in its nonactivated state has an analogous conformation to ErbB1. In order to be 
phosphorylated, ErbB3 needs to heterodimerize with other ErbB receptors. ErbB4 
comprises a functional ligand-binding domain and a tyrosine kinase domain, 
allowing ErbB4 to bind neuregulin as a homodimer (Bao et al., 2003) 
 





The EGF-like domain present in the extracellular domain of neuregulins interacts and 
activates the ErbB receptor and stimulates the different signalling pathways. This is 
accomplished after proteolytic cleavage by 3 different type I membrane proteases: 
tumour necrosis factor-α converting enzyme (TACE/ADAM17), β-site of amyloid 
precursor proteins cleaving enzyme (BACE or also termed memapsin2) or meltrin-β 
(ADAM19). After proteolytic catalysis, the EGF-like domain is released and binds 
specific receptors to initiate autocrine or paracrine/juxtacrine signalling (Goodearl et 
al., 1995; Loeb et al., 1998). Neuregulin 1-type III comprises a CRD-domain which 
remains attached to the membrane after proteolytic cleavage and presents an extra 
binding point, therefore conferring these isoform properties for juxtacrine signalling. 
By contrast, the other Nrg1 isoforms are shed and released as soluble growth factors 
after cleavage and act as paracrine signalling molecules (Gumà et al., 2010). 
 
Activation of ErbB receptors occurs via dimerization mediated by their ligands 
(Schlessinger, 2000). Nrg1 is unable to bind ErbB1. Although Nrg1 only binds 
ErbB3 and ErbB4, Nrg1 can, in theory, interact with all four ErbB receptors by 
inducing formation of heterodimers (Murphy et al., 2002).  Since ErbB2 lacks a 
binding domain but has an active catalytic protein tyrosine kinase, its activation is 
achieved by heterodimerization with the ErbB3 and ErbB4 receptors (Graus-Porta et 
Chapter 4 – Integrins, neuregulins and myelination 
112 
 
al., 1997). ErbB3 is deprived of tyrosine kinase activity, therefore functioning as a 
signalling partner only when dimerized. ErbB3 homodimers can bind to Nrg1 but are 
catalytically inactive (Guy et al, 1994). In contrast, ErbB4 comprises a ligand-
binding and a tyrosine kinase domain, which allows the formation of homodimers 
capable of Nrg1 binding (Gumà et al., 2010). Nrg1 interacts with the homodimer 
Erb4/ErbB4 and the heterodimers ErbB2/ErbB3, ErbB2/ErbB4 and ErbB3/ErbB4 
(Mei and Xiong, 2008). The ability to form different homo- and heterodimers 
explains the importance of ErbB receptors in different organs since they can interact 
with a multitude of ligands, and therefore regulate several signalling pathways. 
 
Nrg1/ErbB signalling activates extra- and intracellular pathways. After Nrg1-ErbB 
binding, the ErbB receptor undergoes conformational changes and dimerizes with 
another ErbB receptor. Dimerization activates the tyrosine kinase and induces 
tyrosine auto- and trans-phosphorylation of the cytoplasmic domain of the receptors, 
which causes the exposure of binding sites for molecules that regulate downstream 
signalling (such as grb2, grb7, PLCγ , shc or p85) (Burden and Yarden, 1997; 
Yarden and Sliwkowski, 2001). ErbB/Nrg1 signalling regulates the MAPK and the 
PI3K/Akt signalling pathways (Yarden and Sliwkowski, 2001, Zorzano et al., 2003) 
that induce cellular responses such as migration, proliferation, differentiation, 
survival and apoptosis (Lemke, 1996; Burden and Yarden 1997; Adlkofer and Lai, 
2000; Garratt et al., 2000; Buonanno and Fischbach 2001; Yarden and Sliwkowski 
2001; Citri et al., 2003; Falls 2003). 
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Figure 4.3 – Bidirectional signalling by neuregulin 1. Interactions between ErbB 
receptors and neuregulins results in both forward and backward signalling. In forward 
signalling, ErbB cleavage by γ-secretase results in the release of the ErbB-intracellular 
domain that can translocate to the nucleus to regulate gene expression in ErbB expressing 
cells. In backward signalling, extracellular cleavage releases the C-terminal of neuregulins 
which can be further cleaved by γ-secretase and generates the intracellular domain that will 
translocate to the nucleus and regulate gene expression. Blue circles represent the nucleus.  
 
Signalling by Nrg1/ErbB can be divided into forward and backward signalling (Fig. 
4.3), with forward signalling being either canonical or non-canonical. In canonical 
forward signalling, ErbB is phosphorylated after ligand binding, and as a 
consequence, docking sites for phosphatase-binding adaptor molecules are exposed, 
which results in ErbB internalization (Gu et al., 2005; Liu et al., 2007; Yang et al., 
2005). This process activates several signalling pathways such as Raf-MEK-Erk and 
PI3K-Akt-S6K, with downstream kinases including c-Abl, JNK, Fyn, CDK5 and 
Pyk2 (Bjarnadottir et al., 2007; Fu et al., 2001; Si et al., 1999; Yarden and 
Sliwkowski, 2001). The wide spectrum of pathways affected by Nrg1/ErbB 
signalling explains the diversity of biological functions regulated by Nrg1. 
 
Non-canonical forward signalling is dependent on ErbB and its subsequent cleavage. 
Initial cleavage of the ErbB4 juxtamembrane by TACE exposes a binding site (ecto-
ErbB4) for Nrg1 after release of a soluble extracellular peptide which in turn leads to 
cleavage of the ErbB4 transmembrane anchored domain by presenilin-dependent γ-
secretase, followed by release of the intracellular domain of ErbB4 (Lee et al., 2002; 
Ni et al., 2001). Transcription is regulated by translocation of the intracellular 
domain to the nucleus (Sardi et al., 2006).  
 
Nrg1 isoforms are synthesized as pro-Nrg1. They are transmembrane proteins that, 
after ligation with a receptor, are either secreted as soluble factors (type I-II and type 
IV-VI) or shed and remain attached to the membrane (type III). The membrane-
associated Nrg1 isoforms can be shed into extra- or intracellular space since they 
have internal proteolytic cleavage sites (Bao et al., 2003). 
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Backward signalling is based on the property of Nrg1 acting as receptors and 
regulating signalling. The first mechanism proposed for backward signalling is based 
on pro-Nrg1 type I-II/IV-VI, where after activation of pro-Nrg1 and extracellular 
cleavage, the intracellular region can be further cleaved by γ-secretase. The cleavage 
of the Nrg1 intracellular domain allows it to be translocated to the nucleus and 
regulate gene transcription. Another mechanism proposed for backward signalling 
consists on the properties of the ErbB4 or the ecto-ErbB4 to act as a ligand for Nrg1, 
and therefore activate downstream pathways. So far, the molecules that regulate the 
nuclear signalling pathways in this model have not been identified. Therefore 
ErbB/Nrg1 signalling is a complex system with Nrg1 functioning as either a ligand 
for ErbBs in forward signalling or a receptor for ecto-ErbB4 in backward signalling 
(Bao et al., 2003; Mei and Xiong, 2008).  
 
Neuregulin 1 and the nervous system 
 
Neuregulin 1 and its receptor ErbB regulate multiple cellular functions and its 
importance is shown by transgenic Nrg1- and ErbB-null mice that are embryonically 
lethal (E10.5-13.5) (Erickson et al., 1997; Gassmann et al., 1995; Kramer et al., 
1996; Lee et al., 1995; Meyer and Birchmeier, 1995; Wolpowitz et al., 2000).  
 
In the nervous system, Nrg1 has a role in functions such as: radial neuron migration, 
axon guidance, myelination and ensheathment in the PNS, oligodendrocyte 
development, neuromuscular junction (NMJ) formation and synapse formation (Fig. 
4.3) (Mei and Xiong, 2008). A brief description of how Nrg1 controls some of these 
processes will follow with a more detailed explanation of the specific effects of Nrg1 
type III in myelination of the PNS and CNS. 




Figure 4.4 – Distinct roles of neuregulin 1 in the central nervous system. The different 
types of neuregulin 1 have been described to play a myriad of roles in both the peripheral 
and central nervous system, such as modulating Schwann cell development, nerve repair 
and remyelination. Neuregulin 1 also plays a role in fundamental processes of the brain such 
as neuronal migration and axon guidance. During oligodendrocyte development, neuregulin 
1 influences the migration and differentiation of oligodendrocyte precursor cells. Since 
neuregulin 1 is involved in so many aspects of nervous system development there is an 
increased interest to delve in its role in myelination. Adapted from Mei and Xiong, 2008. 
 
 
Radial neuron migration and axon guidance 
Neural crest cells are a pluripotent embryonic cell population that arise from the 
dorsal neural tube (Le Douarin et al., 2004) and undergo an epithelial-mesenchymal 
transition, followed by detachment of the neural tube epithelium. These cells then 
migrate substantial lengths to reach specific target sites and differentiate into a 
distinct number of cells that form the peripheral nervous system (such as neuronal 
and glial cells), skin (melanocytes), facial bone and cartilage, and heart (Anderson et 
al., 1997; Groves and Bronner-Fraser, 1999; Crane and Trainor, 2006). Nrg1 is 
expressed in the dorsal neural tube and along the migratory paths and acts as a 
chemoattractive factor for migratory neurons. Nrg1/ErbB signalling regulates 
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tangential migration of GABAergic neurons and radial migration of glutamatergic 
neurons. Radial glial cells express ErbB2 and ErbB3 while neurons express ErbB3 
and ErbB4. In vitro, neural migration along radial fibres is inhibited when glial cells 
express a dominant negative ErbB4 (Rio et al., 1997). In tangential migration of 
interneurons to the cortex, a subset of interneurons expresses ErbB4 and migrates 
along an Nrg1 type III-expressing corridor (Flames et al., 2004; Yau et al., 2003). 
Nrg1 controls short and long range migration of cortical GABAergic interneurons, 
with loss of ErbB4 resulting in a decreased number of interneurons in the cortex 
(Flames et al., 2004). Neurite outgrowth in the hippocampus, retina, thalamus and 
cerebellum is stimulated by recombinant Nrg1 (Bermingham-McDonogh et al., 
1996; Gerecke et al., 2004; Lopez-Bendito et al., 2006; Rieff et al., 1999). The exact 
mechanism of action of Nrg1 in axonal guidance is not fully understood since Nrg1 
knockout mice die at postnatal day 10.5 (P10.5). 
 
Schwann cell and oligodendrocyte development 
Schwann cells derive from the neural crest. Neural crest cells differentiate into 
myelinating or nonmyelinating Schwann cells after migrating through sensory and 
motor Nrg1 expressing neurons (Meyer et al., 1997).  Nrg1 was found to be a key 
regulator of Schwann cell development, regulating the glial fate of the neural crest 
cells (Lai and Feng, 2004), proliferation (Dong et al., 1995; Grispan et al., 1996; 
Marchionni et al., 1993; Schmid et al., 2003; Winseck et al., 2002; Wolpowitz et al., 
2000) and migration of the neural crest cells (Mahanthappa et al., 1996; Wolpowitz 
et al., 2000). Mutant mice for Nrg1, ErbB2 and ErbB3 all show developmental 
abnormalities in neural crest cells (Riethmacher et al., 1997). Once neural crest cells 
have differentiated into Schwann cells, their proliferation and migration, 
differentiation and survival is also regulated by Nrg1 (Scherer et al., 1995; 
Trachtenberg and Thompson, 1996; Winseck et al., 2002). In vitro, Schwann cells 
supplemented with Nrg1 actively proliferate, contrasting with what is seen when 
Schwann cells are cultured with serum present (Brockes et al., 1980; Lemke and 
Brockes, 1984). ErbB3 mutant mice show no heart abnormalities and after analysis 
of the peripheral nervous system, a significant decrease in the number of Schwann 
cells was observed (Riethmacher et al., 1997). Nrg1 and ErbB2 null mice die before 
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birth due to heart defects, a transgenic approach where the heart abnormalities are 
rescued by heart-specific expression of ErbB2 allowed proper investigation into the 
Nrg1/ErbB role in the PNS. These mice show a similar phenotype to the ErbB3 
mutant, lacking Schwann cells and having defasciculated nerve bundles (Woldeyesus 
et al., 1999).   
 
Interestingly, the ErbB mechanism that regulates Schwann cell development is 
conserved in zebrafish. Due to the intrinsic characteristics of zebrafish, it is possible 
to observe their embryonic development and perform time-lapse analysis in vivo. 
Zebrafish mutants for ErbB2 and ErbB3 present a similar phenotype seen in mutant 
mice (Honjo et al., 2008; Lyons et al., 2005). Impaired migration of Schwann cell 
precursors along the developing axon and reduced proliferation rates were observed 
in the ErbB3 mutant embryo. After chemical inhibition of ErbB, it was also reported 
that Schwann cell proliferation is disrupted and these cells show an aberrant 
migratory pattern (Lyons et al., 2005).   
 
Nrg1 and ErbBs are widely expressed in neurons and oligodendrocytes of the 
developing and adult CNS (Meyer et al., 1997; Buonanno and Fishbach, 2001; Falls, 
2003; Anton et al., 2004). Due to the early lethality of Nrg1 and ErbB mutant mice, 
it is difficult to assess their function during CNS development since the developing 
process of the CNS is not constrained to the embryonic period and lasts until after 
birth. Therefore most data that suggest a role for Nrg1 in CNS development was 
generated mainly from in vitro and ex vivo studies. In vitro, Nrg1 was shown to have 
a role in oligodendrocyte specification, proliferation, differentiation and survival 
(Calaora et al., 2001; Canoll et al., 1996; Canoll et al., 1999; Flores et al., 2000; 
Vartanian et al., 1997). Vartanian and co-workers showed that Nrg1 knockout mice 
fail to generate oligodendrocytes after examining cultures of spinal cord explants 
from these mice. This phenotype can be rescued by exogenous Nrg1 (Vartanian et 
al., 1999). In the chicken model, the spinal cord is deprived of oligodendrocyte 
precursors during normal development. Explants from dorsal spinal cord 
supplemented with sonic hedgehog and Nrg1 can give rise to oligodendrocyte 
progenitors (Sussman et al., 2000). In vivo, ErbB2 has also been shown to affect 
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oligodendrocyte development. Dominant negative ErbB2 mice show an increase in 
oligodendrocyte precursor cells and a reduction of myelinating oligodendrocytes 
(Kim et al., 2003).  
 
Neuregulin 1 and myelination – PNS vs. CNS 
 
Glial cells of the nervous system are responsible for ensheathing axons with a 
specialized plasma membrane – myelin – in order to electrically insulate the axon 
and allow a faster propagation of the nervous impulse. Schwann cells in the PNS and 
oligodendrocytes in the CNS myelinate axons using different processes. While 
Schwann cells establish a 1:1 ratio with axons, oligodendrocytes are capable of 
myelinating multiple axons of different sizes showing that axons play an important 
role in the regulation of myelin thickness (Baumann et al., 2001). Friede showed that 
myelin thickness is proportional to axon diameter. This relation is termed the g-ratio 
and is the ratio between the radius of inner and outer circumferences of the myelin 
sheath (Fig.4.5) (Friede, 1972). Nrg1 is expressed on the axon surface and the 
specific Nrg1 type III isoform has been shown to be a key regulator of peripheral 
myelination. 
 
More than a decade ago, it was initially proposed that Nrg1 and its receptors played a 
role in peripheral myelination. Mice with null mutations for Nrg1, ErbB2 or ErbB3 
show aberrant Schwann cell development. Since ErbB2 knockout mice are 
embryonic lethal, Garratt and co-workers applied a conditional inactivation of ErbB2 
strategy specific to Schwann cells, with mice exhibiting a hypomyelination 
phenotype (Garratt et al., 2000). Further transgenic approaches were taken to assess 













 showed that all these 
mice share the same phenotype with decreased myelin thickness (Michailov et al., 
2004). Accordingly, axons that over-express Nrg1 type III have thicker myelin, 
demonstrating that myelin wrapping is proportional to Nrg1 expression levels (Fig. 
4.5) (Michailov et al., 2004). In the PNS, Nrg1 contributes to the initiation of 
myelination. Dorsal root ganglion (DRGs) isolated from mice with reduced Nrg1 
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type III expression failed to be myelinated in culture, even when the number of 
Schwann cells available was increased five-fold. This phenotype can be rescued by 
lentiviral expression of Nrg1 type III. Superior cervical ganglia are characterized by 
small caliber axons and express low levels of Nrg1 type III, and therefore are not 
myelinated in vivo. Lentiviral expression of Nrg1 type III on the surface of these 
axons is sufficient to promote myelination (Taveggia et al., 2005).  
 
Figure 4.5 – Neuregulin 1 controls myelin thickness in the peripheral nervous system. 
Variation in expression of axonal neuregulin 1 regulates the myelin thickness in the PNS, 
with heterozygous mice for Nrg1 showing hypomyelination and overexpression of Nrg1 
leading to hypomyelination.   
 
Contrary to the PNS, the role of Nrg1 in the CNS is not well established. One study 
that can support the view that Nrg1 also plays a role in central myelination used the 
beta-site amyloid precursor protein-cleaving enzyme 1 (BACE 1) knockout mice. 
Bace1 modulates myelination both in the PNS and the CNS, and the Bace1 KO mice 
showed hypomyelination and decreased myelin thickness (Hu et al., 2006). In vitro, 
the addition of exogenous Nrg1 to myelinating co-cultures of oligodendrocytes with 
DRG neurons showed an increase in myelination (Wang et al., 2007), and in co-
cultures of Nrg1 type III-deficient DRG neurons myelination was reduced (Taveggia 
et al., 2008).  In vivo, transgenic mice expressing a dominant-negative ErbB receptor 
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in oligodendrocytes and mice haplosuffficient for Nrg1 type III showed 
hypomyelination  (Taveggia et al., 2008; Roy et al., 2007).  
 
It was therefore likely that neuregulin played a similar role in the CNS to that already 
described in the PNS. However, overexpression of Nrg1 does not promote 
myelination of small diameter and normally unmyelinated axons in co-cultures of 
superior cervical ganglion neurons and oligodendrocytes (Taveggia et al., 2008). It 
was also reported that conditional mutants with ablation of Nrg1, ErbB3 or ErbB4  
had no cortical myelination abnormalities (Brickmann et al., 2008), suggesting that 
Nrg1 signaling it is not required for CNS myelination. 
 
Integrins amplify neuregulin signalling 
 
Integrins, the major family of extracellular matrix (ECM) receptors are involved in 
the regulation of many fundamental cellular functions such as proliferation, survival, 
and migration (reviewed by Laursen and ffrench-Constant, 2007). Integrins are 
heterodimers of an α and β chain that bind the ECM ligands and signal through 
pathways including PI3K and MAPK (Hynes, 2002). Interaction with a wide range 
of receptors including growth factor receptors (such as the ErbB receptor family that 
regulates neuregulin) is well described (reviewed by ffrench-Constant, 2004). One of 
these integrins, α6β1, binds laminins expressed around axons at the time of 
myelination and is known to regulate oligodendrocyte survival signalling by 
amplification of neuregulin activity (Colognato et al., 2002).  
 
In the CNS, growth factors can regulate cell proliferation, survival and differentiation 
in a context-dependent manner. In the course of oligodendrocyte development, 
differentiation and survival are regulated by axonal contact and soluble factors 
(PDGF and Nrg1) (Barres and Raff, 1999; Buonanno and Fischbach, 2001). These 
factors have contradictory effects throughout oligodendrocyte development, acting as 
mitogens and differentiation inhibitors in early stages, and in later stages cease their 
mitogenic and inhibitory function and switch to promote oligodendrocyte survival 
(Colognato et al., 2002). This switch can be explained through integrin signalling 
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and its properties regulating growth factor responses. Integrin α6β1 is one of the 
heterodimers expressed by oligodendrocytes and mediates neuronal survival 
signalling in oligodendrocytes. α6β1 integrin binds laminin-2 which is expressed by 
axons during myelination and this interaction is known to regulate survival of 
oligodendrocytes that contact axons by reducing the threshold requirement for PDGF 
and Nrg signalling. Integrin α6-null mice die at birth but myelination of axon tracts 
of the brainstem and cervical spinal cord is initiated before birth which can be used 
for the analysis of α6 integrin function. In cultures from integrin α6-null mice, a 
decrease in MBP positive cells and an increase in apoptosis were observed when 
compared to wildtype. Axons derived from the integrin α6-null mice were cultured in 
laminin-2 and supplemented with neuregulin switch from a PI3K to a MAPK 
pathway (showed by an increased MAPK phosphorylation). PI3K promotes 
proliferation and survival but inhibits differentiation. MAPK promotes differentiation 
and survival. This switch to MAPK-dependent signalling enhances survival and 
presents a mechanism for axon-mediated survival of oligodendrocytes regulated by 




4.2.1 Analysis of dominant negative β1 integrin // 
neuregulin 1 type III +/- mice 
 
As described in Chapter 3, dominant negative β1 integrin (dnβ1) mice showed that 
integrins mediate the axoglial interactions in myelination (Câmara et al., 2009). 
These mice reduce β1 integrin signalling independently of ligand binding. To test our 
hypothesis, that β1 integrin acts in concert with neuregulin 1 to regulate the initial 
axoglial contact, we crossed the dnβ1 mice with neuregulin 1 type III heterozygous 
(neuregulin 1 type III 
+/-
) mice. These mice were a kind gift from Dr. Carla Taveggia 
and have been described elsewhere (Wolpowitz et al., 2000). The offspring was 
either dnβ1 // neuregulin 1 type III
+/+ 
(used as a control) or dnβ1 // neuregulin 1 type 
III
+/-
. Neuregulin 1 type III haploinsufficient mice showed no defect in myelination 
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in the optic nerve and spinal cord but showed hypomyelination of the corpus 
callosum (Taveggia et al., 2007). 
 
To analyse myelin integrity in the dnβ1 // neuregulin 1
+/-
 mice, we initially 
performed ultrastructural electron microscopy (EM) analysis and measured the ratio 
between the radius of the inner and outer circumferences of the myelin sheath (g-
ratio) on optic nerves of mice at postnatal day 17 (P17), a time at which myelination 
is not yet complete (Figure 4.6). Approximately 100 axons from each sample were 
analysed, in 4 animals of dnβ1//neuregulin 1 
+/+ 
(n  =  400 axons), with an average g-
ratio of 0.82 ± 0.014 in dnβ1//neuregulin 1 +/- mice (n =  596 axons, 6 animals) and 
an average g-ratio of 0.82 ± 0.00 in dnβ1//nneuregulin 1 
+/+
, with no difference 
(P=0.76) observed between genotypes (Fig. 4.6).  
 
Figure 4.6 – Myelin thickness is unaltered in double mutant mice (dominant negative 
β1 integrin // neuregulin 1 type III heterozygous).  Ration between the axon radius and 
axon radius plus myelin (g-ratio) plotted against the axons radius shows no difference 
(P=0.76) in myelin integrity between the dnβ1//nneuregulin 1 type III 
+/+
 (average g-ratio of 
0.82 ± 0.00, n  =  400 axons from 4 animals) and dnβ1//neuregulin 1 type III 
+/-
 mice (average 
g-ratio of 0.82 ± 0.014, n =  596 axons from 6 animals). Statistical analysis performed by 
Student’s t test. 
 
As previously seen in the dnβ1 mice, we saw no significant difference in the g-ratios 
of the dnβ1//neuregulin 1 
+/-
 mice, showing that once oligodendrocytes establish 
contact with the axons, they are capable of correctly myelinating and forming 
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compact myelin. Since the previous phenotype described with the dnβ1 mice was 
detected in small diameter axons, we binned the data to assess whether there were 
any differences in the various axon radius categories (small < 0.3 µm; medium 0.3 – 
0.6 µm, large > 0.6 µm). The binned data did not show any alteration of the myelin 
integrity (Fig. 4.7). 
 
 




Figure 4.7 – Normal myelin thickness in the optic nerve of dominant negative β1 
integrin // neuregulin 1 type III 
+/-
 mice. When the g-ratio is sub-divided according to 
various categories of axon diameter, no change is observed in myelin thickness in any 
particular group.  G-ratio as a function of the different categories of axon diameter (small ≤ 
0.3 μm, medium 0.3 – 0.6 μm and large ≥ 0.6 μm. dnβ1//nneuregulin 1 type III 
+/+
 :  n  =  400 
axons from 4 animals and  dnβ1//neuregulin 1 type III 
+/-
 mice:  n =  596 axons from 6 
animals.  
 
The dnβ1 mice showed a delay in the initiation of myelination of small diameter 
axons, when the percentage of myelination was analysed by plotting the axon 
diameter and the percentage of axons myelinated. To further assess if integrin β1 acts 
in concert with neuregulin 1 type III to regulate the initiation of myelination, we 
repeated the same type of analyses on the dnβ1//neuregulin 1 
+/-
 mice and their 
dnβ1//neuregulin 1 
+/+ 
counterparts. A minimum of 400 axons were analysed for each 
animal, from at least 3 non-overlapping photos. These axons were classified as 
myelinated or unmyelinated and plotted by diameter. In the dnβ1 // neuregulin 1 
+/+
, 
we have analysed 4 animals with an average percentage of myelination of 56.00 ± 
3.305, and 6 animals were analysed for dnβ1 // neuregulin 1 
+/-
 with an average of 
56.00 ± 3.315 (P = 0.41). This shows that neuregulin 1 does not enhance the 
phenotype previously described for the dnβ1 integrin mouse (Fig. 4.8). 




Figure 4.8 – Neuregulin 1 does not enhance the phenotype observed in the dominant 
negative β1 integrin. Percentage of myelinated axons plotted as function of the axon 
diameter shows no difference (P=0.41) between the dominant negative β1 integrin // 
neuregulin 1 type III 
+/+
 (with average of 56.00 ± 3.305, from 4 animals, n = 1780 axons) and 
the dominant negative β1 integrin // neuregulin 1 type III 
+/-
 (with average of 56.00 ± 3.315, 
from 6 animals, n = 2607 axons). These shows that neuregulin does not enhance the 
threshold for myelination observed in the dominant negative β1 integrin mice. A two-way 
ANOVA was performed for statistical analysis. 
 
Since the phenotype observed in the dnβ1 is transient, with older mice not showing a 
delay in the myelination of small diameter axons, and to further test our hypothesis, 
we have analysed mice at postnatal day 21 (P21). A morphological analysis of the g-
ratio in the dnβ1 // neuregulin 1
+/+
 and dnβ1 // neuregulin 1
+/-
 optic nerves of adult 
mice revealed no differences (P=0.22), with average g-ratios of 0.81 ± 0.007 (n = 
592 axons, from 6 animals) and 0.82 ± 0.005 (n = 1301, from 13 animals) for the 
dnβ1 // neuregulin 1 
+/+
 and dnβ1 // neuregulin 1 
+/-
, respectively. 




Figure 4.9 – Morphological analysis of the optic nerve at postnatal day 21 (P21). G-
ratio measurements as a function of axon radius is not significantly different (P=0.22) 
between genotypes, with dnβ1 // nrg1 
+/+
 having an average of 0.81 ± 0.007 (6 animals, n = 
592 axons) and dnβ1 // nrg1 
+/-
 (13 animals, n = 1301 axons) having an average of 0.82 ± 
0.005. A Student’s t test was used for statistical analysis. 
 
We further grouped the axons by radius category and analysed the g-ratios for small 
(< 0.3 µm), medium (0.3 – 0.6 µm) and large (> 0.6 µm) radius. Consistent with the 
previous results, no difference was observed across the different classes of axon 
radius (Fig 4.10). 
 
 





Figure 4.10 - Ultrastructural analysis of the optic nerve of dominant negative β1 
integrin // neuregulin 1 type III 
+/- 
mice shows no abnormalities of myelination in 
different categories of axon diameter at postnatal day 21 (P21). G-ratio was divided 
according to different categories of axon diameter to confirm there was no specific 
phenotype in the different classes of axons. G-ratio measurements as a function of different 
diameters (small ≤ 0.3 μm, medium 0.3 – 0.6 μm and large ≥ 0.6 μm). dnβ1 // nrg1 
+/+
 : 6 
animals, n = 592 axons  and dnβ1 // nrg1 
+/-
 : 13 animals, n = 1301 axons. 
 
To establish if the reduced levels of both integrin and neuregulin affect the threshold 
for myelination, we determined the percentage of myelination of the dnβ1 // 
neuregulin 1 
+/+
 (average of 0.81 ± 0.007) and dnβ1 // neuregulin 1 
+/- 
(average of 
0.82 ± 0.005) mice, which showed no differences (P=0.21) (Fig 4.11). 




Figure 4.11 – The threshold for myelination is not increased in the optic nerve of 
dominant negative β1 integrin // neuregulin 1 type III 
+/- 
mice at postnatal day 21. The 
percentage of myelinated axons in plotted against axon diameter at 0.1 intervals shows no 
difference in between genotypes. dnβ1 // neuregulin 1 +/+ mice show an average of 
percentage of myelinated axons of 0.81 ± 0.007, from 6 animals, n = 2510 axons) and dnβ1 
// neuregulin 1 
+/- 
mice had an average of 0.82 ± 0.005, from 13 animals (n = 5451 axons), 
with a p value of 0.21. A two-way ANOVA was performed for statistical analysis. 
 
While analysing the data, it was apparent that these animals presented different types 
of myelin aberrations. Therefore we categorized them as a) loops, where myelinated 
axon(s) are wrapped with a loop of uncompacted myelin; b) double wraps, where 
more than one axon is wrapped in the same myelin sheath; and c) dystrophies, where 
either there is a spiral of uncompacted myelin due to axon degeneration, or loose 
myelin surrounding multiple axons. After quantifying each category, we found that 
there was no significant difference between any of the categories at the different time 
points.  
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Figure 4.12 – Quantification of myelin aberrations in the optic nerve of dominant 
negative β1 integrin // neuregulin 1 type III +/- mice. Upper panel: representative electron 
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micrographs of the different categories of myelin aberrations: loop, double wrap and 
dysmyelination. Mean for dominant negative β1 integrin // neuregulin 1 type III +/+ mice: loop 
(0.55), double (0.06) and aberrations (0.12) (from 4 animals). Mean for dominant negative β1 
integrin // neuregulin 1 type III +/- mice: loop (0.86), double (0.35) and aberrations (0.09) 
(from 6 animals).   Middle panel: quantification of myelin aberrations in the optic nerve at 
postnatal day 17 (P17). Bottom panel: myelin aberrations in the optic nerve of P21 mice. 
Mean for dominant negative β1 integrin // neuregulin 1 type III +/+ mice: loop (0.63), double 
(0.30) and aberrations (0.14) (from 6 animals). Mean for dominant negative β1 integrin // 
neuregulin 1 type III +/- mice: loop (0.47), double (0.24) and aberrations (0.23) (from 13 
animals).   This analysis was performed by simply counting the number of myelin aberrations 
for each sample, from at least 5 non-overlapping electron microscopy images. A Wilcoxon 
signed-rank test was performed for statistical analysis, this test is performed by hand and 
showed there was no significant difference between both phenotypes, in the different 
categories of myelin aberrations. According to the Wilcoxon signed-rank test a rank of the 
differences between each pair of scores was paired and ranked. A value of the differences 
between the ranks (W) is then compared with the table of critical Wilcoxon values. Since this 
value was higher than the table of critical values for the Wilcoxon test, no statistical 
difference is present in these samples. 
 
Initially, neuregulin 1 type III 
+/-
 mice were reported to be hypomyelinated in the 
corpus callosum (Taveggia et al., 2008). To investigate if the added disruption of β1 
integrin signalling would extend these observations, we analysed the morphology of 
myelin thickness by g-ratio at postnatal day 17 and 21 (Fig 4.13 and 4.14). At P17, 
analysis of 3 animals per genotype showed no differences (P=0.40) between the dnβ1 
// nrg1 
+/+
 (average of 0.73 ± 0.02, n = 321 axons) and dnβ1 // nrg1 
+/- 
(average of 
0.77 ± 0.04, n = 303 axons). Myelin thickness also showed a trend of being unaltered 
in the P21 mice with averages of 0.72 (n=207 axons, from 2 animals) and 0.73 
(n=206 axons, from 2 animals). 




Figure 4.13 – β1 integrin // neuregulin 1 type III signaling does not affect myelin 
thickness in the corpus callosum in vivo at postnatal day 17 (P17). No significant 
difference (P = 0.40) was observed between genotypes, showing a normal myelin integrity 
between the dnβ1 // neuregulin 1 
+/+
 (3 animals; average of 0.73 ± 0.02, n = 321 axons) and 
dnβ1 // neuregulin 1 
+/-
 (3 animals; average of 0.77 ± 0.04, n = 303 axons). Statistical 
analysis performed by Student’s t test. 
 
 




Figure 4.14 – Unaltered myelin morphology in the corpus callosum of dominant 
negative β1 integrin // neuregulin 1 type III heterozygous mice at postnatal day 21 
(P21). Disruption of integrin and neuregulin signaling results in normal myelin thickness in 
the corpus callosum of dnβ1 // neuregulin 1 
+/-
 mice (2 animals, average of 0.73; n=206 
axons) compared with dnβ1 // neuregulin 1 
+/+
 (2 animals, average of 0.72; n=207 axons.   
 
Taken these results together, we conclude that neuregulin 1 type III does not enhance 





Myelination is a key feature for all organisms allowing the nervous impulse to 
propagate faster along the axon. In diseases such as Multiple Sclerosis (MS) where 
new myelination (remyelination) is impaired, it is key to understand the mechanisms 
that control myelination in order to develop drug targets used to promote 
remyelination. In MS lesions, oligodendrocytes are arrested in a premyelinating state 
(Kuhlmann et al., 2008). The ability of oligodendrocytes to extend multiple 
processes and myelinate different internodes points out the complexity of the 
myelination process, where oligodendrocytes must initiate axoglial contact, sense the 
axon size and wrap the necessary number of myelin sheaths to efficiently promote 
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insulation of the axon. Throughout the years researchers have tried to identify the 
molecules that regulate myelination. Work described in this thesis (Chapter 3) 
showed that one of these molecules is β1 integrin. Dominant negative β1 integrin 
mice showed that β1 integrin signalling regulates the initial stage of myelination with 
mutant mice presenting a delay in myelination compared to the wildtype. This effect 
is specific for small diameter axons and suggests that mutant oligodendrocytes are 
unable to recognize or sense these small calibre nerves and initiate myelination. 
Interestingly, the alteration described in myelination is transient with older mice 
showing that oligodendrocytes eventually recover their ability to successfully 
myelinate small calibre fibbers. Neuregulin 1 type III is expressed on the axonal 
surface and in the PNS (where Schwann cells – cells responsible for myelination – 
establish axoglial contact with only one axon) has been identified as a key axonal 
signalling molecule that regulates myelin thickness and glial fate. 
 
In the PNS, neuregulin I type III has been identified as a necessary and sufficient 
signal that regulates axoglial interaction. The levels of axonal Nrg1 regulate whether 
an axon is myelinated and also controls myelin thickness.  Overexpression of 
neuregulin 1 type III on normally unmyelinated axons promotes their myelination in 
vivo, while transgenic mice expressing higher than normal levels on peripheral nerve 
axons generate thicker myelin sheaths (Michailov et al., 2004; Taveggia et al., 2005).  
 
In the CNS, the action of neuregulin remains unknown with conflicting reports 
showing that neuregulin 1 can regulate myelination in vitro (Taveggia et al., 2008; 
Wang et al., 2007) and in vivo. Mice haploinsufficient for neuregulin 1 type III show 
hypomyelination of the corpus callosum, but no defects in the optic nerve and spinal 
cord (Taveggia et al., 2008). Contrasting with these reports, Brickmann and co-
workers described no alterations of cortical myelination in mice with ablated 
neuregulin (Brickmann et al., 2008).  
 
As mentioned above, our dominant negative β1 integrin mice presented a transient 
effect showing that disruption of β1 integrin signalling is either only necessary for 
the initial stages of myelination or that compensatory mechanisms act to restore 
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normal myelination. Given the evidence from the PNS, we hypothesised that integrin 
and neuregulins act in concert and form a signalling complex responsible for 
initiation of myelination. If this was the case, disruption of both signalling molecules 
would have a greater effect than the one seen in the dnβ1 and the neuregulin 1 type 
III 
+/-
 mutant mice alone. To test our hypothesis, we crossed these mice and predicted 
an enhanced phenotype to the one described in the optic nerve of the dnβ1 and 
further hypomyelination of the corpus callosum. By analysing the optic nerve and 
corpus callosum of the offspring of this cross at postnatal day 17 and 21, we 
conclude that this is not the case. In neither the structures analysed was the 
morphology of the myelin sheath or its thickness altered, and percentage of 
myelinated axons did not intensify the shift to the right of the dose-response curve 
initially observed in the dnβ1.   
 
From previous studies in the PNS it is clear that neuregulin 1 type III controls the 
Schwann cell differentiation mechanism and myelination (Garrat et al., 2000; Jessen 
and Mirsky, 2005; Nave and Salzer, 2006). Given the similarities in the myelin 
sheath composition of the PNS and CNS, it would be expected that Nrg1 had an 
analogous function in central myelination. This would make neuregulin 1 a 
particularly good candidate for clinical applications, both in multiple sclerosis and 
also in schizophrenia. Work described in this chapter together with the results of 
Brickmann and colleagues (2008) points to different molecular factors that contribute 
to PNS and CNS myelination, with neuregulin 1 being redundant for central 
myelination. Both these results are in conflict with other in vivo and ex vivo data. It is 
difficult to reconcile both in vivo studies, since neuregulin 1 type III 
happloinsufficient mice present hypomyelination of the corpus callosum (Taveggia et 
al., 2008). One possible explanation would be the background of the strains used in 
both studies. Ex vivo data, where spinal cord explants from mice with ablated 
neuregulin 1 and ErbB2 were cultured showed that oligodendrocytes are unable to 
differentiate (Park et al., 2001; Vartanian et al., 1999). Brickmann proposed that the 
lack of electrical activity in these cultures could force myelination into a parallel and 
simplified mechanism of myelination (Brickmann et al., 2008).  
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It is important to note the complexity of central myelination, when compared to PNS. 
Oligodendrocytes can myelinate up to 40 internodes, therefore they need to extend 
several processes that would have to be tightly regulated. While Schwann cells 
establish a 1:1 ratio with the respective internode of interest, these cells would, in 
theory, require just one transcription machinery, in contrast to oligodendrocytes that 
would require further post-transcriptional modification. It is also important to note 
that possible compensatory mechanisms, either by other neuregulins (such as 
neuregulin 2 or neuregulin 3) or neuregulin isoforms, could explain this lack of 
phenotype. It has been described that neuregulin 2 is structurally similar to 
neuregulin 1 type III and is expressed by DRGs (Carraway et al., 1997). Although 
neuregulin 3 is not structurally similar to neuregulin 1 type III, both neuregulin 2 and 
neuregulin 3 transgenic mice show normal myelination (Zhang et al., 1997). 
Although PNS and CNS share some features between them, the possible rationale to 
support these studies would be that PNS and CNS myelination diverged during 
evolution and Schwann cells retained simpler and ancestral regulatory mechanism 
for myelination, whilst oligodendrocytes developed a highly intricate network of 


























Given the interest in neuregulin 1, next we decided to look at schizophrenia, a 




Neuregulin 1 type IV overexpressing mice show a behavioural phenotype and 
reduced fractional anisotropy and white matter density in the corpus callosum 
compared to wild type mice. Therefore we hypothesised that these could be due to a 
myelination defect.  
 
Statement of aims 
1. To characterize myelination in the neuregulin 1 type IV overexpressing mice 
at different time points by analysing the g-ration through electron 
microscopy. 
2. To test if mice overexpressing neuregulin 1 type IV show changes in myelin 
staining using immunohistochemistry at postnatal day 17 and 60. 
 
Etymology of schizophrenia 
 
Schizophrenia is one of the most common psychiatric illnesses. It is a chronic and 
debilitating disorder characterized by a triad of positive (e.g. delusions, 
hallucinations), negative (e.g. apathy, social withdraw) and cognitive (e.g. attention, 
working memory) symptoms (Rico and Marín, 2011). Historically, schizophrenia has 
long been reported (Jeste et al., 1985), with Emil Kraepelin first describing it as 
“dementia praecox” (dementia of the young) based on the young age of patients and 
a chronic dementia. Although the typical age of onset is around 20 to 25 years of age, 
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this varies among patients, together with the fact that not all patients will develop 
dementia means that Kraepelin’s definition was misleading (DeLisi, 1992). The term 
schizophrenia was later coined by Eugen Bleuer and etymologically means “split 
personality” and defined by “ambivalence, disturbance of association and affect, and 
a preference for fantasy over reality” (reviewed by Walker et al., 2004).  Once 
thought to be a neurodegenerative disease, it is now clear that schizophrenia is 
instead a neurodevelopmental disease since patients do not present 
neurodegeneration and present symptoms associated with schizophrenia (i.e. 
cognitive and social impairment) before onset of psychosis (Lewis and Lieberman, 
2000). 
 
Etiology of schizophrenia 
 
Due to the multifactorial aspects surrounding schizophrenia the exact etiology of this 
disorder remains elusive. Apart from the different susceptibility genes involved with 
schizophrenia (such as neuregulin and DISC1) and environmental factors that are 
linked with neurodevelopment (such as pregnancy related, child and adult risk 
factors), and drug use, there are different theories about the neuropathological 
changes observed in schizophrenic patients which include various brain regions and 
the connection between them (Andreasen, 1996; Pulver, 2000; Tsuang et al., 2001; 
Weinberger, 1995).  
One of the current models to explain the symptomatology of schizophrenia is the 
dopamine hypothesis, where dysregulation of dopamine in the mesolimbic pathways 
leads to the positive symptoms, while negative symptoms and cognitive impairments 
are associated with disruptive mesocortical dopamine pathways (Bensherif et al., 
2012). This hypothesis is based on the altered dopamine D2 receptor levels observed 
in post-mortem schizophrenic brains, as well as the levels of dopamine occupancy of 
these receptors, the induction of psychosis by dopamine agonists – such as 
amphetamine – in both humans and animal models, as well as the pharmacological 
action of neuroleptic drugs – that act as antagonist of the dopamine receptors (Ross 
et al., 2006). Although this is the most accepted hypotheses of the etiology of 
schizophrenia, the dopamine hypothesis does not explain all the underlying 
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symptoms of schizophrenia. The current knowledge of the interaction of different 
neurotransmitters in the brain has led to an increasing interest on their role in 
schizophrenia, suggesting that different neurochemical systems might be involved in 
this pathology. Since most antipsychotics target the dopamine receptor, it would be 
expected (based on the dopamine hypothesis) that these would be an effective 
treatment, unfortunately (with exception of clozapine) most neuroleptic drugs only 
affect positive symptoms.  
 
One of the complementary hypotheses involves glutamate, a neurotransmitter 
mediated by three different types of receptors, AMPA, kainite and NMDA. The 
NMDA receptor hypofunction hypothesis is based on the evidence that NMDA 
receptor antagonists (eg, phencyclidine – PCP, ketamine and MK-801) can mimic a 
different range of psychotic features of schizophrenia in normal individuals, and 
these are reproducible in experimental animals (reviewed by Coyle, 2012). The 
disruptions generated by the NMDA receptor antagonists resemble some of the 
negative and neurocognitive symptoms associated with schizophrenia.  
 
Although the dopamine and glutamate hypothesis shed light into the positive and 
negative symptoms associated with schizophrenia, patients also present cognitive 
deficits that do not seem to be fully regulated by either neurotransmitter system. A 
decreased level of gamma-aminobutyric (GABA) neurotransmitter and GABA 
transporter is thought to underlie the cognitive impairments of schizophrenia, since 
both have been observed in schizophrenic patients (Yoon et al., 2010). The 
GABAergic system has a role in the excitation/inhibition balance in the brain and is 
ubiquitously present in the CNS, therefore one of the hypotheses is that GABA, 
which can regulate the glutamate-induced excitation, is that a disruptive interaction 
between GABA and the glutamate and/or dopamine systems is involved in the 
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Diagnosis of schizophrenia 
 
The most widely used criteria for the diagnostic of schizophrenic patients is based in 
the America’s Association Diagnostic and Statistical Manual of Mental Disorders 
(version DSM-5) (American Psychiatric Association, 2013).  According to DSM-5 a 
patient has to present signs and symptoms for six months or longer. At least two or 
more of the following symptoms should be present for at least a month: 
hallucinations, delusions, disorganized speech, grossly disorganized behaviour or 
catatonic behaviour, and negative symptoms such as lack or decline of emotional 
response, lack or declined in speech and lack or decline in motivation (American 
Psychiatric Association, 2013).  Although these diagnostic guidelines are currently in 
use it is to note that diagnosing patients with schizophrenia is difficult since some 
symptoms might be due to other mood disorders such as bipolar disease (Kendell, 
1975).  Currently, a patient can only be diagnosed based on the clinical features and 
medical assessment, but this can prove a difficult task due to heterogeneity of 
schizophrenia and overlapping symptomatology with other psychiatric disorders. 
Biomarkers that can be used as a diagnostic tool in schizophrenia have long been 
sought after (Takesada et al., 1965). Substantial research has been done since, but 
thus far no biomarker (either for diagnosis, prognosis or a theranostic biomarker) for 
clinical use has been documented (reviewed by Weickert et al., 2013). 
 
Treatment of schizophrenia 
 
Schizophrenia has no known cure. All treatments available target specific symptoms 
associated with the disorder, with long term treatment available for management of 
positive symptoms, and some negative symptoms. The cognitive deficits associated 
with schizophrenia have a modest response to the current available treatments (Furth 
et al., 2013). Current treatment consists of typical and atypical antipsychotics. 
Typical antipsychotics (also known as first generation antipsychotics) such as 
chlorprozamine, fluphenazine and perphenazine, have a long history of use, being 
introduced for the treatment of schizophrenia in the 1950s. Their mechanism of 
action is associated with a high affinity for dopamine D2-receptors that regulate the 
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release of dopamine and this characteristic can lead to severe extrapyramidal side 
effects such as tardive dyskinesia, as a result of hypodopaminergic transmission. 
Atypical antipsychotics (or second generation antipsychotics) such as clozapine, 
quetiapine and ziprasidone were introduced in the last three decades and share a 
similar pharmacological mechanism as their typical counterparts but have a lower 
risk of extrapyramidal side effects, and have therefore become the first line 
prescription. The contrast in terms of extrapyramidal side effects is thought to be due 
to differential effects of typical and atypical antipsychotics on the striatal striosome 
and matrix compartments (Bubser and Deutch, 2002). 
 
Treatment for schizophrenia has had a few major innovations in the last decade, but 
due to the highly polygenetic nature of schizophrenia, new therapies should be based 
on genetic and epigenetic studies in order to provide a full understanding of the 
neuropathology of schizophrenia and a more adequate and targeted therapy (Marden 
et al., 2011). 
 
5.1.1 Risk factors of Schizophrenia 
 
Schizophrenia underlies a combination of environmental and genetic factors that are 
thought to contribute to a disturbed neurodevelopment, but a single (and exclusive) 
factor that regulates the pathophysiology of schizophrenia has not been identified.  
Epidemiological studies show that 1% of the population worldwide is affect by 
schizophrenia and studies point out for an estimated heritability between 66% and 
80% (Cardno et al., 1999; Owen et al., 2005).  




Figure 5.1 – Confounding factors of schizophrenia. Schizophrenia is a multifactorial 
psychiatric disorder with multiple genetic and environmental associated risk factors. In 
individuals with a genetic load of susceptibility to environmental factors, a potential cofactor - 
such as perinatal trauma - can lead to spontaneous schizophrenia. In some cases, even if 
the individual does not carry a susceptibility gene a neurochemical disbalance caused by 
external factors such as substance abuse, neurotrauma or even a stressful life event can 




Schizophrenia is a complex multigenetic disease. Multiple genetic risk factors have 
been identified (such as neuregulin and DISC1), but the onset of the disease is also 
dependent on environmental factors. A potential cofactor such as perinatal trauma 
can lead to spontaneous schizophrenia in individuals with a genetic predisposition. 
Additionally, a disbalance of external factors such as substance abuse, infectious 
agents, aging or psychotrauma can lead to a late onset of schizophrenia, without a 
genetic predisposition.  
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Epidemiological studies have suggested that prenatal infection and the successive 
activation of the maternal immune system is linked with the risk of developing 
schizophrenia later in life (Canetta and Brown, 2012). Most of the studies associating 
prenatal infection with the risk of schizophrenia (and psychosis) were based on 
cohorts studies of maternal infection based on serology or medical records (reviewed 
by Brown and Derkits, 2010). These epidemiological studies combined with human, 
preclinical and animal studies have unveiled the morphological, molecular and 
neurochemical alterations present in both schizophrenic patients and animal models 
of prenatal immune activation. Neurochemical features show alterations in 
neurotransmitters such as dopamine, serotonin and glutamate. Consistent with reports 
from schizophrenic patient, animal models show reduced white matter volume and 
hippocampal neurogenesis and raised microglial activation.  Other environmental 
factor that have been associated with schizophrenia consist of obstetric 
complications, that comprise both birth and pregnancy complications. Different 
cohort studies have shown that intrauterine growth retardation, preterm births, 
perinatal trauma (such as brain injuries or hypoxia-ischemia), low birth weight or use 
of resuscitation or incubator increases the risk of schizophrenia (Geddes et al., 1999; 
Hultman et al., 1999; Jones et al., 1998). Remarkably, month of birth is also a 
cofounding factor in schizophrenia with late winter/early spring births having a 
higher risk of developing schizophrenia, thought to be related to maternal infection 
(since the births succeed the typical months for influenza infection) that may lead to 
abnormal brain development (reviewed by McDonald and Murray, 1999). 
 
Although the genetic and environmental factors are the core features of 
schizophrenia, it is interesting that the onset of the disease is predominantly during 
adolescence since most of these factors are present since birth. Most individuals that 
develop schizophrenia show some mild debilitating characteristics early on, either 
cognitive (with learning difficulties or low IQ) or social (Done et al., 1994; Foerster 
et al., 1991), demonstrating that some of the traits of the disease are present before 
onset. One of the explanations proposed is the theory of “doomed from the womb”, 
although the genetic and environmental predisposition are present from early life, 
and some traits are shown since childhood these might be due to abnormal neuronal 
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adaptation and maturation that will subsequently impair neuronal networks and 
promote the development of psychosis (reviewed by McDonald and Murray, 1999).   
 
Drug abuse and traumatic life events are also thought to be risk factors for 
developing schizophrenia, usually with a later onset. Substance abuse (especially 
cannabis) can lead to psychotic episodes that can develop into schizophrenia, with a 
correlation between the amounts of cannabis used and development of schizophrenia 
(Andreasson et al., 1987). Cannabis, specifically its main component THC, interacts 
with the dopaminergic system raising dopamine in the brain and therefore increases 




Schizophrenia is a complex disease, with multiple genetic, environmental, and 
stochastic factors that can act as cofactors. It is therefore important to identify the 
genetic basis of schizophrenia for a better understanding of the etiopathogenesis of 
this disorder, as this will grant a better knowledge for the development of targeted 
therapies. It is thought that genetic factors contribute to 50% of the risk of 
developing schizophrenia (Siegel and Ralph, 2011). So far, 15 possible genetic loci 
linked with schizophrenia have been identified mainly through linkage and 
association studies from family, twins and adoption cases (Marden et al., 2011).  
 
One of the candidate genes for risk of susceptibility in schizophrenia (disrupted in 
schizophrenia 1 - Disc1) was identified in a Scottish family with high prevalence of 
mental illness such as schizophrenia, bipolar affective disorder and major depression 
(Millar et al., 2000) and these findings have been corroborated by post-mortem, 
genetic and animal studies (reviewed by Hennah et al., 2006; Porteous and Millar., 
2006). This gene is expressed in humans, rodents and non-human primates and it is 
expressed both in neurons and glial cells, reaching its peak levels during 
neurogenesis and adolescence (Brauns et al., 2011).  Research has undercover a role 
for Disc1 in several aspects of mental illness such as working memory deficits, a 
decrease in volume and density of grey matter, impaired function and volume of the 
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hippocampus, and interestingly psychosis-related traits in healthy controls (Cannon 
et al., 2005; Hashimoto et al., 2006, Hennah et al., 2005, Tomppo et al., 2009). 
Disc1 has been implicated in an array of biological processes regarding development 
and maturation such as extracellular signalling, neurogenesis, cytoskeletal 
modulation, neurite proliferation, migration and outgrowth, synapse formation and 
maturation, decreased brain volume and altered behavioural phenotypes resembling 
schizophrenia and major depression in mutant mice  (Clapcote et al., 2007; Lee et 
al., 2011; Morris et al., 2003), To further investigate the role of Disc1 diverse mutant 
mice lines have been established, providing insight into the biological and 
behavioural role of Disc1. Interestingly, Clapcote and co-workers generated two 
different mutations on exon 2 of Disc1 gene with different outcomes. Mutation Q31L 
showed a behavioural phenotype that resembles depression, while the L100P 
mutation resulted in a schizophrenia-like phenotype, demonstrating that these two 
pathologies have a common genetic factor (Clapcote et al., 2007). Transgenic mice 
for Disc1 also present an increased level of dopamine D2 receptors in the striatum, a 
brain structure highly implicated in mental illness, and these results were also 
corroborated in human patients (Chakracarty et al., 2012).  In humans, there has been 
extensive screening of patient’s cohorts and linkage studies for Disc1 mutations all 
demonstrating a correlation between Disc1 and mental illness (reviewed by Porteous 
et al., 2006).  Human research has showed that individuals affected by mental illness 
and carrying a DISC1 mutation present a decreased volume of the prefrontal cortex 
and left supramarginal gyrus, consistent with the typical MRI scans of schizophrenic 
patients (Brauns et al., 2011; Szeszko et al., 2008),  
 
Neuregulin 1 was originally associated as a susceptibility gene for schizophrenia in 
studies of families in Iceland that identified an encoding region for neuregulin 1 
(Stefansson et al., 2002). Epidemiology studies suggest a link between several 
mutations of the neuregulin 1 gene (around 80 single-nucleotide polymorphisms 
(SNPs) have been identified so far) and schizophrenia in distinct populations’ 
worldwide (reviewed by Mei and Xiong, 2008). Although neuregulin 1 is a candidate 
gene for schizophrenia-associated mutations a correlation between neuregulin 1 and 
schizophrenia was not observed in specific populations such as Japanese, Irish and 
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Spanish (Iwata et al., 2004; Rosa et al., 2007; Thiselton et al., 2004). This suggests 
that neuregulin 1 can influence the onset of schizophrenia but other factors/genes are 
involved in this pathology.  
 
Other genes have been implicated along with neuregulin and Disc1, are dysbindin, 
which in healthy individuals is associated with working memory, but in 
schizophrenic patients, which have a reduced expression level of dysbindin in the 
hippocampus and prefrontal cortex, results in a decreased excitatory cortical limbic 
synapses that contributes to the cognitive deficits seen in these subjects (Carlson et 
al., 2011; Gill et al., 2010; Jaaro-Peled et al., 2009); and Neurexin-1, which has also 
been implicated in autistic spectrum disorder, plays a role in the formation and 
maintenance of synapse. In schizophrenic patients two of the proteins encoded by the 
neurexin-1 gene are affected differently, with no changes in expression in neurexin-
1β and a deletion of the neurexin-1α promoter leading to an absence of neurexin-1α 
in these subjects (Zweir et al., 2009). Transgenic mice lacking neurexin-1α 
expression show a decreased spontaneous excitatory synaptic transmission and in 
behavioural tests present a decrease in prepulse inhibition (PPI), a measurement of 
sensory gating that is also observed in schizophrenic patients (Etherton et al., 2009). 
This is not a comprehensive list of genes that have been associated with 
schizophrenia, and for the context of this thesis the focus will be on Nrg1/ErbB role 
in schizophrenia.  
 
As a future research target, further studies onto these interchangeable  cofactors 
(environmental and genetic) should be carried out in order to address whether solely 
environmental factors can lead to schizophrenia, or if a genetic coadjuvant needs to 
be present, and if this is the case, if there is a specific relationship between distinct 
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5.1.2 Neuregulin 1 and ErbB signalling in Schizophrenia 
 
The features of the symptoms of schizophrenic patients, together with a known 
neurodevelopment pathophysiology indicates that there is a genetic predisposition, in 
addition to environmental factors, involved in this psychiatric disorder. Recently, 
gene expression studies have found various genes in the prefrontal cortex of patients 
with mental disorders, including schizophrenia, that have an altered expression and 
are involved in myelination, such as neuregulin 1. Neuregulin 1 (Nrg1) is the most 
well studied member of the neuregulin family (comprising neuregulin 1-4) and 
belongs to the epidermal growth factor (EGF) superfamily. NRG1 gene encodes 
different isoforms through alternative splicing and differential promoter usage that 
have been previously described in Chapter 4. In recent years the human specific type 
IV isoform (specifically the [T/T] allele) has been associated with schizophrenia.  
 
Neuregulin 1 type IV levels are higher in schizophrenia patients when compared to 
control individuals (Law et al., 2006). Initial demonstration of association between 
Nrg1/ErbB signalling and schizophrenia was provided by studies of gene expression 
profile in the prefrontal cortex of schizophrenic patients that showed decreased levels 
of ErbB3, leading to a decreased expression of oligodendrocyte-specific genes 
(Hakak et al., 2001). In vivo, ablation of one copy of the Nrg1 gene, results in 
abnormal behavioural phenotype in mice similar to schizophrenic symptoms, such as 
hyperactivity and decreased prepulse inhibition. These are reversible with anti-
psychotic drugs (Stefansson et al., 2002). To further deepen the knowledge of the 
relationship of neuregulin 1 and environmental factors, Desbonnet and colleagues 
analysed transgenic mice (heterozygous for neuregulin 1) with another cofounding 
factor – chronic social stress (Desbonnet et al., 2012). Mice with heterozygous 
deletion of the neuregulin 1 transmembrane display a range of behavioural deficits 
consistent with schizophrenia such as an increased exploratory behaviour when in a 
new environment (O’Tuathaigh et al., 2010), in contrast animals exposed to social 
defeat showed anhedonia, and a decrease level of explorative behaviour. When the 
neuregulin 1 transgenic mice were exposed to social defeat, the initial exploratory 
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effect was absent, leading to the conclusion that environmental factors can influence 
genetic behavioural outcomes (Desbonnet et al., 2012). 
 
Several functions have been attributed to the Nrg1/ErbB signalling in the nervous 
system such as radial neuron migration, axon guidance, oligodendrocyte and 
Schwann cell development (previously described in Chapter 4) but Nrg1/ErbB have 
also been implicated in synapse formation and recent research has focus on the role 
of this signalling pathway in wiring of the cerebral cortex.  
 
Nrg1 type I induces the synthesis of acetylcholine receptor (AChR) (Falls et al., 
1993). Nrg1-controlled synthesis of AChR decreases with inhibition of ErbB 
activation and Erk, JNK and CDK5 kinases (reviewed by Mei and Xiong, 2008). 
Contrasting in vivo results suggest that Nrg1/ErbB signalling pathway has a 
redundant effect in the postsynaptic development. Nrg1 happloinsufficient mice 
show a reduced AChR density (Sandrock et al., 1997), while conditional ablation of 
ErbB2 and ErbB4 showed a normal development of neuromuscular junction (Escher 
et al., 2005).  
Schizophrenia has been associated with anomalous synaptic plasticity and 
neurotransmission. Both these processes have been associated with Nrg1 in the adult 
brain. Neuregulin 1 type III regulates expression of AChR while neuregulin 1 type I 
and II have been associated with modifications of the GABA receptors (Stefansson et 
al., 2002). All three isoforms are capable of regulating NMDA and AMPA receptors. 
ErbB4 signalling was also shown to regulate excitatory synapses and disruption of 
Nrg1/ErbB4 signalling affects the AMPA receptors, leading to loss of NMDA 




Neuropathological features associated with schizophrenia mainly comprise 
macroscopic and histological changes such as enlargement of the ventricles, 
abnormal cortical thickness, reduced cerebral volume, morphological  and molecular 
changes in the hippocampus, dorsal thalamus and dorsolateral prefrontal cortex 
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characterized by atypical clusters of neurons, as well as their aberrant location, and  
cerebral asymmetry (Harrison and Weinberger, 2005). Although all of these 
characteristics are subtle, they are not present across all cases of schizophrenia.  
Clinical studies combined with neuroimaging and post-mortem studies have 
identified the superior temporal gyrus (STG) and prefrontal cortex (PFC) as the main 
brain structures implicated in schizophrenia. These specific brain structures may help 
elucidate some of the main symptoms related to schizophrenia. The STG controls 
speech, auditory processing and social cognition and changes in this brain structure 
may be linked with the common positive symptoms of schizophrenia, such as 
delusions, disordered thoughts and speech and different types of hallucination (ie, 
auditory, visual and olfactory). The normal function of the PFC comprises complex 
cognitive behaviour, decision making and restraining social behaviour. In 
schizophrenic patients it is thought that the PFC dysfunction is linked with cognitive 
disturbances and abnormalities of synaptic structure and function in this cortical 
region (Keshavan et al., 1998; Shapleske et al., 1999).  
 
Loss of grey matter in Schizophrenia 
 
Using magnetic resonance imaging (MRI) it has been showed that during normal 
human development the grey matter volume is spatiotemporally altered (Gogtay and 
Thompson, 2010). Cortical development is characterized by a dynamic rate of  
maturation of the distinct lobes of the cortex, with lower-order somatosensory and 
visual centre maturation preceding higher order association cortices (i.e., language 
related areas) and maturation of grey matter (Gogtay et al., 2004).  During 
development the brain goes through a re-wiring process which involves the loss of 
cortical grey matter and a decrease of synapse density in order to maximize the 
efficacy of transmission of synapses (Bennet, 1999; Huttenlocher and Dabholkar, 
1997). In studies of patients with schizophrenia, MRI investigations show a decrease 
in grey matter volume in the prefrontal temporal network of the brain specifically in 
the insula cortex, the superior temporal gyrus, medial temporal lobe, medial and 
inferior frontal gyrus and the anterior cingulate gyrus (reviewed by Bennet, 2011). 
Loss of grey matter during normal development is completed around 22 years of age, 
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when MRI from brains of patients with schizophrenia are compared with healthy 
individuals this loss is accentuated by 10 percent. A possible explanation for a 
greater loss of grey matter in these patients is the potential depletion of synapses.  
 
Loss of white matter in Schizophrenia 
 
White matter abnormalities are a common feature of schizophrenia and bipolar 
disease. Research using MRI has detected a decrease in white matter density in the 
anterior limb of the internal capsule and in the prefrontal subgyral white matter 
(McIntosh et al., 2005; Zhou et al., 2003).  Interestingly, these studies provided 
evidence for a genetic background since this phenotype is shared by the control 
individuals (unaffected relatives of patients) (McIntosh et al., 2006). Studies 
performed in post mortem-tissue have identified high levels of expression of Nrg1 
type IV, specifically the SNP rs6994992 (SNP8NRG243177) that affects white 
matter integrity and density (Law et al., 2006; McIntosh et al., 2008; Sprooten et al., 
2009).   
 
Involvement of myelination in schizophrenia 
 
The pathogenesis of schizophrenia is associated with different areas of the brain, 
their respective connections and morphological change. Although the etiology of 
schizophrenia remains elusive, and the primary concept of schizophrenia being a 
neurodegenerative disorder (now know to be mainly a neurodevelopmental disease) 
has led researchers to investigate the role played by myelin and the myelinating cells 
of the brain – oligodendrocytes. 
 
Although this is a recent topic of research there is some evidence that myelination 
plays a role in schizophrenia. The loss of white matter in patients with schizophrenia 
is attributed to myelination defects throughout development. In these patients there is 
a decreased volume, compromised integrity and abnormal growth of white matter 
which translates into cognitive and sensorimotor coordination deficits (Chew et al., 
2013). Areas such as the corpus callosum, frontal lobe and temporal lobe are linked 
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with the neuropathological traits of schizophrenia and are associated with myelin 
aberrations and oligodendrocyte degeneration. Hakak and co-workers (2012) shed 
some light into the dysregulation associated with myelination in schizophrenia with a 
genome-wide expression analysis. After analysing the dorsolateral prefrontal cortex 
of schizophrenic patients and matching controls the study identified various genes 
related to myelination, and also other biological processes such as synaptic plasticity, 
neurotransmission, neuronal development and signal transduction (Hakak et al., 
2012). Interestingly, this study identified four genes specifically related to 
myelination and oligodendrocyte development (myelin and lymphocyte protein - 
MAL, myelin associated glycoprotein - MAG, 2’,3’-cyclic nucleotide 3’-
phosphodiesterase – CNPase and transferrin). All of these genes were down 
regulated in the post-mortem brains of schizophrenics implying a failure of 
oligodendrocyte function (Hakak et al., 2012). Another recent study expanded the 
search for glial genetic links in schizophrenic patients (Goudriaan et al., 2013). 
Oligodendrocytes have been implicated in the pathophysiology of schizophrenia due 
to the decreased white matter volume, but there are new lines of evidence showing 
that astrocytes and microglia also contribute to the pathophysiology of schizophrenia 
via neuroinflammatory processes (Goudriaan et al., 2013). 
 
Myelination alterations have also been shown in the phencyclidine (PCP)-induced 
neurodevelopmental animal model of schizophrenia. The pharmacological animal 
model of PCP administration results in prepulse inhibition (PPI) deficits and 
hyperlocomotor activity in rats, which have both been extensively described in 
schizophrenic subjects. Progenitor oligodendrocytes express NMDA receptors, PCP 
is an NMDA receptor antagonist and after administration of PCP in rats at postnatal 
day 2, animals were subjected to behavioural tests (locomotion and PPI) and 
subsequently, analysed for myelin aberrations and oligodendrocyte maturation. 
Myelin was quantified by MBP expression at postnatal days 16, 22 and 32, showing 
a decreased MBP expression in the frontal cortex. Oligodendrocyte maturation was 
analysed by glutathione S-transferase-π (a marker of oligodendrocyte maturation), 
showing a loss of mature oligodendrocytes also in the frontal cortex (Zhang et 
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al.2012). Together, these results show a correlation between the behavioural deficits 
present in schizophrenia with the abnormalities observed in the white matter.  
 
5.1.5 Animal models of schizophrenia 
 
Schizophrenia is a complex disorder presenting a constellation of positive, negative 
and cognitive deficit symptoms. Due to the range of the many symptoms presented 
by different patients and the non-existence of a single risk-factor modelling 
schizophrenia remains one of the most difficult tasks in the psychiatric field. 
Therefore the field has evolved to generate models that mimic specific functions 
instead of the entire array of symptoms. These animal models need to be able to 
characterize genetic, neural and neurochemical features that can be correlated with 
the human pathology. In the case of schizophrenia the negative symptoms are shared 
between depression and autism, consequently models for these disorders are also 
useful to partially understand schizophrenia. Thus far, different types of approaches 
have been made to generate such models which involve a) pharmacological or drug-
induced models, involving the manipulation of different neurotransmitters systems 
(e.g. Amphetamine: dopamine indirect agonist and phencyclidine/ketamine: NMDA 
receptor antagonist); b) lesion models that modulate the neurodegeneration (e.g. 
neonatal ventral hippocampal lesion); c) development models that allow 
neurodevelopment characterization (e.g. gestational X-irradiation); and d) genetic 
models associated with the genetic candidates as risk factors (e.g. neuregulin and 
DISC1 disruption) (Fernando and Robbins, 2011).   
 
Modelling positive symptoms associated with schizophrenia such as delusions and 
hallucinations is far more complex since the diagnosis of these features in human 
patients are based on verbal description; therefore it is necessary to overcome such 
issues in animal models. It has been reported that rhesus monkeys treated 
subchronically with amphetamine exhibit signs of hallucinations (Nielsen et al., 
1983). Cognitive disturbances associated with schizophrenia such as working 
memory, planning, cognitive flexibility and control can be measured in animals 
(Hagan and Jones, 2005; Robbins and Moore, 2008). The cognitive deficits observed 
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in this disorder correlate with the anatomical features observed in patients, where 
there is a loss of grey and white matter (Robbins and Moore, 2008). Currently, 
research is being focused in genetic models disturbing different signalling pathways 
that may lead to decreased density of white and grey matter, such as the Nrg1. 
Models to converge both the behavioural and anatomic relation and its association 
with genetic and environmental factors have been proposed over the years. One of 
these models is the dominant-negative mice for the human DISC1 that were 
embryonically injected with polyriboinosinic-polyribocytidilic acid (polyI : C) which 
promotes a time-limited production of maternal pro-inflammatory cytokines in 
uterus. During adulthood these mice show signs of behavioural, cognitive and 
pharmacological abnormalities, being the prime example for modulation of genetic 




According to several studies, schizophrenia patients show decreased cerebral 
(cortical and hippocampal) volume (reviewed by Harrison, 1999).  Several structural 
changes have been observed such as ventricle enlargement, reduction of frontal and 
temporal lobe volume as well as cerebellum (Schroder et al., 2002). Changes in the 
hippocampus have also been described in schizophrenia, with hippocampal volume 
reduction being a prominent feature in the brain of these patients, thought to 
contribute to the deficits in working memory observed in these individuals (Heckers, 
2001). These brain alterations have been linked to myelination, with different 
explanations arising, such as a decrease in axonal number or diameter, an overall 
reduction of myelination, or oligodendroglial dysfunction (Chew et al., 2013; 
Palaniyappan et al., 2013). Neuregulin 1 has been identified as a genetic risk factor 
for schizophrenia, and since it has been demonstrated that these patients have 
increased levels of neuregulin 1 type IV in a multi-collaboration project we set out to 
investigate and characterize myelination in mice overexpressing neuregulin 1 type 
IV, in order to assess if neuregulin 1 type IV regulates any of the morphological 
aspects that have been described in schizophrenic individuals. 
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To investigate the role of neuregulin 1 type IV in the central nervous system we 
analysed the morphological structure of the brain by immunohistochemistry using 
haematoxylin and eosin staining and luxol fast blue. Mice were perfused with 4% 
paraformaldehyde in 0.1M phosphate buffer and post fixed overnight. Brains were 
dissected and snap freezed for cryosectioning. Immunohistochemistry was performed 
after these brains were scanned for MRI by Dr. Andrew McIntosh.  Haematoxylin 
stains for cells nuclei in a deep-blue colour and eosin stains proteins nonspecifically 
and has a pink colour. Analysing sagittal sections of the cerebellum and coronal 
sections of the hippocampus showed no structural differences between wildtype and 
overexpressing neuregulin 1 type IV mice (Fig. 5.1 – 5.4). To test whether these 
mice had any alterations in myelination we also performed a luxol fast blue staining. 
Luxol fast blue is the alcohol soluble counterpart of the water soluble alsian blue and 
stains for myelin lipoproteins. Analysis of sagittal and coronal sections showed no 
myelin abnormality in the corpus callosum, cerebellum and hippocampus of 
overexpressing neuregulin 1 type IV mice when compared with their wildtype 
counter parts (Fig. 5.5 – 5.8).  
 
Figure 5.1 – Normal morphology of cerebellum in mice overexpressing neuregulin 1 
type IV at postnatal day 17 (P17). Haematoxylin and eosin staining cerebellum sagittal 
sections of wildtype and Nrg1 type IV overexpressing mice at P17 (4x magnification, scale 
bar: 100μm). 




Figure 5.2 – Overexpression of neuregulin 1 type IV does not alter the morphology of 
hippocampus (P17). Coronal sections of hippocampus with haematoxylin and eosin 
staining of wildtype and neuregulin 1 type IV overexpressing mice at P17 (4x magnification, 
scale bar: 100μm).  
 
 
Figure 5.3 – Overexpression of neuregulin 1 type IV shows normal morphology of 
cerebellum in older mice. Sagittal sections of cerebellum stained for haematoxylin and 
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eosin of wildtype and neuregulin 1 type IV overexpressing mice at postnatal day 60 (P60) (4x 
magnification, scale bar: 100μm). 
 
 
Figure 5.4 – Normal morphology of hippocampus with overexpression of neuregulin 1 
type IV in mice at postnatal day 60. Coronal sections of hippocampus with haematoxylin 
and eosin staining of wildtype and neuregulin 1 type IV overexpressing mice at P60 (4x 
magnification, scale bar: 100μm).  
 
 
Figure 5.5 – Myelin morphology is unaffected by overexpression of neuregulin 1 type 
IV. Sagittal sections of cerebellum stained for luxol fast blue of wildtype and neuregulin 1 
type IV overexpressing mice at postnatal day 17 (P17) (4x magnification, scale bar: 100μm). 




Figure 5.6 – Unaltered myelin morphology of hippocampus and corpus callosum of 
overexpressing neuregulin 1 type IV mice. Sagittal sections of hippocampus stained for 
luxol fast blue of wildtype and neuregulin 1 type IV overexpressing mice at postnatal day 17 
(P17) (4x magnification, scale bar: 100μm). 
 
 
Figure 5.7 - Overexpression of neuregulin 1 type IV shows normal myelination of the 
cerebellum in older mice. Sagittal sections of cerebellum stained for luxol fast blue for 
wildtype and neuregulin 1 type IV overexpressing mice at postnatal day 60 (P60) (4x 
magnification, scale bar: 100μm). 
 




Figure 5.8 – Normal myelination of hippocampus and corpus callosum of neuregulin 1 
type IV mice at postnatal day 60 (P60).  . Coronal sections of hippocampus with luxol fast 
blue staining of wildtype and neuregulin 1 type IV overexpressing mice at P60 (4x 
magnification, scale bar: 100μm).  
 
An analysis of immunohistochemistry images is complex since most of it is based on 
intensity of staining, which can be affected by the exposure of the tissue to the 
staining agent. In this project we focused on qualitative measures to assess integrity 
of structures, distribution and localization of staining and myelin abnormalities. All 
structures analysed (corpus callosum and hippocampus) showed structure integrity 
with no noticeable qualitative change of size, shape or volume. Distribution and 
localization of staining showed no qualitative abnormalities of myelin thickness or 
myelin track integrity. Throughout all sections staining was uniform with no patchy 
staining, no signs of cysts or myelin aberrations, or myelin outside the tracts. 
Complementary data (not shown) from MRI performed in our collaborator’s 
laboratory confirmed that no abnormalities were seen in the neuregulin 1 type IV 
overexpressing mice when compared to wildtype. 
To further test if overexpression of neuregulin 1 type IV in mice would affect white 
matter myelination and structure we analysed the optic nerve and corpus callosum of 
these animals at postnatal day 17 (P17), a time point where myelination is not yet 
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completed and postnatal day 60 (P60) a time point when myelination has reached a 
stable turnover. Mice were perfused intracardially with a fixative solution of 4% 
paraformaldehyde and 3% glutaraldehyde in 0.1M phosphate buffer and post-fixed 
overnight (perfusions were carried on in Dr. Amanda Law’s lab, Maryland, USA). 
Tissue was dissected and processed for electron microscopy and ultra-thin sections 
(prepared in the Department of Anatomy, University of Cambridge, UK) were used 
to photograph non-overlapping regions of both optic nerve and corpus callosum. G-
ratio measurements were done using Openlab image analysis software (Improvision) 
with at least 100 axons measured per animal. Early in development, when 
myelination is not yet completed (P17) we saw no differences (P = 0.23) between the 
g-ration of wild type mice (average g-ration of 0.81 ± 0.02, n = 404 axons, 4 
animals) and neuregulin 1 type IV overexpressing mice (average g-ration of 0.80 ± 
0.02, n = 406 axons, 4 animals) in the optic nerve (Fig 5.9). In the corpus callosum, 
no differences were observed (P = 0.16) when comparing neuregulin 1 type IV 
overexpressing mice (average of 0.84 ± 0.02, n = 405 axons, 4 animal) to wild type 
mice (average of 0.80 ± 0.02, n = 302 axons, 3 animals) (Fig 5.9). In the optic nerve 
at P60 there was no difference between genotypes with wildtype average g-ratio of 
0.86 ± 0.01, and neuregulin 1 type IV overexpressing mice 0.84 ± 0.01 (Fig. 5.10). 
Similarly in the corpus callosum overexpression of neuregulin 1 type IV at P60 
(average g-ratio 0.78 ± 0.01, n = 363, 4 animals) did not affect myelin thickness 
when compared to wildtype (average of 0.76 ± 0.02, n = 405, 4 animals) (P = 0.45) 
(Fig. 5.10).  
 





5.9 - Unaltered myelin morphology in overexpressing neuregulin 1 type IV mice at 
postnatal day 17. Upper panel: g-ratio measurements as function of axon radius of optic 
nerve is not significantly (P=0.23) between wildtype (average of 0.81 ± 0.02, n = 404 axons 
per 4 animals) and neuregulin 1 type IV overexpressing mice (average of 0.80 ± 0.02, n = 
406 axons per 4 animals). Bottom panel:  overexpression of neuregulin 1 type IV does not 
alter myelin integrity in the corpus callosum (average of 0.84 ± 0.02, n = 405 axons per 4 
animal) when compared with wild type mice (average of 0.80 ± 0.02, n = 302 axons per 3 
animals) (P = 0.16). Statistical analyses performed by Student’s t-test. 
 
 





Figure 5.10 – Unaltered myelin morphology in overexpressing neuregulin 1 type IV 
mice. Upper panel: g-ratio measurements as function of axon radius of optic nerve is not 
significantly (P=0.31) between wildtype (average of 0.86 ± 0.01, n = 300 axons per 3 
animals) and neuregulin 1 type IV overexpressing mice (average of 0.84 ± 0.01, n = 307 
axons per 3 animals). Bottom panel:  overexpression of neuregulin 1 type IV does not alter 
myelin integrity in the corpus callosum (average of 0.78 ± 0.01, n = 363 axons per 4 animal) 
when compared with wildtype mice (average of 0.76 ± 0.02, n = 405 axons per 4 animals) (P 
= 0.45).  
 





Schizophrenia is a mental disorder that affects 0.5% to 1% of the general population 
(Stefansson et al., 2002). It manifests itself in a wide range of symptoms that are 
variable between patients. There is no known cause for schizophrenia but recent 
research has pointed that a combination of genetic and environment factors is the 
base of this disorder. Typically, schizophrenia comprises a triad of negative, positive 
and cognitive symptoms.  Some of these symptoms can be alleviate with medication, 
but no cure has yet been found. It is therefore important to understand the 
mechanisms that underlie this disorder. Different studies have suggested a genetic 
association between specific genes and different population. One of these genes was 
neuregulin 1 that was initially reported to be a susceptibility gene after studies in 
patients in Iceland (Stefansson et al., 2002). Functional studies of neuregulin 1 
support the view that neuregulin 1 is involved in the pathogenesis of schizophrenia, 
with elevated neuregulin 1 and ErbB4 protein detected in the prefrontal cortex of 
schizophrenic patients (Chong et al., 2008). Two transgenic mice lines support this 
view, with mice hypomorphic for neuregulin 1 and mice hypomorphic for ErbB4 
showing behavioural abnormalities (Gerlai et al., 2000).  Interestingly, the 
neuregulin 1 mice recover after administration of the drug clozapine. These mice also 
showed a decreased in functional NMDA receptor which is consistent with human 
studies (Ibrahim et al., 2000). 
 
New technologies such as MRI have been a helpful tool to understand and 
characterize abnormalities in the brain that could then be linked to specific 
factors/genes. There is evidence that schizophrenic patients present structural 
changes in their brains (Arnold and Trojanowski, 1996). In studies of monozygous 
twins, where only one of the individuals is affect by schizophrenia, there is an 
enlargement of the lateral ventricles and a decreased cortical area in the affect 
patient. One possible explanation could be an impairment in neurodevelopment, such 
as abnormal neural migration and differentiation. This could be controlled by 
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Nrg1/ErbB signalling since this molecule complex is involved in migration by 
promoting the formation and differentiation of radial glia. 
 
Hippocampal electrophysiology studies suggest that neuregulin 1 affects long term 
potentiation (Chen et al., 2010; Huang et al., 2000; Kwon et al., 2005, 2008; Pitcher 
et al., 2008). Different MRI studies have also shown a loss of hippocampal grey 
matter in schizophrenic patients (Glahn et al., 2008; Honea et al., 2005; Wright et 
al., 2000; Nelson et al., 1998; Fornito et al., 2009). It has been suggested that this 
loss might be due to a combination of decreased numbers of interneurons (Benes et 
al., 1986; Jeste and Lohr, 1989; Weis et al., 2007) and oligodendrocytes (Chambers 
and Perrone-Bizzozero, 2004). Other reports have shown a decreased of hippocampal 
synapses and their dendrites (Rosoklija et al., 2000; Tcherepanov and Sokolov, 
1997).  
 
Although in humans myelination is fully complete around two years of age, this 
process extends throughout adolescence and early adulthood, a time typically 
associated with the first onset of schizophrenia.  Alterations in myelination in this 
later stage have been observed through histological and imaging studies. Microscopy 
studies revealed white matter alterations in schizophrenia, such as abnormal myelin 
sheath lamellae, decreased mitochondrial volume in oligodendrocytes, and 
oligodendrocyte apoptosis and necrosis in the prefrontal cortex (Uranova et al., 
2001). In the prefrontal cortex, it was also shown by microarray data a decreased in 
oligodendrocyte-related mRNA (Hakak et al., 2001). Nrg1/ErbB signalling is known 
to regulate oligodendrocyte development (reviewed in Chapter 4), and by inducing 
oligodendrocyte differentiation or promoting survival of progenitor 
oligodendrocytes, could promote myelination. 
 
Recently, neuregulin 1 type I and type IV overexpressing mice have been developed 
by modifying the isoform-specific promoter regions (Deakin et al., 2009). These 
mice have been behaviourally characterized but their white and grey matter 
phenotypes were not the focus of investigation. In this project we tested if there were 
white matter abnormalities in the neuregulin 1 type IV overexpressing mice, 
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specifically if these mice showed a reduced g-ratio in the optic nerve and corpus 
callosum. In parallel, our collaborator Dr. Andrew McIntosh tested for a decreased in 
white matter density by performing MRI techniques (diffusion tensor and T2-
weighted imaging) of fixed brains. These mice showed normal myelin morphology 
and by analysing light microscopic slides of coronal and sagittal section of these 
brains, no clear abnormality was observed in either white or grey matter. These 
results are corroborated by our collaborator Dr. Andrew McIntosh which imaged 
these brains using diffusion tensor and T2-weighed and saw no evidence of loss of 
white matter (unpublished data).  
 
The absence of phenotype in the neuregulin 1 type IV overexpressing mice can be 
explained by either a compensatory mechanism that buffers the high levels of 
neuregulin 1 (Tan et al., 2007), since neuregulin 1 type IV (and type I) cellular 
distribution is similar to one observed for neuregulin 2 (Longart et al., 2004). Or it is 
possible that the interactions in mice do not mimic the human and therefore no 
phenotypical changes would be observed.  Interestingly, molecular and cellular 
characterization of the human neuregulin 1 type IV isoform shows that when this 
human brain specific isoform is transfected to rat hippocampal neurons, it is 
biologically functional (Shamir and Buonanno, 2011). This isoform is restricted to 
the neuronal soma and dendrites and it is absent from the axonal surface (Shamir and 
Buonanno, 2011). These studies were performed in rat, so it is still a possibility that 
mice specificity is lacking in this isoform and does not interact with its partners. It is 
also possible that due to the neuronal distribution of neuregulin 1 type IV not being 
concentrated in the axon, no effect would be detected in myelination but possibly in 
synapses, so further studies should focus on electrophysiology since it is a highly 
significant area for exploratory studies, with imbalance of synapses possibly leading 
to schizophrenia (Terauchi et al., 2010). It would be an important step for the full 
characterization of these mice to understand the full spectrum of overexpression of 
neuregulin type IV, not only through behavioural studies but also a complete set of 
molecular profiling. 
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A careful analysis of obtained data shows no major alteration in morphology or 
myelination pattern. It would be interesting to investigate if these mice show any 
specific phenotype associated with oligodendrocytes. One of the possible ways to 
access the impact in oligodendrocyte development would be in vitro, by using a co-
culture system and confirm if there were any alterations in myelination, number of 
oligodendrocyte processes or internodal length. Due to the expression pattern of the 
neuregulin 1 type IV, it is possible that this isoform targets glial cells (Shamir and 
Buonanno, 2011). 
 
Our work shows that even after identification of a susceptibility gene it is difficult to 
attribute a specific schizophrenic symptom with a specific mutation. Several genes 
have been proposed to affect schizophrenic patients, but the environmental factors 
might have a stronger impact in the course of the disease than expected. As 
prospective future work, a comorbidity animal model should be used, with the 
genetic factor (overexpression of neuregulin 1 type IV) and an environmental factor 
such as maternal infection, in order to assess the magnitude of the combined effect 
and contribution of both factors. In light of the recent study published by Makinodan 
and colleagues (2012), where the existence of a critical period for social isolation 
(two weeks after weaning) leads to disruption of prefrontal cortex function and 
myelination impairments (with reduced levels of the neuregulin 1 receptor ErbB3), it 
would be interesting to reproduce this experiments with the overexpressing 
neuregulin 1 type IV mice. If juvenile social isolation leads to a reduction of ErbB 
receptor, that in turn results in myelination abnormalities, we could hypothesise that 
these changes would be enhanced in the overexpressing neuregulin 1 type IV mice, 
explaining why we did not see a myelinating phenotype in these mice, because the 
alterations would be dependent on social cues.  
 
Schizophrenia is a debilitating disease with no effective treatment. Diagnose is based 
on patients’ profiling according to different symptoms and the durations of those 
symptoms. Since some of the symptomatology of schizophrenia is shared with other 
psychiatric disorders (such as bipolar disorder) it may be the case that what the 
scientific and medical community describe as schizophrenia is actually a series of 
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psychiatric diseases within a schizophrenic spectrum. It is therefore important to 
shed light into the etiology of schizophrenia as a whole, potentially looking for a 
biomarker and focus on the integration of multiple hypothesis of etiology, with 
special focus on how neurotransmitters and myelination affect each other, and the 




























Conclusions and Perspectives 
Myelination is a tightly controlled process where a glial cell wraps several layers of 
myelin around an axon in order to insulate it, improve conduction performance, and 
provide long term integrity of the axons (Griffiths et al., 1998; Huxley and Stampfli, 
1949). Central nervous system (CNS) and peripheral nervous system (PNS) 
myelination differ in terms of the cells responsible for myelination (oligodendrocytes 
and Schwann cells, respectively) and some of the core proteins that constitute the 
myelin layer (PLP in the CNS vs P0 in the PNS). Oligodendrocytes can extend 
several processes and myelinate different axons, while Schwann cells can only 
myelinate one internode. For myelination to occur a glial cell needs to establish 
contact with an axon and identify the number of wraps that will provide complete 
insulation of the axon. The thickness of the myelin sheath is regulated by the axon 
diameter (Friede, 1972) with an axonal threshold of 0.2 µm in CNS and 1 µm for the 
PNS (Waxman and Bennet, 1972; Voyvodic, 1989) necessary for myelination to 
occur. The existence of a threshold for myelination together with the observation that 
in vitro oligodendrocytes are able to extend processes in the absence of neurons, but 
can only form compact myelin layers in the presence of axons, shows that axonal 
signalling and/or secreted molecules are necessary for initiation of myelination 
(Lubetski et al., 1993). Further, transplantation of oligodendrocytes from the optic 
nerve (an area characterized by small calibre axons) into the spinal cord (with 
typically large diameter axons) myelinate the correct amount of myelin sheaths 
showing that myelin thickness is not an intrinsic property of the oligodendrocyte, but 
regulated by the axon (Fanarraga et al., 1998). 
Myelination in the CNS is a very intricate process and the major players that regulate 
this process have yet to be identified. Central myelination is performed by 
oligodendrocytes which after development acquire the capacity of myelinating 
multiple axons. Different approaches to study oligodendrocyte development and key 
players during myelination have been made throughout the years. In 1980, McCarthy 
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and Vellis described the first protocol for isolation of relatively pure 
oligodendrocytes (McCarthy and Vellis, 1980). This was a major step towards 
understanding the myelination process since it was now possible to study 
oligodendrocyte development in vitro. New advances were made with the co-culture 
system that has been established as an in vitro model to study myelination. In these 
cultures it is possible to culture axons and glial cells, and track the developmental 
process of axon ensheathment (Lubetzki et al., 1993). Although these models 
allowed major breakthroughs in the field, new and more complex systems are needed 
to fully understand myelination, taking into account not only axoglial interaction but 
also the full environment that can influence myelination. Ex-vivo models have also 
been described, where slices of tissue are maintained in culture permitting a better 
overview of myelination, since these cultures provide cell-cell and cell-ECM 
interaction. All of these techniques are crucial for myelination research, but an in 
vivo approach is necessary to fully understand the complexity surrounding 
myelination, such as transgenic animals. Mutant models provide insight into the 
molecules regulating different aspects of myelination and associated diseases. 
 
In this thesis I have asked the question of whether integrins play a role in the 
regulation of myelination, either by contributing to the signals that initiate 
myelination or by regulating the myelin sheath thickness. I found that mice 
expressing a dominant negative β1 integrin (that reduces β1 integrin signalling 
independently of ligand binding) in myelinating oligodendrocytes require a larger 
axon diameter to initiate myelination. However, this phenotype is transient, with 
older mice not showing the shift present in younger mice; and large axons are 
myelinated normally (Câmara et al., 2009). These results suggest that there are other 
signals in the axon that also contribute to initiation of myelination. Previous studies 
described neuregulin 1 type III as a regulator of PNS myelination, controlling the 
decision to myelinate and myelin thickness, although the role of neuregulin 1 type III 
in the CNS is controversial (Fig. 4.5). 




Figure 6.1 – Contrasting effect of neuregulin 1 in the peripheral nervous system and 
β1 integrin in the central nervous system. In the PNS, overexpression of neuregulin 1 
results in a shift to the left of the dose-response curve representing the percentage of 
myelinated axons plotted against the axon diameter. In the CNS, β1 integrin has the 
opposite effect with dominant negative β1 integrin mice showing a shift to the right of the 
diameter threshold for myelination. Reproduced from Câmara et al., 2009. 
Since this phenotype is transient it would be interesting to investigate if a delay of 
the activation of the dominant negative β1 integrin (in these mice under the control 
of MBP) would result in the same phenotype, or if there is a timely window when β1 
integrin is necessary for the correct myelination of small diameter axons. It would 
also be interesting to repeat this same approach with different integrins that are 
normally expressed in myelinating oligodendrocytes or even a combination of 
dominant negative β integrins to assess if different integrins cooperate in the initial 
axoglial contact and myelination, and possibly in a timely matter in the same pattern 
that they are expressed biologically to understand if there are any compensatory 
mechanisms to integrin signalling. To complement these results, a battery of in vitro 
tests could also be performed, such as mixed species cocultures (with either rat 
neurons and mice oligodendrocytes, or mice neurons and rat oligodendrocytes) with 
animal specific blocking of β1 integrin, to determine the role of β1 integrin in both 
neuros and oligodendrocytes. 
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My second major objective was to establish if oligodendrocyte integrins act in 
concert with neuregulin 1 expressed in the axons surface to form a recognition 
complex for axonal signals that determine whether or not myelination occurs. My 
hypothesis was that in the CNS there are different signalling pathways that contribute 
to the precise relationship between axon and oligodendrocyte, explaining the lack of 
phenotype in the neuregulin 1 null mice (Brickmann et al., 2008). This would be 
consistent with a model where in the CNS ErbB receptors in the oligodendrocyte 
recognize the axonal neuregulins, which by integrin amplification would generate a 
signal to initiate myelination. This hypothesis of a multi-molecular signalling 
complex could explain the transient effect observed in the dominant negative β1 
integrin, where older animals seem to recover from the myelination delay seen in 
younger animals, with a different signalling pathway possibly being involved as a 
compensatory system that later on restores the normal axoglial interactions. 
Initiation of myelination is a crucial step highlighted by studies of post-mortem 
brains of MS patients (Chang et al., 2002). During early stages of MS, demyelinating 
lesions can repair effectively through remyelination achieved by newly formed 
oligodendrocytes. Interestingly, these remyelinating regions show thinner myelin 
thickness than the one previously achieved during normal development, with 
progression of MS the remyelination process fails and leads to chronic demyelination 
and consequently to axon degeneration. Since oligodendrocyte numbers in these 
chronic lesions are similar to the ones observed in normal development, it is thought 
that this subsequent inability to remyelinate is due to axoglial contact impairment 
(Chang et al., 2002). 
Studies in the PNS have identified neuregulin 1 type III as a sufficient and necessary 
signal that controls myelin thickness and the decision for Schwann cell myelination. 
In contrast to the PNS, in the CNS one such single factor that controls myelination 
has not been described. This might be due to differences in the process of 
myelination in the PNS and CNS. 
In the PNS, myelination begins with radial sorting, where Schwann cells interact 
with a bundle of unmyelinated axons and establish a 1:1 relationship with the 
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correspondent axon to myelinate. During this process β1 integrin and focal adhesion 
kinase (FAK, a downstream signalling molecule of β1 integrin) are required (Grove 
et al., 2007; Nodari et al., 2007). Subsequent interaction between axonal neuregulin 
1 type III and ErbB2 and ErbB3 receptors expressed in the Schwann cells control the 
myelination process. As it has been previously described, in the CNS neuregulin 1 
type III ablation, and also lack of ErbB3 and ErbB4 has no effect in myelination 
(Brickmann et al., 2008). Furthermore, oligodendrocytes expressing constitutively 
active Akt (part of the downstream PI3K signalling pathway) show 
hypermyelination, contrasting with the PNS where no phenotype was observed 
(Flores et al., 2008).  
Together, these studies highlight the major differences between CNS and PNS 
myelination. This is likely due to biological differences between the specific glial 
cells of each system. While Schwann cells align themselves along the axon it will 
eventually myelinate during the initial stage of myelination, oligodendrocytes need to 
extend several processes and contact multiple axons before myelination. These 
means that Schwann cells only have to form a single myelin sheath, while 
oligodendrocytes will have to form multiple sheaths.  This would probably lead to 
differences in transcriptional mechanisms, with oligodendrocytes needing additional 
post-transcriptional mechanisms to regulate its different processes. This would 
emphasize the need for parallel pathways in the CNS responsible for coordination of 
regulation of myelination, therefore explaining the lack of phenotype observed in the 
neuregulin 1 knockout, which would be due to compensatory mechanisms. The 
existence of parallel pathways would mean that in the oligodendrocytes several 
molecules act in concert to regulate myelination. The identification of such 
molecules, or complexes of molecules, would prove invaluable to stimulate 
myelination and remyelination and be targeted for MS therapies.  
Since the work described in this thesis shows that β1 integrin and neuregulin 1 type 
III do not act in concert to control myelination, a possible candidate for regulation of 
myelination would be contactin. β1 integrin has been shown to control the initial 
axoglial contact in the CNS and provide a threshold for myelination (Câmara et al., 
2009). In an immunoprecipitation assay for α6 integrin (the α subunit that 
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heterodimerises with β1 and is expressed in myelinating oligodendrocytes) and a 
proteomic analysis of associating proteins, contactin was one of the proteins shown 
to associate with the α6 integrin (Laursen et al., 2009). Contactin is expressed both in 
axons and oligodendrocytes. Axonally expressed L1 and neurofascin 186 are both 
ligands for glial contactin 1.  Therefore contactin-1 would be an ideal candidate for 
regulation of initiation of myelination. 
Mackinodan and co-workers (2012) reported that mice display a critical period where 
behavioural and cognitive dysfunction will appear after social isolation. Mice 
isolated for a period of two weeks after weaning show loss of oligodendrocyte ErbB3 
receptors and decreased expression of neuregulin 1 (an ErbB3 ligand), together with 
behavioural and working memory dysfunction. This phenotype is not transient and if 
mice are then presented with an enriched environment they do not recover, showing 
that this critical period is fundamental for normal brain function. It would be 
interesting to take the same approach with the dominant negative β1 integrin // 
neuregulin 1 type III mice 
+/-
, and assess if an isolating period would lead to the same 
phenotype or if this phenotype would be enhanced by the dominant negative β1 
integrin component of these mice. 
Multiple sclerosis has been associated with a higher risk of developing schizophrenia 
(Benros et al., 2011). Interestingly, myelination abnormalities have also been 
described in the pathophysiology of schizophrenia. Multiple sclerosis and 
schizophrenia share symptoms that can be attributed to this disruption such as 
cognitive deficit (e.g. working memory) to an onset of dementia. There are a number 
of parallels between these two conditions. Not only the presence of myelination 
abnormalities but a change of brain volume (a trade mark of schizophrenia) has also 
been observed in patients suffering from relapsing-remitting multiple sclerosis 
(although, in a transient matter) (Rovaris et al., 2001). Linkage between autoimmune 
diseases and psychosis (schizophrenia is considered a psychotic disorder) has been 
established, since schizophrenia has been associated with factors that modulate the 
immune system. These can either be explained by genetic factors shared by both 
autoimmune disorders and psychosis, or common etiological factors such as 
infections/inflammation (reviewed by Benros et al., 2014).  
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Neuregulin 1 is also involved with schizophrenia. Although our results did not show 
a phenotype in the overexpressing neuregulin 1 type IV mice, it is of note that one 
single family of proteins can regulate distinct pathways and affect functions such as 
myelination and be implicated in mental disorders. It would be interesting to further 
analyse these mice in vitro. Oligodendroglial cultures could be used to check 
oligodendrocyte morphology, and myelinating cocultures could be used to observe 
oligodendrocyte myelination up-close. Another approach would be to perform mixed 
cocultures with wild type and overexpressing neuregulin 1 type IV cells, to assess if 
myelination would be compromised at the level of neurons or/and oligodendrocytes. 
As with the dominant negative β1 integrin // neuregulin 1 type III mice 
+/-
, following 
Makinodan work (Makinodan et al., 2012) and since social isolation is known to be a 
model of schizophrenia, a period of social isolation could also be imposed to these 
mice to assess any behavioural and morphological brain changes. Schizophrenia is a 
multifactorial disorder with different environmental and genetic factors being 
implicated; inducing in utero inflammation in the overexpressing neuregulin 1 type 
IV mice would be an interesting comorbidity model of schizophrenia. Further 
investigations would need to be carried out in order to fully unravel the mysteries 
behind schizophrenia, with more than just one single genetic factor and a 
combination of environmental factors that would allow a closer scenario to what is 
seen in schizophrenic patients. 
There are a number of weaknesses in this thesis. In terms of technical deficiencies 
present in these studies the most evident one are the low number of animals used for 
each set of experiments, with some of them relying on only one or two animals.  This 
is due to the retrospective way these experiments were performed. The main 
hypothesis of Chapter 3 was that β1 integrin would affect myelination, and the 
assumption was made that a phenotype would be more prominent in a context of 
small diameter axons that are present in structures like the optic nerve. Analyses of 
the optic nerve confirmed our hypothesis by showing a shift to the right of the 
response curve of the percentage of myelination, with dominant negative β1 integrin 
mice showing a higher threshold of axon diameter for myelination.  Therefore I 
decided to examine other structures to ask whether this was a tract specific 
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phenotype, and analyse the tracts of the same animals in order for an unbiased 
comparison.  Unfortunately at the time of dissection not all tissue was dissected and 
for some animals it was discarded, leaving some of the data sets incomplete and only 
included in this thesis as an indication of the trend seen in such structures.  
Considering the results in Chapter 3, where a phenotype was only observed in the 
optic nerve for the dominant negative β1 integrin mice, and given that previous 
research of the neuregulin 1 type III 
+/-
 mice had only showed a phenotype in the 
corpus callosum, I decided to focus my attention in these two brain structures.  In 
hindsight, different structures of the brain should have been considered and analysed.  
To overcome this frailty more animals should have been bred and analysed, for a 
complete overview of the effect of integrins and neuregulins in the different 
structures of the brain.  
These leads to another shortcoming identified in this thesis: the lack of power 
calculation studies. It would have been advantageous to perform a small systematic 
review at the beginning of each project of all studies published of the current 
research of β1 integrin (Chapter 3), neuregulin 1 type III (Chapter 4) and neuregulin 
1 type IV (Chapter 5) and use these publications and preliminary studies to calculate 
the number of samples necessary for effect size of event data. A power calculation 
study would allow for more robust results and better interpretation of data.  
Regarding the outcome measures it is important to note that these are mainly from 
electron microscopy studies.  For an extensive characterization of all transgenic lines 
used, it would have been interesting to not only focus on anatomical changes but 
complement these studies with behavioural and electrophysiological data. Research 
published after the conclusion of this work showed that social isolation can impact 
neuregulin and its receptor ErbB expression, especially in the prefrontal cortex 
(Makinodan et al., 2012) and is also associated with altered behaviour and reduced 
learning. This remarkable work therefore shows how conditioning animals (here by 
varying social stimulation) can lead to modifications in terms of cognitive functions 
and   myelination. Given this, it would have been interesting not only to analyse the 
behaviour of all the transgenic lines described in this work, but also vary social 
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stimulation in these animals and examine a possible exacerbation of the phenotypes 
associated with each genotype.  
Further in vitro experiments would also be interesting; by manipulating more than 
one integrin in vitro a better understanding of the interconnection of these proteins 
would be possible and would be an important set of data to understand the role of 
integrins in myelination. Additionally, a time-course of integrin blocking in co-
cultures (where blocking could be species specific for oligodendrocytes, or axons, 
using a mix culture of rat and mice cells) would enhance our understanding of 
integrin modulation of myelination.  
In terms of experimental designs some of the flaws identified concern the age points 
chosen. Instead of only two data points (before and after completion of myelination), 
that in the case of the dominant negative β1 integrin project showed a transient 
effect, with the phenotype being present in the earlier time point and absent in the 
later one, at least two other time points should have been included. An earlier time 
point, such as P10, when myelination is under way, and a later time point such as 
P120 or later should have been considered to give insight into the timeline of the 
effect of integrins and neuregulins in myelination. Furthermore, this project did not 
take into account the contribution or compensation of other integrins. The fact that 
we see a transient phenotype might be explained by compensatory mechanisms of 
the full range of integrins expressed in oligodendrocytes. To address this problem, 
further integrin transgenic lines should have been engineered, the different mice lines 
crossed and analysed.  
In conclusion, a number of weaknesses have been identified and there is scope to 
improve this work with a further set of experiments that would characterize all 
transgenic animals in terms of behavioural, electrophysiological and in vitro data. 
Myelination defects are linked with a myriad of pathologies, such as MS and 
schizophrenia. Understanding this complex biological process is of keen importance, 
as the discovery of the molecules responsible for myelin regulation could be used as 
a drug therapy target and prevent or ameliorate these conditions. Therefore, it is 
relevant for science that myelination research focus on the axoglial contacts but in a 
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more integrative way, with genetic and environmental factors being consider in the 
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